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1 Introduction 
 The public health impact of obesity 1.1
The prevalence of overweight and obesity is increasing substantially worldwide at 
an alarming rate, in both developed and developing countries among adults and children 
(1, 2). According to the World Health Organization (WHO), a body mass index (BMI) of 
<18.5 kg/m² is classified as underweight, a BMI of 18.5-24.9 kg/m² as normal weight is, 
and a BMI of 25.0-29.9 kg/m² as overweight. A BMI of ≥30.0 kg/m² is classified as 
obesity. Globally, the age-standardized prevalence of overweight increased from 24.6% 
in 1980 to 34.4% in 2008 (3). Moreover, during the same time period, the age-
standardized prevalence of obesity nearly doubled from 6.4% to 12.0%. Currently, 
excess weight is causing about 3.4 million annual deaths and 3.8% of the global burden 
of disease (4). 
In Germany, more than 50% of individuals aged 18 to 79 years are overweight (5). 
Further, 67.1% of men and 53.0% of women are overweight, and 23.3% of men and 
23.9% of women are obese (5). From a societal perspective, the total costs of obesity 
are estimated to total up to euro 5.7 million annually, imposing a major burden on the 
healthcare system (6). Several meta-analyses have provided a comprehensive estimate 
of the co-morbidities attributable to overweight and obesity and confirm that overweight 
and obesity carry a profound health burden and have a significant impact on health 
expenditures (7). Specifically, overweight and obesity were found to be associated with 
the incidence of type 2 diabetes mellitus, numerous cancers, cardiovascular disease, 
asthma, gallbladder disease, osteoarthritis, and chronic back pain (7-13). Moreover, the 
risks (as defined by hazard ratios) of diabetic, renal, and hepatic mortality associated 
with overweight and obesity are as high as 60–120% (14). In addition, about 40% of 
cardiovascular mortality is caused by obesity, and obesity is responsible for almost 20% 
of respiratory and all other mortality (14).  
To some extent, the burden of obesity-associated diseases may be attributable to 
prolonged life expectancy and may additionally be determined by non-modifiable factors, 
such as sex, ethnicity and genetic predisposition. Nevertheless, obesity-associated 
diseases are also a result of behavior and lifestyle choices, including a hyper-caloric 
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diet, physical inactivity, and smoking (15). These modifiable factors also offer a great 
potential to develop and implement prevention strategies to counteract the global burden 
of obesity (16, 17). The early application of intervention strategies may enhance quality 
of life and reduce healthcare costs. Consequently, it is important to understand the 
underlying biological mechanisms and to identify individuals at risk for obesity-
associated diseases.  
 How obesity causes chronic diseases 1.2
Adipose tissue consists of a large number of adipocytes, other non-fat cells, 
connective tissue matrix, vascular and neural tissues (18). The non-adipocytes cellular 
component includes inflammatory cells (macrophages), immune cells, pre-adipocytes, 
and fibroblasts. The main cellular components of adipose tissue are adipocytes that 
represent the primary storage depots of energy in form of triglyceride (TG) droplets. New 
smaller adipocytes can act as buffers to absorb free fatty acids (FFAs) and TGs in the 
postprandial period. As adipocytes grow larger, they become dysfunctional. Specifically, 
large adipocytes are insulin-resistant, hyperlipolytic, and resistant to the anti-lipolytic 
effect of insulin (18). Adipose tissue is recognized as an endocrine organ secreting 
cytokines, chemokines, growth factors, and hormones. Moreover, adipose tissue 
dysfunction is a central component of obesity-related inflammation and the main 
instigator of the pathological consequences of obesity, mostly through its association 
with insulin resistance (19-21). In addition, there has been an increasing appreciation of 
the role of inflammation both in the pathogenesis of atherosclerosis (22, 23) and as a 
key factor in insulin resistance (24).  
Low-grade chronic inflammation can be characterized by increased systemic levels 
of some inflammatory parameters, including interleukin-6 (IL-6), tumor necrosis factor α 
(TNF-α), C-reactive protein (CRP), and resistin, and decreased levels of adiponectin. 
These inflammatory parameters have been proposed as intermediates that might 
explain the association between obesity and obesity-associated diseases. In particular, 
a number of studies have confirmed an association of inflammatory parameters with 
atherosclerosis, type 2 diabetes, and numerous cancers (25, 26). For instance, 
increased levels of TNF-α, IL-6, and CRP have been associated with type 2 diabetes 
(27, 28). Moreover, increased circulating levels of TNF-α, IL-6, and CRP play a major 
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role in all stages of atherosclerosis, from plaque formation over progression to rupture of 
atherosclerotic plaques (29) and are associated with worse cardiovascular outcomes 
(30, 31). In addition, a recent meta-analysis of prospective cohort studies reported that 
elevated levels of CRP are associated with an increased risk of all-cancer, lung cancer, 
and possibly breast, prostate, and colorectal cancer (25). Yet another study found 
positive associations of resistin and TNF-α with colorectal cancer (32). Decreased 
adiponectin levels have been related to type 2 diabetes, cardiovascular diseases, and 
numerous cancers, including breast, endometrial, prostate, colon, gastric, pancreatic, 
and hematological malignancies (33, 34).  
Obesity is also associated with increased macrophage infiltration of adipose tissue, 
and these macrophages may be an important component of the inflammatory response, 
playing a crucial role in the development of insulin resistance (35). Adipose tissue 
inflammatory factors are produced by both adipocytes and associated inflammatory 
cells, such as adipose tissue-related macrophages. Evidence suggests that adipose 
tissue macrophages may be responsible for a large proportion of adipose tissue TNF-α 
expression and significant amounts of other inflammatory factors such as IL-6, resistin, 
and adiponectin (36-38). Moreover, increased inflammatory parameters derived from 
adipose tissue, are also promoting inflammatory responses from other body organs. For 
instance, CRP is secreted by the liver in response to adipocyte or adipose tissue IL-6 
release (12).  
However, it has been recognized that the level of risk to develop obesity-
associated diseases differs among obese individuals. Specifically, research suggests 
that about 20% of people, who are characterized as obese, are apparently insulin 
sensitive and metabolically normal (39). These individuals have been categorized as 
metabolically healthy but obese (MHO) (40). In contrast, approximately 18% of the 
general population that have been defined as being normal weight, are metabolically 
obese displaying several of the metabolic abnormalities associated with the metabolic 
syndrome (40). It has been shown that MHO often have less visceral adipose tissue 
(VAT) than obese patients with cardiometabolic diseases (40, 41). Conversely, patients 
who are normal weight, but metabolically obese, tend to have more VAT than individuals 
of similar weight and no metabolic disease (40). Mechanisms explaining such clinical 
findings are not fully understood.  
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Part of the problem is due to the fact that BMI has been used to characterize the 
obese phenotype. However, BMI is not a biological trait but a calculated value (i.e., body 
weight in kilograms divided by height in meters squared), which is widely used in clinical 
practice to categorize individuals (42). Body weight is the sum of the different body 
components; however each body component (e.g., adipose tissue, skeletal muscle 
mass, and fat-free mass) has its own regulatory basis (43). Thus, emerging research 
has begun to address body fat distribution as an important factor that might help explain 
the robust association of BMI with various diseases and mortality that has been found in 
observational research. Abdominal obesity, as characterized by waist circumference 
(WC) and waist-to-hip ratio (WHR), were shown to more accurately measure body fat 
distribution than BMI, which is more closely related to general adiposity (44). Moreover, 
abdominal obesity is a strong correlate of adverse metabolic profiles and their resulting 
diseases (45). WC and WHR have been suggested to be better predictors of the risk of 
disease than BMI (43, 44, 46). For instance, according to the Health Professionals’ 
Follow-up Study (HPFS) among men, WC is a more powerful predictor of type 2 
diabetes than WHR or BMI (47). Moreover, WC or WHR better discriminated and 
calibrated 5-year mortality risk than BMI in men and for women from the European 
Prospective Investigation into Cancer and Nutrition (EPIC) study (48). Further, evidence 
suggests that WC and WHR but not general adiposity were associated with increased 
risk of death in diabetic men and women (49).   
Nevertheless, there are regional differences between abdominal adipose tissues in 
relation to metabolic outcomes (50). VAT has been considered to have multiple 
endocrine, metabolic, and immunological functions and may be more strongly 
associated with metabolic risk factors than abdominal subcutaneous adipose tissue 
(SAT) (51-55). Moreover, an independent curvilinear association between VAT and 
mortality has been reported for men (56), suggesting that a large amount of VAT is 
required for an increased risk of mortality (57). Although it remains unclear what drives 
the association between VAT and obesity-associated diseases, the most accepted 
theory is that VAT releases excess FFAs, which results in insulin resistance in the liver 
and acts as a trigger for obesity-associated diseases such as type 2 diabetes (58, 59), 
cardiovascular diseases (57-61), and some cancers, including colorectal (62), hepatic 
(63), pancreatic (64), breast (65), endometrial (66), and urinary tract malignancies (67). 
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Specifically, elevated FFAs in the plasma cause decreased glucose transport into the 
muscle cells and increased fat breakdown, subsequently leading to elevated hepatic 
glucose production (59). A combination of insulin resistance and pancreatic β-cell 
dysfunction is responsible for the development of type 2 diabetes (68). Insulin resistance 
increases cardiovascular risk through dyslipidaemia, hypertension, and glucose 
dysmetabolism. Moreover, the aforementioned inflammatory parameters secreted by 
adipocytes and macrophages infiltrating adipose tissue may lead to increased oxidative 
stress and endothelial dysfunction, which promotes atherosclerosis (57). Several studies 
proposed possible mechanisms explaining the underlying mechanisms of increased VAT 
and the increased risk of cancer (61, 69-71). These studies have demonstrated 
sustained hyperglycaemia, hyperinsulinemia, insulin resistance, and hyperinsulinemia-
related increase of insulin-like growth factor-1 (IGF-1) in cancer promotion and 
progression. 
Anatomic location is one of the more important reasons why different fat depots 
have different pathogenic potential. VAT accounts for up to 10–20% of total fat in men 
and 5–8% in women (72). The amount of VAT increases with age in both sexes (72). 
Because VAT is predominantly located in the mesentery and omentum, it drains directly 
through the portal circulation to the liver (18). By comparison, SAT presents the largest 
fat storage site (approximately 80% of total body fat) and occurs over the whole body 
below the skin and between the skeletal muscles (intermuscular fat) (73). VAT contains 
a greater number of large adipocytes in contrast to SAT that contains small adipocytes 
(74). The deposition in non-adipose tissue of small adipocytes is prevented by the 
enhanced insulin-sensitivity and a high affinity for FFA and TG uptakes (74, 75). In 
contrast, during positive caloric balance, the recruitment and proliferation of smaller and 
more functional subcutaneous adipocytes occurs and the risk of developing metabolic 
diseases may be decreased (75) and thus may explain the proposed protective effects 
of SAT.  
However, the role of abdominal SAT regarding the development of obesity-
associated diseases is not well understood (28). Some studies have suggested that SAT 
in the abdominal region has metabolic activity, such as lipolysis and the release of 
inflammatory factors if subcutaneous adipocytes become sufficiently enlarged (28, 38, 
51, 76). Yet, data examining potential differences between VAT and SAT are not entirely 
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consistent (28). Moreover, because the absolute quantification of VAT or SAT does not 
reflect its relative distribution in the human body, the assessment of the visceral-to-
subcutaneous-fat ratio (VSR) may provide additional information with respect to 
metabolic regulation perturbed by obesity (77). However, the propensity whether fat is 
stored viscerally rather than subcutaneously has rarely been targeted by previous 
research (77-79). Most previous studies investigating the associations between obesity 
and inflammatory parameters used BMI, WC, or WHR as an underlying metric of 
adiposity (80-92). Although a number of studies did consider body fat distribution and 
examined relations of VAT (79, 83, 85, 93-98) and/or SAT (83, 93-104) to parameters of 
systemic chronic inflammation, results are inconsistent and only few studies (94, 98, 
102) reported results from multivariable analyses that adjusted for common confounding 
factors (Supplementary Table 1). Only one previous study (79) among obese 
adolescents examined the VSR in relation to hs-CRP and IL-6. Moreover, to date no 
previous study has compared different measures of obesity with regards to their 
relations to parameters of chronic inflammation and no previous study examined 
numerous inflammatory parameters at the same time. However, to better understand 
biological mechanisms that link obesity to obesity-associated diseases and to further 
improve the prediction of those diseases, it is indispensable to comprehensively 
characterize the obese phenotype by including the examination of adipose tissue 
compartments. 
 Transition from single biomarker investigation to systems epidemiology 1.3
Although a number of important risk factors of obesity-associated diseases, 
including inflammatory parameters, have been  identified, the underlying metabolic 
pathways of obesity-associated diseases are not yet fully understood (105). Obesity 
itself is a complex disease and very challenging with respect to its pathophysiologic 
consequences, heterogeneity in phenotypes, and multifactorial origin (106). To enhance 
the understanding of the pathophysiologic consequences of obesity and to better 
address potential biological mechanisms underlying obesity-associated diseases, a 
more comprehensive approach seems to be necessary that does not only focus on 
individual biomarkers. A more systematic approach to investigate biological mechanisms 
and pathways has been introduced by the “–omics”-sciences, such as genomics 
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(genetic predisposition), transcriptomics (expression of genes), proteomics (enzymes), 
and metabolomics (substrates and products of enzymes) (Figure 1). In general, the 
focus of the –“omic”-sciences is directed on the entire systems (e.g., the complete 
human metabolism) rather than on single biomarkers. 
 
Figure 1: Hierarchy of the "-omic"-sciences 
Source: (107). 
Metabolomics is described as the concurrent study of all measurable low-weight 
molecular compounds present in a biological system such as biological fluids (e.g., urine 
or blood), tissues, or cells (108). Metabolites are defined as compounds with less than 1 
kDa of molecular weight (e.g., amino acids, mono- and di-saccharides, lipids, organic 
acids, steroids, nucleotides); the entity of metabolites represents the metabolome (108). 
Depending on their origin, metabolites can further be categorized as endogenous (e.g., 
derived from de-novo synthesis) or exogenous (e.g., ingested with diet or medication) 
(109). Metabolomics focuses on substrates, intermediates, and end products of 
Introduction 
8 
 
metabolic pathways and it reflects cellular processes, such as substrate fluxes and 
enzyme activities. Furthermore, by representing a unique snapshot of metabolic 
phenotypes, metabolomics has the potential to depict genetic predisposition and 
modulation as well as environmental and lifestyle exposures, including obesity. Thus, 
metabolic perturbations linked to chronic disease risk can be identified (108, 110) and 
biological mechanisms may be unraveled to gain information about how habitual factors 
and phenotypes are linked to metabolism (105). Knowledge about these mechanisms 
may offer great potential in terms of understanding the development and consequently 
the prevention of chronic diseases, which are strongly linked to human behavior and 
phenotypes (16, 111).  
The exploratory nature, covering a whole biological system with multiple factors, is 
an important attribute of the systemic metabolomics approach. To date, “-omic”-sciences 
have mostly been applied in the context of experimental studies, e.g., animal studies or 
small scale clinical trials. However, the combination of an observational study design 
with the innovative measurements from molecular biology, might offer the potential to 
unravel the “black box” of biological mechanisms and pathways that underlie the 
observed associations between environmental and lifestyle exposures and chronic 
disease risk (105, 112, 113). To describe this concept, the term “systems epidemiology” 
has been proposed (114). Systems epidemiology concatenates the molecular 
underpinnings with multiple environmental interaction, including behavioral and 
sociodemographic levels that may influence health and disease, with the aim of a 
comprehensive and more complete description of the physical state of an individual 
(115, 116).  
However, the description of the obese phenotype often fails to capture the diverse 
subclasses of those phenotypes that predict the outcome or response to treatment 
(117). Specifically, although BMI and WC are frequently used to categorize individuals 
as overweight or obese, these parameters cannot reflect biological mechanisms 
because they are no biological traits (43). Overcoming these difficulties requires an 
exhaustive examination of the discrete components of the obese phenotypes that goes 
beyond BMI and WC measurements. Integrating the examination of different body fat 
tissues, including VAT and SAT, such deep phenotyping, gathers details about related 
disease mechanisms more precisely (118). In line with a more comprehensive 
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characterization of the obese phenotype by considering general adiposity, abdominal 
adiposity, different abdominal adipose tissue compartments, and the relative distribution 
of different abdominal adipose tissue compartments, the thorough investigation of the 
metabolic phenotype by considering the explorative examination of the metabolome, 
may further enhance the understanding of metabolic consequences of obesity and 
mechanisms linking obesity to obesity-related diseases.  
Intermediate metabolic markers may be identified that mirror different stages of 
progression from a healthy state to disease and the development of obesity-associated 
diseases may be more comprehensible. Similar to the findings that WC, WHR, and VAT 
are better predictors of morbidity and mortality from obesity-associated diseases than 
BMI (43, 48, 52, 56, 119-123), the investigation of the complex human metabolism in 
addition to already known obesity-related biomarkers such as inflammatory parameters, 
may also improve the prediction of morbidity and mortality attributable to obesity (105, 
115, 116). Taken together, the described deep phenotyping of the exposure and 
outcome adds to our ability to unravel the “black box” between obesity and obesity-
related diseases. Ultimately, metabolic markers may contribute to the identification of 
individuals at high-risk for the development of obesity-associated diseases and facilitate 
administering adequate prevention and treatment strategies.  
Including metabolomics in epidemiologic studies requires a shift in paradigm of 
research design from hypothesis-driven approaches and the investigation of single 
biomarkers, towards exploratory approaches to examine the complex human 
metabolism and provide important information on underlying biochemical pathways and 
interrelations, thus enriching the biological context and clinical relevance. The 
exploratory approach does not require an a priori hypothesis and can be used to 
discover novel metabolic associations and disease pathways to gain scientific insight in 
an incremental manner. However, metabolomic data pose a challenge in epidemiologic 
research in that they possess high dimensionality, some degree of collinearity and 
missing data, non-linearity, and non-normality (124). Moreover, effect sizes and most 
metabolites are unknown in the exploratory mode, which also challenge power 
calculations because of the unknown number of features and tests that will be 
performed. Finally, findings need to be validated in external, independent data sets 
following exact analytical procedures and identical preprocessing methods (124). 
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Metabolomics has raised particular interest of clinicians and epidemiologists (112, 
125, 126). A number of obesity-related metabolites have been identified by 
metabolomics that affect metabolic pathways in humans (127). However, to date no 
consistent results have been identified and little is known about the relations of VAT and 
SAT or VSR to metabolic profiles and whether the contributions of those parameters 
differ regarding their relation to metabolic regulation compared to simpler obesity 
measurements, such as BMI and WC. Previous studies examining the association of 
obesity with metabolite levels in human blood or urine specimens reported positive 
relations of BMI to branched chain amino acids (BCAA) (128-133), and carnitine 
concentrations (131, 132) (Supplementary Table 2). Moreover, inverse relations were 
found between BMI and microbial metabolites, such as hippuric acid (131, 133, 134). 
Both, positive and inverse relations were found between obesity and amino acid-related 
metabolites (129-133, 135). Two studies measured abdominal obesity by dual x-ray 
absorptiometry (DXA) and reported positive relations to intermediates of BCAA among 
older adults (136) and BCAAs among overweight men and women (130). Only one study 
measured VAT and SAT by magnetic resonance imaging (MRI) and reported a positive 
relation of VAT to serum isoleucine in overweight men and women (130).  
Thus, there is a need to describe biologically sound, multifaceted, and robust 
phenotypes to provide useful information about physiological and pathological states. In 
particular, to overcome the limitations of BMI, the investigation of relations of abdominal 
obesity, abdominal adipose tissues, and the relative distribution of abdominal adipose 
tissues with metabolite regulation aims at a better understanding of metabolic pathways 
that are perturbed by obesity and may consequently improve the understanding of the 
development of obesity-related diseases.  
 Measurement of visceral and subcutaneous adipose tissue 1.4
The recognition of the importance of body fat distribution has led to a variety of 
methods to assess abdominal fat tissue, spanning from WC and WHR, to more 
sophisticated methods, such as computer tomography (CT) (137) and MRI (138). 
Population-based epidemiologic studies have often used BMI, WC, and WHR to 
characterize body weight and the distribution of body fat. Despite being cost and time 
efficient, these parameters are indirect measurements that have serval methodological 
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shortcomings because these simple measures are not capable of adequately 
discriminating between VAT and SAT. However, to achieve a thorough understanding of 
obesity-related chronic diseases, new measurements that apply deep phenotyping of 
obesity measurements are needed. 
For the investigation of the pathophysiology of obesity accurate measures to 
differentiate and quantify VAT and SAT are of major importance as they improve the 
understanding of mechanisms underlying obesity-related morbidity (139). CT and MRI 
are considered the reference methods for the measurement of VAT and SAT (140). 
However, MRI and CT approaches are limited in field conditions due to their associated 
costs and issues regarding accessibility, contraindications, and in terms of CT 
examinations, potential adverse effects of radiation. One possible non-invasive and cost-
effective alternative to differentiate and quantify VAT and SAT is ultrasound.  
1.4.1 Ultrasound to measure visceral and subcutaneous adipose tissue 
Although ultrasound has been commonly used to assess soft tissue structures in 
clinical diagnoses, ultrasound as an imaging modality can also measure tissue 
thicknesses such as SAT and VAT. Sound waves of high frequency (1-10MHz) are 
produced by vibrations of an electrically stimulated piezoelectric crystal within a 
transducer and are used by brightness-modulation (B-mode) instruments (141). The 
interfaces of dissimilar underlying tissues partially reflect the ultrasound beam that is 
disseminated through the skin. One part of the beam is reflected back to the transducer 
as an echo, while the remainder of the beam continues to travel through the interface to 
deeper tissues. The strength of the reflection, which in turn depends on the acoustic 
impedance properties of different tissues and the number of tissue interfaces that the 
ultrasonic beam transverses, determine the quality of an image (142). The density of the 
medium times the velocity of ultrasound wave propagation in the medium defines the 
intrinsic physical property of a medium (143). The lowest acoustic impedance is 
produced by air-containing organs such as the lung, while dense organs such as bone 
have very high-acoustic impedance (144). Finally, the transducer converts and amplifies 
the echoes into electric signals to form an enlarged image on a display device (145).  
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1.4.2 Reliability and validity of ultrasound-based measurements of visceral and 
subcutaneous adipose tissue 
The sonographic-based quantification of VAT and SAT offers great potential for 
epidemiological research. As a non-invasive method, abdominal fat can time- and cost-
efficiently be examined and body fat compartments can be differentiated and quantified 
(Table 1). However, limitations of the ultrasound method include the requirement of 
experienced technicians with considerable skills. In addition, the ultrasound examination 
is of higher cost compared to field methods, although it is of lower cost compared to 
laboratory methods such as CT and MRI.  
 
Table 1: Advantages and limitations using ultrasound for assessing body fat. 
Advantages Limitations 
- Lower costs than laboratory 
methods 
- Higher costs than field methods 
- High accuracy and precision in the 
hands of an experienced 
technician 
- Requires experienced technician, 
considerable skill is necessary 
- Capable of regional and segmental 
measurements 
- Measurement procedures and 
techniques are not yet standardized 
- Minimal tissue compression - Inherent artifacts (e.g., fascia) 
- Noninvasive and no ionizing 
radiation 
 
- Applicable for testing in the field  
- Short testing time, rapid procedure  
Reproduced from Wagner, 2013 (146). 
In 1966, ultrasound was introduced for the measurement of SAT (147). The first 
application of ultrasound for the measurement of VAT in a population-based 
epidemiological study dates back to 1990 (148). Ever since, the ultrasound method to 
quantify VAT and SAT has been subject to research to explore the reliability and validity 
of using different measurement protocols to differentiate and quantify VAT and SAT. 
Some studies that have examined the validity of ultrasound for the assessment of VAT 
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and SAT compared these measures with reference methods (CT or MRI) and concluded 
that ultrasound is a suitable technique to accurately measure VAT and SAT (51, 52, 149, 
150), while other studies showed inconsistent results for the precision of the ultrasound 
measurement of VAT and SAT (52, 140, 148-158) (Supplementary Table 3). Moreover, 
only few studies examined the reproducibility of the sonographic-based measurement of 
VAT (153, 157, 159-161), and none of those studies examined the reproducibility of 
measuring SAT. In addition, results were inconsistent showing favorable results, with 
intra-class correlation coefficients of 0.90-0.99 (157, 159) and mean differences ranging 
from 0.25-0.69 mm (153, 160) and less favorable results with a correlation coefficient of 
0.64 (161). 
 Objectives 1.5
Against this background, the present thesis aimed to examine metabolic 
differences between visceral and abdominal subcutaneous adipose tissue. A systematic, 
multiple step approach was taken and the following objectives were of interest:  
1) Reproducibility of the sonographic quantification of VAT and SAT 
2) Validity of the sonographic quantification of VAT and SAT 
3) Relations of VAT, SAT, VSR, BMI, and WC to parameters of chronic inflammation  
4) Associations between VAT, SAT, VSR, BMI, and WC with concentrations of 
quantified urinary and serum metabolites applying a targeted metabolomic 
approach 
5) Using an untargeted metabolomic approach to detect differences between VAT, 
SAT, VSR, BMI, and WC regarding a) their relations to urinary and serum 
metabolic fingerprints adopting cluster analyses and related methods to identify 
groups of metabolites and b) their relations to individual urinary and serum bins 
applying multiple regression analyses and subsequent metabolite identification  
To examine the inter- and intra-observer reproducibility of the ultrasound-based 
quantification of VAT and SAT, a reproducibility study was conducted among 127 
participants from two study centers in Germany. In total, 30 participants were recruited 
for the validity study to evaluate the validity of the ultrasound method to measure VAT 
and SAT compared with the gold standard method MRI. The inflammation study was 
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conducted in a sample of 97 participants. In this context, VAT, SAT, VSR, BMI, and WC 
were surveyed and related to serum concentrations of parameters of chronic 
inflammation, including hs-CRP, TNF-α, IL-6, resistin, and adiponectin. Nuclear 
magnetic resonance spectroscopy (NMR) was used to measure metabolites in 228 
urinary and 200 serum specimens in the metabolomics study. A targeted metabolomics 
approach was used to quantify concentrations of urinary and serum metabolites and the 
relations of VAT, SAT, VSR, BMI, and WC to metabolite concentrations were examined. 
An untargeted metabolomics approach was used to detect differences between obesity 
measures with respect to their relations to urinary and serum features (bins).   
2 Methods 
 Study population 2.1
The present thesis emerged from the pre-test studies of the German National 
Cohort study (GNC). The study aim of the GNC, a joint interdisciplinary endeavor of 
scientists from the Helmholtz and the Leibniz Associations, universities and other 
German research institutes, is to investigate the development of major chronic diseases, 
the subclinical stages and functional changes (162). Therefore, a population-based 
sample of 200,000 men and women was drawn in in 18 study centers across Germany 
(162). The logistics, feasibility and other elements of the study, including measurement 
instruments, were tested during pre-test and pilot studies. These pre-test studies were 
conducted from June 2011 to April 2013 in all 18 GNC study centers. The pre-test 
studies were based on a cross-sectional study design.  
An age- and sex stratified sample of the population was drawn by the local 
population registries in Regensburg and adjacent areas. Participants that were included 
in the pre-test studies were aged between 20 and 70 years, were living in Regensburg 
or adjacent areas, and were German speaking. Participants were recruited in two 
phases (pre-test I and pre-test II). Pre-test I was conducted between June and August 
2011 and pre-test II was conducted between October 2012 and April 2013. Participants 
were invited to take part of the study by invitation letters and no incentives were given to 
the participants. Overall, 233 of the 949 sampled individuals agreed to participate, which 
corresponds to a response proportion of 24.6%. Of those, five participants were 
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excluded from analyses due to pregnancy (n=1) or diagnosed chronic diseases including 
diabetes (n=2), pancreatic cancer (n=1), or hepatitis (n=1). Urine samples were 
collected from all participants (n=228) and blood samples were collected from 88% of 
participants (n=200). In addition, data from 30 subjects participating in the GNC pre-test 
studies in Kiel were included for specific data analyses. In Kiel, the same recruiting 
strategies were used as in Regensburg. Another sample of 30 subjects also aged 
between 20 and 70 years were patients of the local hospital in Regensburg undergoing 
MRI examination of the abdomen or they were volunteers. All pre-test studies were 
conducted according to the Declaration of Helsinki guidelines and were approved by the 
ethics committee of the local hospitals. Written informed consent was obtained from all 
participants.  
Each previously described objective (chapter 1.5) is examined based on a study 
specific population comprised from the GNC pre-test studies. Information about each 
study population considered for each objective is described in the flow chart (Figure 2). 
In detail, data from pre-test I and the additional data from 30 subjects participating in the 
GNC pre-test studies in Kiel were included in the data analyses for the reproducibility 
study (n=127). For the validation study, data from volunteers and patients of the local 
hospital in Regensburg was included (n=30). The inflammation study was conducted 
with data from pre-test one (n=97) and for the metabolomic studies data from both pre-
test studies were considered, resulting in a total study sample of 228 participants. 
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Figure 2: Study population for each objective. 
Assessed for elegibility:  
- GNC Regensburg  n=949 
- GNC Kiel   n=30 
- Patients/ Volunteers  n=30 
Total recruited:  
- GNC Regensburg  n=233 
- GNC Kiel   n=30 
- Patients/ Volunteers  n=30 
Excluded for data analyses:  
- Prevalent diseases  n=5  
Data available for analysis: 
- Reproducibility study  n=127 
- Validity study   n=30 
- Inflammation study  n=97 
- Metabolomics studies  n=228 
 - urine samples:  228 
 - blood samples: 200 
Excluded: 
- Non-responder  n=716 
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 Measurements 2.2
2.2.1 Sonographic-based measurement of visceral and subcutaneous adipose 
tissue 
A standard operation procedure (SOP) (Appendix 1) for the ultrasound 
measurements was developed based on the protocol introduced by Stolk et al., who 
reported reproducibility correlation coefficients of 0.97 (p<0.001), mean differences of 
0.3 cm (±0.6), and a coefficient of variation of 4.3% for the measurement of VAT. They 
also reported Pearson correlation coefficients of 0.81 (p<0.001) for validity of the 
ultrasound measurement of VAT compared to CT and MRI measurements of VAT (157). 
VAT and SAT were quantified using a Mindray DP-50 (Regensburg) or GE 
Healthcare Logic 700 (Kiel) B-mode ultrasound machine with a 3.5 – 5.0 MHz convex 
array transducer. Examiners were trained to perform the measurements according to the 
developed ultrasound SOP. Measurements involved multiple image planes that provided 
information on adipose tissue thickness. For all images, the transducer was placed on a 
marked position drawn at the cut-point between the left and right midpoint of the lower 
rib and the iliac crest on the median line of the abdomen (Figure 3).  
 
 
Figure 3: Position for ultrasound measurements and waist circumference 
measurement. 
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The measurement of SAT involved one individual image plane at the median line 
extending from the skin to the linea alba (Figure 4).  
 
Figure 4: Sonographic-based measurement of subcutaneous adipose tissue. 
 
VAT was measured as a second image plane from the linea alba to the lumbar 
vertebra corpus at the median line (Figure 5).  
 
Figure 5: Sonographic-based measurement of visceral adipose tissue. 
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All measurements were performed manually by the same examiner at the end of 
normal expiration applying minimal pressure without displacement of the abdominal 
contents as observed by the ultrasound image. The parameters assessed were 
extracted manually from the images with the electronic onboard caliper and stored in a 
database. Reproducibility of the ultrasonographic quantification of VAT and SAT was 
assessed by examining each participant twice by two observers, each using the same 
examination protocol. The examinations were performed consecutively without any other 
examinations in-between. The second observer was blinded to the results of the first 
observer. The VSR was calculated by dividing visceral thickness in centimeters by 
subcutaneous thickness in centimeters. 
2.2.2 MRI-based measurement of visceral and subcutaneous adipose tissue 
MRI was performed with a clinical whole body 3T system (Magneton Sykra, 
Siemens Healthcare, Erlangen, Germany). Subjects were placed in supine position and 
three T1-weighted turbo spin echo, water suppressed, transaxial slices with a thickness 
of 10 mm were acquired and centered on the L2-L3 vertebral body as well as 10 mm 
above (L2-L3+) and 10 mm below (L2-L3-) by trained radiographers. The in-plane 
resolution was 1.3 × 1.3 mm, field of view 500 × 500 mm, repetition time = 400 ms, echo 
time = 21 ms, 2 averages, 3 concatenations. The software analyze 11.0 (BIR; Mayo 
Clinic, Rochester, MN) was used to quantify VAT and SAT areas. Areas of VAT and 
SAT were calculated using a semi-automated method and a threshold map in 
combination with manual input to distinguish between the VAT and SAT compartments 
(Figure 6). To avoid inter-reader variation, all images were reviewed and calculations 
performed by the same person. Because the ultrasound-based parameters are one-
dimensional and the MRI measures are two-dimensional, the validity of ultrasound 
measurement to predict VAT and SAT cannot be directly assessed. Thus, in addition to 
the calculated area of VAT and SAT, MRI images of VAT and SAT thicknesses were 
determined using the MicroDicom Viewer. 
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Figure 6: MRI-based measurement of visceral and subcutaneous adipose tissue. 
VAF=visceral adipose tissue (red circled); SAF=subcutaneous adipose tissue (green and yellow circled). 
 
 
2.2.3 Anthropometric measurements 
Height in centimeters and weight in kilograms were measured with two decimal 
places using a digital measuring station (seca285 measuring station, SECA, Hamburg, 
German). Participants were wearing underwear without shoes and were positioned on 
the measurement station according to the GNC anthropometric SOP. BMI was 
calculated by dividing body weight in kilograms by height in meters squared. WC in 
centimeters was measured using an inelastic tape (SECA measuring tape 201, SECA, 
Hamburg, Germany) with two decimal places and was measured at the mid-point 
between the lower rib and the iliac crest. Measurements were taken with the participant 
standing in an upright position (Figure 3). 
2.2.4 Blood and urine measurements 
Venous blood was drawn by qualified medical staff. Blood was immediately 
fractionated into serum, plasma, buffy coat, and erythrocytes, and aliquoted into 
specimens of 0.5 mL each according to a standardized protocol. During blood 
withdrawal and processing, time and room temperature were steadily documented. The 
serum specimens were tilted twice and kept at room temperature for 30 minutes before 
they were centrifuged by 2500g for exactly 10 minutes at 15°C. Serum aliquots of 0.5 
mL each were stored at -80°C. Serum concentrations of TNF-α, IL-6, resistin, and 
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adiponectin were measured by an external laboratory (Synlab, Labordienstleistungen, 
Labor Zentrum München) using an enzyme linked immunosorbent assay (ELISA) 
(Immundiagnostik, Bensheim, Germany), hs-CRP was determined by 
immunonephelometry (Behring Nephelometer II, Dade Behring, Marburg, Germany), 
and creatine was measured using a calorimetric method according to the Jaffé reaction. 
Midstream urine specimens were collected from participants and centrifuged by 2000xg 
for exactly 10 minutes at 15°C. Supernatant urine was immediately stored at -80°C. 
2.2.5 NMR Analyses 
Four hundred microliters of urine were mixed with 200 μL of phosphate buffer, pH 
7.4, and 50 μL of D2O containing 0.75 (w%) 3-trimethylsilyl-2,2,3,3-
tetradeuteropropionate (TSP) as internal standard. Serum specimens (0.5 mL) were 
ultrafiltered at 4000xg for 60 minutes at 8°C using Millipore Amicon 10kDa-Filters, which 
had been prewashed once with 3 mL of distilled water by centrifugation at 4000g for 30 
minutes at 22°C to remove filter preservatives. Subsequently, 400µL of the serum 
ultrafiltrate were mixed with 200 μL of phosphate buffer, pH 7.4, and 50 μL of D2O 
containing 0.75 (w%) TSP. NMR experiments were carried out on a Bruker Avance III 
600 MHz spectrometer employing a triple-resonance (1H, 13C 31P, 2H lock) cryogenic 
probe equipped with z-gradients and an automatic sample changer. All spectra were 
acquired following established protocols (163). For each sample, the probe was 
automatically locked, tuned, matched, and shimmed, using shim files optimized for urine 
and serum as starting point for the automated shimming procedure.  
All spectra were measured at 298 K, and every sample was allowed to equilibrate 
for 5 minutes in the magnet before measurement. 1D 1H and 2D 1H−13C heteronuclear 
single quantum coherence (HSQC) spectra of each sample were automatically collected 
using the Bruker automated acquisition suite ICON-NMR. 1D 1H NMR spectra were 
obtained using a 1D nuclear Overhauser enhancement spectroscopy (NOESY) pulse 
sequence with presaturation during relaxation and mixing time and additional spoil 
gradients for water suppression. 1D spectra were automatically Fourier transformed and 
phase corrected, applying a line broadening of 0.3 Hz and zero filling to 128k points. A 
flat baseline was obtained by using the “baseopt” option of the program TopSpin, which 
performs a correction of the first points of the free induction decay (FID). For the 2D 
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HSQC spectra, water suppression was achieved using presaturation during the 
relaxation delay. 2D spectra were semi-automatically processed employing a 90o shifted 
squared sine-bell window function in both dimensions. For increased resolution in the 
indirect dimension, forward linear prediction was used to double the number of data 
points prior to Fourier transformation. Spectra were manually phase corrected and a 
polynomial baseline correction was applied. All spectra were chemical shift referenced 
relative to the TSP signal.  
Signal assignment was performed by overlaying 1D and 2D spectra with reference 
spectra of pure compounds taken in most cases from the commercially available Bruker 
Biofluid Reference Compound Database BBIOREFCODE 2-0-3. Assignments were 
validated by high-resolution 2D 1H-13C HSQC, 2D 1H-13C HMBC and 2D 1H-1H TOCSY 
spectra. 
2.2.6 Targeted metabolomics approach 
Employing the Analytical Profiler module of AMIX 3.9.13 (BrukerBioSpin), 30 urine 
and 20 serum metabolites were quantified by integrating well-resolved signals of these 
metabolites in the acquired 2D 1H-13C HSQC and 1D 1H spectra relative to the TSP 
reference signal. From the obtained relative integrals, absolute concentrations were 
calculated employing individual peak calibration factors using the NMR quantification 
tool MetaboQuant (164). All metabolites quantitated yielded concentration values at or 
above the individual lower limits of quantification (LLOQ) for at least 10% of the spectra. 
For a detailed list of the 30 urinary metabolites quantitated and the corresponding 
information for the 20 serum metabolites can be found in Table 2 and Table 3.  
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Table 2: Sex-dependent urinary metabolite concentrations. 
Metabolite 
(µmol/mmol creatinine) 
LLOQ 
Total Men Women 
conc. range N/228 conc. range N/107 conc. range N/121 
min max 
 
min max 
 
min max 
 
²Alanine 0.078 6.52 76.70 227 6.52 76.70 106 6.91 70.73 121 
²Glycine 0.156 13.06 923.12 204 28.99 341.51 92 13.06 923.12 112 
²Taurine 0.312 17.44 324.20 88 17.44 186.10 60 18.71 324.20 28 
²Glutamine 0.312 19.10 98.87 80 19.83 82.58 49 19.10 98.87 31 
²3-Methylhistidine 0.078 7.25 650.17 125 7.25 406.68 68 9.84 650.17 57 
²Betaine 0.078 2.76 109.74 112 6.14 54.68 63 2.76 109.74 49 
²Phenylcompound* 0.141 17.12 416.80 154 17.12 416.80 71 21.16 274.71 83 
²Serine 0.281 13.18 323.41 65 27.77 323.41 42 13.18 139.48 23 
²D-Glucose 0.563 36.27 593.79 45 40.14 593.79 26 36.27 467.01 19 
²Choline+ 0.141 6.71 97.19 90 10.93 97.19 59 6.71 55.48 31 
²Lactic acid 0.078 5.94 954.05 97 9.04 512.95 44 5.94 954.05 53 
²Methanol 0.141 4.17 217.43 78 8.42 155.69 31 4.17 217.43 47 
²Ascorbic acid 0.312 13.15 1125.48 55 17.92 1125.48 27 13.15 569.02 28 
²Creatine 0.156 7.83 1131.94 68 7.83 391.44 22 11.07 1131.94 46 
²L-Pyroglutamic acid 0.312 12.98 106.57 32 16.48 59.15 16 12.98 106.57 16 
²Hippuric acid 0.312 20.02 1947.11 208 20.02 1467.01 93 25.43 1947.11 115 
²Ethanolamine 0.312 14.69 190.90 101 18.45 95.71 57 14.69 114.18 44 
²Trimethylamine-N-oxide 0.039 7.40 494.26 210 7.40 494.26 100 10.84 166.39 110 
²Citricacid 0.312 50.52 838.99 212 54.30 654.03 94 50.52 838.99 118 
²Dimethylamine 0.156 19.26 98.70 130 20.90 98.70 76 19.26 77.10 54 
²D-Mannitol 0.268 21.46 1138.04 130 21.46 1138.04 66 21.99 717.36 64 
²Guanidinoacetic acid 0.312 16.43 171.40 78 16.43 104.02 38 16.75 162.41 40 
²Glycolic acid 0.312 23.78 137.74 97 36.03 114.23 59 23.78 137.74 38 
1Formic acid 0.003 3.97 188.19 227 4.02 59.89 106 3.97 188.19 121 
1Tyrosine 0.002 0.82 31.53 196 2.09 31.53 95 0.82 24.85 101 
Methods 
 
 
2
4
 
Table 2 continued: Sex-dependent urinary metabolite concentrations. 
Metabolite 
(µmol/mmol creatinine) 
LLOQ 
Total Men Women 
conc. range N/228 conc. range N/107 conc. range N/121  
min max  min max  min max  
1Fumaric acid 0.002 0.08 4.36 107 0.08 1.94 50 0.13 4.36 57 
1Orotic acid 0.002 0.11 12.32 68 0.11 12.32 38 0.15 1.45 30 
1Leucine 0.002 0.54 11.56 217 0.54 7.35 106 1.13 11.56 114 
1N,N-Dimethylglycine 0.020 2.38 17.99 157 2.50 13.40 80 2.38 17.99 77 
1Trigonelline 0.020 0.87 187.33 196 0.87 133.54 90 1.11 187.33 106 
All metabolites were quantified by 1D or 2D nuclear magnetic resonance spectroscopy: 
1
Metabolites quantified from 1D spectra, ²Metabolites quantified from 2D spectra, 
LLOQ=lower limit of quantification, conc.=concentration, min=minimum, max=maximum, N=number of values above LLOQ. 
*Concentrations are influenced by Phenylalanine, Phenylacetyl-glycine und Phenylacetyl-glutamine. 
+
Choline concentrations are likely to be influenced by other compounds including creatinine.  
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Table 3: Sex-dependent serum metabolite concentration. 
Metabolite  
(µmol/L) 
LLOQ 
Total Men Women 
conc. range N/200 conc. range N/90 conc. range N/110 
min max 
 
min max 
 
min max 
 
²Alanine 0.078 144.94 596.96 200 144.94 596.96 90 174.20 576.65 110 
²Glycine 0.156 157.63 535.34 157 158.13 535.34 71 157.63 445.24 86 
²Glutamine 0.312 316.92 800.05 186 322.97 718.42 81 316.92 800.05 105 
²D-glucose 0.563 2614.40 10283.96 200 2628.09 10006.38 90 2614.40 10283.96 110 
²Lactic acid 0.078 875.12 3865.71 200 937.85 3205.56 90 875.12 3865.71 110 
²Methanol 0.141 142.84 401.21 105 144.98 401.21 55 142.84 364.13 50 
1L-isoleucine 0.002 24.06 120.62 200 24.06 120.62 90 29.57 119.39 110 
1Threonine 0.002 26.28 205.32 200 47.30 200.00 90 26.28 205.32 110 
1Valine 0.002 118.01 348.86 200 118.01 346.28 90 146.22 348.86 110 
1Acetone 0.002 5.60 197.62 200 5.60 197.62 90 8.11 106.92 110 
1Formic acid 0.003 5.23 63.52 200 5.23 41.78 90 5.72 63.52 110 
1Tyrosine 0.002 23.81 123.39 200 26.03 123.39 90 23.81 109.13 110 
1Pyruvic acid 0.001 8.33 132.23 200 8.33 64.89 90 9.53 132.23 110 
1Creatinine 0.003 35.33 148.86 200 35.55 120.32 90 35.33 148.86 110 
1Acetic acid 0.003 7.79 87.69 200 8.96 87.69 90 7.79 83.55 110 
1Creatine 0.005 6.36 148.87 200 6.36 123.24 90 7.06 148.87 110 
1Ketoleucin 0.001 2.58 11.00 150 2.63 10.69 70 2.58 11.00 80 
1Phenylalanine 0.003 13.63 72.95 184 14.21 71.39 83 13.63 72.95 101 
1Leucine 0.003 45.78 202.29 200 45.78 202.29 90 55.84 189.02 110 
13-Hydroxybutyric acid 0.002 9.48 978.88 189 9.48 978.88 87 10.42 329.56 102 
All metabolites were quantified by 1D or 2D nuclear magnetic resonance spectroscopy: 
1
Metabolites quantified from 1D spectra, ²Metabolites quantified from 2D spectra, 
LLOQ=lower limit of quantification, conc.=concentration, min=minimum, max=maximum, N=number of values above LLOQ. 
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2.2.7 Untargeted metabolomics approach 
The untargeted approach involves a large number of metabolites and does not 
depend upon a priori assumptions. Urinary and serum data sets were subjected to a 
comparable pre-processing routine, starting with equidistant binning of the 1D 1H 
spectra to compensate for slight shifts in signal positions across spectra due to small 
variations in sample pH, salt concentration, or temperature. The spectral regions 
9.5−0.5 ppm were evenly split into bins of 0.01 ppm, employing Amix 3.9.13 
(BrukerBioSpin). The region between 6.2−4.6 ppm, which contains the broad urea and 
water signals, was excluded, resulting in a total of 740 spectral bins. After exclusion of 
additional bins that had yielded in less than 90% spectra signals, a total of 701 urinary 
bins remained. In case of serum, the region corresponding to residual glycerol, which 
served as a filter preservative (3.81–3.76 ppm, 3.68–3.52 ppm), was excluded in 
addition, resulting in 678 bins. All urine metabolites were scaled and normalized to 
creatinine, and serum samples were scaled and normalized to the reference signal 
(TSP) to remove disturbing technical or biological variances. 
Chemical compounds in biological specimens were identified by their characteristic 
peak patterns and signal positions in the NMR spectra using reference spectra from the 
commercially available Bruker Biofluid Reference Compound Database BBIOREFCODE 
2-0-3 and the Human Metabolome Database (HMDB). The HMDB is an extensive, freely 
available electronic database that stores >40,000 different metabolite entries, with 
exhaustive biological metadata and NMR spectral references (165). Bins were identified 
when relations of adiposity measures to urinary or serum bins were statistically 
significant and reproduced in sensitivity analyses. Confirmation of metabolite 
identification was achieved by spike-in experiments. Specifically, 2.5 millimolar standard 
solutions were added to serum or urine and spectra checked for increase of the 
corresponding signals. In addition, concentrations of well-resolved compounds were 
calculated using calibration curves that had been generated from serially diluted external 
standards over a concentration range of 0.0012 – 10.0 mmol/L. For compounds like 
urinary creatinine that exceed this concentration range in some instances spike-in 
experiments were used to verify that measurements were still in the linear range. 
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 Covariate assessment 2.3
Data were collected by certified personnel with respect to participants’ socio-
demographic characteristics, medical history, health related behavior, and lifestyle 
factors. Potential confounding variables including age, sex, current smoking status, 
physical activity, fasting status (overnight fasting), use of aspirin or non-steroidal anti-
inflammatory drugs (NSAIDs) (WHO Anatomical Therapeutic Chemical (ATC) 
Classification System codes: A01AD05, B01AC06, N02BA01), and menopausal status 
(women only) were assessed by standardized computer-assisted personal interviews. 
Physical activity levels were calculated from Metabolic Equivalents of Task (METs) by a 
24-hour physical activity recall (166). The estimated glomerular filtration rate (eGFR) 
was calculated from serum creatinine using the four-variable Modification of Diet in 
Renal Disease (MDRD4) (167). Overnight fasting status (yes or no) was determined 
from self-reports of the participants before collecting urine and blood specimens. 
 Statistical analyses  2.4
For each study aim, descriptive statistics were used to characterize the study 
population. Arithmetic means (and standard deviations) were provided for continuous 
variables and percent values for categorical variables. In addition, the target population 
of the inflammation study was directly standardized to the age distribution of the study 
population and stratified by VAT and SAT tertiles. Differences between men and women, 
lean (BMI≤25.0 kg/m²) and overweight/obese (BMI>25.0 kg/m²) individuals, smokers 
and non-smokers, users and non-users of aspirin or NSAIDs, fasting and non-fasting 
participants, subjects with elevated urinary glucose and subjects with no urinary glucose 
were tested using Kruskal-Wallis and χ² tests. In sensitivity analyses, age and sex 
interaction was examined by fitting multiplicative interaction terms in the regression 
models and testing their significance using likelihood ratio tests. All reported p values 
are two-tailed and values <0.05 were deemed statistically significant. IBM SPSS 19.0 
and the statistical software R version 3.1.2 were used for analyses.  
2.4.1 Reproducibility study  
The test-retest reliability of ultrasound-based measurements of VAT and SAT was 
quantified using intra-class correlation coefficients (ICC) with 95% confidence intervals 
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(CI), estimated using a linear random effects model (168). The intra-rater reproducibility 
for VAT and SAT was assessed by comparing the mean of the two measurements from 
image 1 and the mean of the two measurements from image 2. Inter-rater reproducibility 
was calculated by comparing the mean of 4 measurements from two images by 
observer 1 and the mean of 4 measurements from two images by observer 2. Results 
were classified as high, modest, and low when ICC≥0.8, ICC≥0.7-0.79 and ICC≤0.69, 
respectively (169). The Bland-Altman method was used to illustrate the difference 
between the two measurements for each sample (vertical axis) and the average of the 
two measurements (horizontal axis) (170). In addition, three horizontal reference lines 
represent the mean difference between the measurements and the upper and lower 
control limits of the standard deviation. Results were regarded as strong agreement of 
intra- and inter-rater reproducibility when 5% or fewer values were seen outside the 
upper and lower levels of agreement. Findings were rated as good agreement when 
10% or fewer values were seen outside the upper and lower levels of agreement (171).  
2.4.2 Validity study  
The validity of the sonographic-based quantification of VAT and SAT was 
assessed by comparing VAT and SAT thicknesses with VAT and SAT areas at 
vertebrae L2/L3 as obtained by three single MRI slices. In addition to the calculated area 
of VAT and SAT, thicknesses of MRI measured VAT and SAT were also compared to 
ultrasound measured VAT and SAT thicknesses. The VAT and SAT thicknesses on the 
MRI slice and those for the ultrasound measures were based on the same anatomical 
landmarks. Validity was examined calculating ICCs with 95% CI and Bland-Altman plots 
were produced when possible to show the difference between the two methods of 
measuring VAT and SAT thicknesses with ultrasound and MRI. For the evaluation of the 
ICCs with 95% CI and Bland-Altman plots, the same classification as in the 
reproducibility study was applied (high: ICC≥0.8; modest: ICC≥0.7-0.79; low: ICC≤0.69; 
strong agreement of Bland-Altman plots: disagreement ≤5%; good agreement of Bland-
Altman plots: disagreement ≤10%) (169-171). In addition, Spearman’s rank ordered 
correlation coefficient (ρ) was calculated to evaluate the correlation between thicknesses 
and area parameters of VAT and SAT. Correlation coefficients were classified as high 
when ρ≥0.8, as modest when ρ≥0.7-0.79, and as low when ρ≤0.69 (169, 172).  
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2.4.3 Inflammation study  
The relation of body composition to parameters of chronic inflammation was 
examined by associating VAT, SAT, VSR, BMI, and WC with the inflammatory 
parameters hs-CRP, TNF-α, IL-6, resistin, and adiponectin. To assure that distributions 
follow an approximate normal distribution, hs-CRP, TNF-α, IL-6, resistin, and 
adiponectin were logn transformed. Partial correlation coefficients were calculated 
between inflammatory parameters adjusted for age (continuous), sex (men, women), 
smoking status (current, former, never smokers), physical activity (continuous), 
menopausal status (pre-, peri-, or postmenopausal), and aspirin or NSAID use (drug use 
during the past 7 days: yes; no).  
Multiple linear regression analysis was performed to estimate relations of VAT, 
SAT, VSR, BMI, and WC (independent variables) to log hs-CRP, log IL-6, log TNF-α, log 
resistin, and log adiponectin (dependent variables). Model 1 was adjusted for age 
(continuous), sex (men, women), smoking status (currently smoking; non-smoking), 
physical activity (continuous), menopausal status (pre-, peri-, or postmenopausal), and 
aspirin or NSAID use (drug use during the past 7 days: yes; no). In a second model, all 
parameters of chronic inflammation were mutually adjusted, in addition to the 
adjustments described in the first model. In a third model, VAT and SAT were mutually 
adjusted and BMI and WC were mutually adjusted. Also, exploratory analyses were run 
stratified by sex, BMI, smoking status, and aspirin or NSAID use. Before fitting the linear 
regression models, all variables (independent and dependent) were standardized by 
subtracting the mean and dividing by the standard deviation to assure that effect sizes 
are comparable across regression models. When reporting the results from the linear 
regression models, ß-coefficients were considered weak (ß≤0.3), moderate (ß>0.3-
≤0.6), or strong (ß>0.6) (173).  
2.4.4 Metabolomics studies   
An untargeted metabolomics approach was used to detect relations of VAT, SAT, 
VSR, BMI, and WC, respectively, to individual bins of urinary and serum metabolic 
fingerprints. For the detection of unbalanced regulation of compounds, the total spectral 
area for each NMR spectrum was calculated and tested for normal distribution using the 
Shapiro-Wilk test (174). To reduce heteroscedasticity, urinary and serum metabolic data 
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were normalized using variance stabilization (VSN) with 60% of the urinary and 65% of 
the serum features, respectively. To detect general trends in the data and to reduce the 
large amount of metabolic data, cluster analysis was performed. Thereby, subjects with 
similar metabolic profiles are grouped into clusters. Subsequently, clusters were 
investigated to detect whether these clusters, which differ in their metabolic profile, also 
differ regarding the obese phenotype. Affinity propagation (AP) clustering was used to 
determine clusters by taking negative squared Euclidean distances as input measures of 
similarity between pairs of data (175). AP clustering algorithm automatically finds a 
subset of exemplar points, which can best describe the data groups by exchanging 
messages. Each data point is assigned to its nearest exemplar with the aim of splitting a 
whole data set into clusters. Thereby, the maximization of the overall sum of the 
similarities between data points and their exemplars is obtained. Input preferences were 
set to q=0.1 to obtain a minimum number of clusters. To detect differences regarding 
distributions of VAT, SAT, VSR, BMI, and WC between clusters compared to the grand 
mean of these adiposity measures, marginal effects at the mean for each cluster were 
estimated using a linear regression model adjusted for age and sex. Predicted mean 
values of VAT, SAT, VSR, BMI, and WC were plotted for each cluster. 
In addition, multiple linear regression analyses were applied to estimate relations 
of VAT, SAT, VSR, BMI, and WC (independent variables) to urinary and serum bins 
(dependent variables). In sensitivity analyses, it was examined whether the model fit 
was improved by inclusion of squared and cubic terms of the independent variables as a 
test of linearity. Multiple linear regression models were adjusted for study (pre-test I 
or II), age (10 year age categories) and sex (men, women) (Model 1). In a second model 
(fully adjusted model), additional adjustments for multiplicative age-sex interaction, 
smoking status (former, current, never smoking), physical activity level (continuous), 
menopausal status (pre-, peri-, postmenopausal), fasting status (overnight fasting: yes, 
no), urinary glucose (elevated glucose: yes, no), and eGFR (continuous) were applied 
(Model 2). Stratified analyses were performed regarding sex, fasting status, and 
elevated urinary glucose. 
Multiple linear regression models were also used to examine associations of VAT, 
SAT, VSR, BMI, and WC to the quantified urinary and serum metabolite concentrations 
using a targeted metabolomics approach. In addition, a third regression model (mutually 
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adjusted model) was applied to mutually adjust for VAT and SAT, VSR and BMI, and 
BMI and WC respectively, in addition to the adjustments in Model 2 (Model 3). Prior to 
further analyses, quantified metabolites were log2 transformed to achieve normally 
distributed data and to reduce heteroscedasticity. To account for the considerable 
amount of values below the LLOQ of some metabolites among the set of quantified 
urinary and serum metabolites (Tables 2 and 3), linear regression models were only 
calculated for those metabolites, for which at least 75% of data were available. 
Otherwise, metabolites were dichotomized as detectable and undetectable and logistic 
regression models were calculated considering the same adjustment variables as 
described for linear models. Pearson correlations between all quantified, log2 
transformed metabolites were calculated. Pearson correlation coefficients were 
considered weak (r<0.4), moderate (r≥0.4-<0.6), or strong (r≥0.6) (173). Among serum 
metabolic data, logistic regression models were additionally calculated to detect 
differences between the age and sex-specific lower and upper quartiles of VAT, SAT, 
VSR, BMI, and WC (dependent variables) regarding quantified serum metabolite 
concentrations (independent variables).  
In order to increase the comparability of results from both, targeted and untargeted 
regression models, all variables (independent and dependent) were standardized by 
subtracting the mean and dividing by the standard deviation. Regression models were 
calculated for each bin or metabolite separately. Analyses were corrected for multiple 
testing. Because the analytical metabolomics dataset includes partly highly correlated 
metabolites and to reduce the type II error, multiplicity was corrected by controlling the 
false discovery rate (FDR) according to Benjamini and Hochberg (176) at a level of 5%.  
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3 Results 
 Reproducibility study 3.1
The mean age of the population of the reproducibility study from both study centers 
was 51.15 years and there were 72 women (57%) and 55 men (43%). The mean BMI 
was 26.54 kg/m² and the mean WC was 91.21 cm. Mean VAT thickness measured by 
ultrasound was 6.82 cm (±3.47 cm) and the mean thickness of SAT was 1.89 cm (Table 
4). 
Table 4: Characteristics of the study population. 
  Min Max Mean (SD) 
Age (years)  20 70 51.15 (13.50) 
VAT thickness US (cm)  2.93 19.08 6.82 (3.47) 
SAT thickness US (cm)  0.52 4.70 1.89 (0.79) 
WC (cm)  64.31 124.84 91.21 (14.01) 
Hip circumference (cm)  83.03 134.07 101.70 (8.95) 
BMI (kg/m²)  17.49 43.75 26.54 (4.70) 
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, WC=waist 
circumference, BMI=body mass index, Min=minimal, Max=maximal, SD=standard deviation, n=127. 
 
Results from the reproducibility study are presented in Table 5. For VAT, the ICCs 
for the intra-rater reproducibility of observers 1 and 2 were 0.996 and 0.999, 
respectively. The Bland-Altman method for comparing the intra-rater reproducibility of 
VAT measurements showed a mean difference of -0.219 mm for observer 1 (8.7% 
disagreement) and a mean difference of -0.087 mm for observer 2 (5.5% disagreement) 
(Supplementary Figure 1). 
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Table 5: Intra- and inter-rater reproducibility of ultrasound-based measurements 
of visceral and subcutaneous fat thickness. 
 Intra-rater reproducibility Inter-rater reproducibility 
 Observer 1 Observer 2 Observer 1 – 2 
 
ICC 
(95 % CI) 
Mean 
difference 
(mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean 
difference 
(mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean 
difference 
(mm) 
(95% LOA) 
VAT 
0.996 
(0.994-0.997) 
-0.219 
(-3.43-2.99) 
0.999 
(0.999-0.999) 
-0.087 
(-3.07-2.89) 
0.998 
(0.997-0.999) 
-0.095 
(-3.57-3.34) 
SAT 
0.992 
(0.988-0.994) 
-0.076 
(-2.08-1.99) 
0.992 
(0.989-0.995) 
0.008 
(-1.95-1.97) 
0.989 
(0.985-0.992) 
0.168 
(-2.13-2.46) 
VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, ICC=Intra-class correlation coefficient, CI=confidence interval, 
LOA=limit of agreement, n=127. 
 
For SAT, the ICCs for the intra-rater reproducibility of observers 1 and 2 were 
0.992 and 0.992, respectively. The mean difference of SAT measurements 
was -0.076 mm for observer 1 (4.7% disagreement) and 0.008 mm for observer 2 (6.3% 
disagreement) (Table 5). The ICCs for the inter-rater reproducibility for SAT and VAT 
were 0.989 and 0.998, respectively. The Bland-Altman method for comparing the inter-
rater reproducibility showed a mean difference of -0.095 mm for VAT measurements 
(3.9% disagreement) and a mean difference of 0.168 mm for SAT measurements (5.5% 
disagreement). Results from the Bland-Altman plots showed no systematic differences 
for the measurements of VAT and SAT (Figure 7). Results for reproducibility were 
similar when both study centers were analyzed separately (Supplementary Table 4). 
Subgroup analyses stratified by BMI, WC, and VAT tertiles showed similar results for 
intra-and inter-rater reproducibility of VAT and SAT measurements (Supplementary 
Table 5). 
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Figure 7: Bland-Altman Plots for the inter-observer agreement between visceral 
adipose tissue respectively subcutaneous adipose tissue measurements. 
(a) Agreement between VAT measurements from observer 1 and 2; (b) Agreement between SAT measurements from observer 1 
and 2; VAT=visceral adipose tissue; SAT=subcutaneous adipose tissue, n=127 
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 Validity study 3.2
The mean age of subjects included in the validation study was 43.50 years. There 
were 16 women (53%) and 14 men (47%), with a mean BMI of 24.87 kg/m² and a mean 
WC of 86.05 cm. The mean VAT area measured by MRI was 114.05 cm². The mean 
VAT thickness was 5.89 cm when measured by MRI and it showed the same value of 
5.89 cm when measured by ultrasound. The mean SAT area measured by MRI was 
130.06 cm². The mean SAT thickness measured by MRI was 1.78cm and it was 1.74 cm 
when measured by ultrasound (Table 6). 
Table 6: Study population characteristics.  
   Min Max Mean (SD) 
Age (years)   20 70 43.50 (16.21) 
VAT area MRI (cm²)   22.89 408.94 114.05 (90.82) 
VAT thickness MRI (cm)   3.52 12.71 5.89 (2.16) 
VAT thickness US (cm)   3.38 13.15 5.89 (2.36) 
SAT area MRI (cm²)   35.64 336.74 130.06 (69.98) 
SAT thickness MRI (cm)   0.47 3.82 1.78 (0.89) 
SAT thickness US (cm)   0.47 3.75 1.74 (0.88) 
WC (cm)   67.20 116.50 86.05 (15.01) 
Hip circumference (cm)   85.50 116.50 98.87 (6.61) 
BMI (kg/m²)   19.48 36.02 24.87 (4.45) 
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, WC=waist 
circumference, BMI=body mass index, Min=minimal, Max=maximal, SD=standard deviation, n=30. 
 
The correlation of VAT thickness as measured by ultrasound with VAT area as 
measured by MRI was 0.898. A comparison of VAT thickness measurements and VAT 
area, both measured by MRI, resulted in a correlation of ρ=0.863 (Table 7). By 
comparison, BMI and WC showed similar correlations with VAT area (BMI: ρ=0.841; 
WC: ρ=0.834). The correlation of SAT thickness measured by ultrasound with SAT area 
measured by MRI was 0.705. A slightly higher correlation of ρ=0.781 was noted 
between SAT thickness and SAT area, both measured by MRI. The correlation 
coefficients of BMI and WC with SAT area were 0.697 and 0.663, respectively.  
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Table 7: Correlation of MRI-based visceral and subcutaneous adipose tissue areas 
with ultrasound-based and MRI-based visceral and subcutaneous adipose tissue 
thicknesses and anthropometric measures of adiposity. 
  
  
 VAT area MRI (cm²)  
 
 SAT area MRI (cm²) 
 ρ p-value   ρ p-value 
 
 VAT thickness US (cm)   0.898 <0.001  SAT thickness US (cm)  0.705 <0.001 
 VAT thickness MRI (cm)   0.863 <0.001  SAT thickness MRI (cm)  0.781 <0.001 
 WC (cm)  0.834 <0.001  WC (cm)  0.663 <0.001 
 Hip circumference (cm)  0.634 <0.001  Hip circumference (cm)  0.717 <0.001 
 BMI (kg/m²)  0.841 <0.001  BMI (kg/m²)  0.697 <0.001 
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, WC=waist 
circumference, BMI=body mass index, r=Spearman correlation coefficient (ρ), n=30. 
 
A comparison of measurements of VAT thickness by ultrasound and MRI yielded 
an ICC of 0.990 (Table 8). The Bland-Altman plot showed a mean difference 
of -0.124 mm (±3.21 mm) for the measurement of VAT. In addition, Bland-Altman plots 
showed no systematic differences between methods when measuring VAT thickness 
(Figure 8). By, comparison, when comparing measurements of SAT thickness by 
ultrasound and MRI, the correlation between the two was 0.976. The Bland-Altman 
method showed a mean difference of 0.392 mm (±1.96 mm) for the measurement of 
SAT and no systematic differences between both methods measuring SAT thickness.  
Table 8: Intra-class correlation between measurements of visceral respectively 
subcutaneous adipose tissue thickness by ultrasound. 
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, ICC=Intra-
class correlation coefficient, CI=confidence interval, LOA=limit of agreement, n=30. 
 ICC (95% CI) Mean difference (mm) (95% LOA) 
VAT thickness (US/MRI) 0.990 (0.979-0.995) -0.124 (-6.42-6.17) 
SAT thickness (US/MRI) 0.976 (0.950-0.988) 0.392 (-3.45-4.24) 
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Figure 8: Bland-Altman Plots on the agreement between MRI and US 
measurements of visceral and subcutaneous adipose tissue. 
(a) Agreement between measurements of VAT thickness by US and MRI; (b) Agreement between measurements of SAT thickness 
by US and MRI; VAT=visceral adipose tissue; SAT=subcutaneous adipose tissue; US=ultrasound; MRI=magnetic resonance 
spectroscopy; n=30. 
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Subgroup analyses stratified by BMI showed slightly weaker correlations in 
overweight/obese than lean subjects for the measurements of VAT (overweight/obese: 
ρ=0.643, lean: ρ=0.777) and SAT (overweight/obese: ρ=0.594; lean: ρ=0.802) 
(Supplementary Table 6-11). By comparison, the correlation between WC and VAT area 
was stronger among overweight/obese (ρ=0.783) than among lean subjects (ρ=0.383). 
Similar relations were found between BMI and VAT area among overweight/obese 
(ρ=0.587) and lean (ρ=0.480) subjects. Relations between WC and SAT area were 
weaker among overweight/obese (ρ=0.070) and lean subjects (ρ=0.398). Also, relations 
between BMI and SAT area were weaker in the group of overweight/obese (ρ=0.189) 
than in lean subjects (ρ=0.527). 
 Inflammation study 3.3
Characteristics of the study population are presented in Table 9 and Table 10. The 
mean age of study participants was 53.49 years. Compared to those in the lower VAT 
tertile, participants in the upper VAT tertile were older (p=0.008), had a higher VSR 
(p<0.001), BMI (p<0.001), and a higher WC (p<0.001) Table 9. There were no 
differences in physical activity levels, smoking, or use of aspirin or NSAIDs according to 
VAT. Participants in the upper SAT tertile were more likely to have higher levels of BMI 
(p<0.001) and WC (p<0.001) but a lower VSR (p<0.001). There were no differences in 
smoking status, physical activity levels, or use of aspirin or NSAIDs according to SAT.  
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Table 9: Characteristics of participants according to tertiles of visceral and subcutaneous adipose tissue. 
Characteristic  VAT    SAT   
 
T1 
(≤5.66 cm) 
T2 
(5.67-≤8.06 cm) 
T3 
(≥8.07 cm) 
p 
value 
T1 
(≤1.62 cm) 
T2 
(1.63-≤2.14 cm) 
T3 
(≥2.15 cm) 
p 
value 
N 32 33 32  32 33 32  
Age (years)  48 55 58 0.008 49 59 52 0.003 
Sex (% men) 29 46 59 0.074 47 44 35 0.719 
VSR 3.1 3.7 5.7 <0.001 5.9 4.3 3.0 <0.001 
BMI (kg/m²)  23.5 26.1 31.6 <0.001 24.0 27.6 29.4 <0.001 
WC (cm)  80.9 90.1 105.0 <0.001 84.1 92.6 97.6 <0.001 
Smoking (%) 24 19 19 0.923 24 23 14 0.788 
Physical activity level 1.7 1.7 1.7 0.903 1.7 1.8 1.7 0.716 
Use of aspirin or 
NSAIDs (%) 
5 21 21 0.165 11 19 16 0.634 
Entries are mean (standard deviation) for continuous variables and percentages for categorical variables. VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-
to-subcutaneous-fat ratio, BMI=body mass index, WC=waist circumference, T1-3=tertiles of VAT, respectively SAT, n=97, p-value from Kruskal-Wallis test (continuous variables) or Χ² test 
(categorical variables). 
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The mean concentrations of selected parameters of chronic inflammation were 
similar in men and women, with the exception of adiponectin, which was higher in 
women than men (p=0.003) (Table 10). In addition, differences between lean and obese 
subjects were found for hs-CRP (p<0.001) and IL-6 (p=0.020) concentrations. Smokers 
and non-smokers showed differences in mean hs-CRP (p=0.031) and adiponectin 
(p=0.047) concentrations, and aspirin or NSAID users differed in their mean hs-CRP 
concentration (p=0.009) (Supplementary Table 12). 
 
Table 10: Sex-dependent distribution of age, anthropometric variables, and 
concentrations of inflammatory markers. 
 
Total 
Mean (SD) 
Women 
Mean (SD) 
Men 
Mean (SD) 
p-value 
Age (years) 53.49 (12.41) 55.55 (10.18) 50.81 (14.52) 0.188 
VAT (cm) 7.48 (3.48) 6.79 (3.22) 8.39 (3.64) 0.009 
SAT (cm) 1.98 (0.82) 2.05 (0.77) 1.89 (0.89) 0.207 
VSR 4.27 (2.47) 3.61 (2.12) 5.12 (2.64) 0.001 
BMI (m/kg²) 26.94 (4.68) 26.46 (4.91) 27.57 (4.39) 0.201 
WC (cm) 91.51 (13.86) 86.60 (12.30) 97.83 (13.30) <0.001 
hs-CRP (mg/dl) 0.17 (0.19) 0.15 (0.12) 0.20 (0.26) 0.878 
TNF-α (pg/ml) 6.49 (2.31) 6.18 (2.10) 6.89 (2.53) 0.101 
IL-6 (pg/ml) 2.67 (3.76) 2.42 (2.48) 3.00 (4.97) 0.051 
Resistin (ng/ml) 3.56 (1.12) 3.49 (1.16) 3.65 (1.07) 0.457 
Adiponectin (µg/ml) 12.00 (5.28) 14.04 (5.25) 9.34 (4.04) 0.003 
Entries are mean value (standard deviation). VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-to-
subcutaneous-fat ratio, BMI=body mass index, WC=waist circumference, n=97 (women: n=55; men: n=42), p-value from Kruskal-
Wallis test. 
 
Hs-CRP was positively correlated with TNF-α (r=0.21; p=0.04) but was not 
correlated with IL-6, resistin, or adiponectin (Table 11). After adjustment for age, sex, 
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smoking, physical activity, menopausal status and aspirin or NSAID use, the only 
significant partial correlation that was found was between adiponectin and TNF-α 
(r=0.31; p=0.02). 
 
Table 11: Correlation matrix with selected parameters of systemic chronic 
inflammation. 
 log hs-CRP log TNF-α log IL-6 log Resistin 
log hs-CRP     
Model 1 1    
Model 2 1    
log TNF-α     
Model 1 r=0.21, p=0.04 1   
Model 2 r=0.18, p=0.15 1   
log IL-6     
Model 2 r=0.16, p=0.11 r=0.10, p=0.34 1  
Model 2 r=0.11, p=0.42 r=-0.07, p=0.58 1  
log Resistin     
Model 2 r=0.10, p=0.30 r=0.09, p=0.37 r=-0.01, p=0.90 1 
Model 2 r=0.09, p=0.52 r=-0.01, p=0.97 r=0.03, p=0.84 1 
log Adiponectin    
Model 1 r=-0.14, p=0.16 r=0.06, p=0.53 r=-0.00, p=0.97 r=0.06, p=0.56 
Model 2 r=-0.11, p=0.41 r=0.31, p=0.02 r=0.02, p=0.89 r=0.08, p=0.53 
Model 1: Pearson correlation between parameters of systemic chronic inflammation. 
Model 2: Pearson correlation between parameters of systemic chronic inflammation adjusted for age, physical activity level, sex, 
menopausal status (women only), smoking, and aspirin or NSAID use. 
 
Multiple linear regression analyses adjusted for age, physical activity level, sex, 
smoking, menopausal status, and aspirin or NSAIDs but unadjusted for parameters of 
systemic chronic inflammation (Model 1) showed that VAT was positively associated 
with hs-CRP (ß=0.12; p=0.004), IL-6 (ß=0.33; p=0.002) and inversely associated with 
adiponectin (ß=-0.20; p=0.048) (Table 12). SAT was positively associated with hs-CRP 
(ß=0.60; p=0.0005) but it was unrelated to any of the other parameters. VSR was 
inversely related to resistin (ß=-0.31; p=0.023). No associations were found between 
VSR and any of the other parameters. BMI showed positive associations with hs-CRP 
(ß=0.39; p=0.004) and IL-6 (ß=0.22; p=0.034). An inverse association was found 
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between BMI and adiponectin (ß=-0.32; p=0.002). WC was positively associated with 
hs-CRP (ß=0.46; p=0.001) and inversely associated with adiponectin (ß=-0.28; 
p=0.012). 
 
Results 
 
 
4
3
 
Table 12: Relations of adiposity measures to inflammatory parameters. 
 
VAT SAT VSR BMI WC 
ß p ß p ß p ß p ß p 
log hs-CRP           
Model 1 0.12 0.004 0.60 0.0005 -0.06 0.657 0.39 0.004 0.46 0.001 
Model 2 0.33 0.02 0.42 0.001 -0.08 0.608 0.36 0.013 0.41 0.006 
Model 3 0.17 0.25 0.35 0.01 -0.19 0.183 0.05 0.88 0.36 0.26 
log TNF-α           
Model 1 0.14 0.31 -0.07 0.61 0.13 0.263 0.01 0.94 0.08 0.61 
Model 2 0.16 0.27 -0.11 0.44 0.13 0.244 0.05 0.73 0.07 0.69 
Model 3 0.22 0.15 -0.19 0.22 0.13 0.269 -0.05 0.88 0.11 0.76 
log IL-6           
Model 1 0.33 0.002 0.13 0.22 0.02 0.910 0.22 0.034 0.14 0.32 
Model 2 0.22 0.12 0.17 0.23 0.05 0.745 0.11 0.44 0.13 0.42 
Model 3 0.18 0.24 0.10 0.50 0.01 0.942 0.03 0.92 0.10 0.77 
log Resistin           
Model 1 -0.09 0.49 0.15 0.26 -0.31 0.023 -0.05 0.73 -0.05 0.74 
Model 2 -0.14 0.38 0.15 0.33 -0.31 0.030 -0.07 0.66 -0.09 0.62 
Model 3 -0.22 0.20 0.22 0.18 -0.32 0.034 0.04 0.91 -0.13 0.74 
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Table 12 continued: Relations of adiposity measures to inflammatory parameters. 
 VAT SAT VSR BMI WC 
 ß p ß p ß p ß p ß p 
log Adiponectin           
Model 1 -0.20 0.048 -0.15 0.12 0.03 0.806 -0.32 0.002 -0.28 0.012 
Model 2 -0.19 0.17 -0.12 0.37 -0.01 0.978 -0.28 0.035 -0.18 0.24 
Model 3 -0.16 0.26 -0.06 0.68 0.09 0.493 -0.58 0.035 0.39 0.19 
Model 1 was adjusted for age, physical activity level, sex, smoking, menopausal status (women only), and aspirin or NSAID use. 
Model  2 was adjusted for age, physical activity level, sex, smoking, menopausal status (women only), aspirin or NSAID use, and mutually adjusted for all parameters of systemic chronic 
inflammation. 
Model  3 was adjusted for age, physical activity level, sex, smoking, menopausal status (women only), aspirin or NSAID use, and mutually adjusted for all parameters of systemic chronic 
inflammation and mutually for VAT and SAT, VSR and BMI, and BMI and WC respectively. VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-to-
subcutaneous-fat ratio, BMI=body mass index, WC=waist circumference. ß=standardized linear regression coefficient, p=p-value. 
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After mutual adjustment of parameters of systemic chronic inflammation (Model 2), 
VAT remained significantly associated with hs-CRP but not with IL-6 or adiponectin 
(Table 12). Likewise, SAT was associated with hs-CRP after adjustment for the other 
inflammatory parameters. VSR remained significantly inversely related to resistin and 
BMI remained significantly associated with hs-CRP and adiponectin. WC remained 
significantly associated with hs-CRP. When VAT and SAT were simultaneously included 
in the model (Model 3), only SAT remained significantly associated with hs-CRP. After 
mutually adjusting for VSR and BMI, VSR remained significantly inversely related to 
resistin when BMI was additionally included in the model. When BMI and WC were 
simultaneously included in the model, BMI remained significantly inversely related to 
adiponectin. 
Results from sex-stratified analyses are presented in Table 13. In women, an 
inverse association was noted between BMI and adiponectin (ß=-0.42; p=0.045). In 
men, VAT and BMI were positively related to IL-6 (ß=0.47; p=0.01 and ß=0.36; p=0.049, 
respectively). No relations were observed between VAT, SAT, VSR, BMI, or WC and 
other inflammatory parameters in men or women, although some sex differences for all 
inflammatory parameters were noted. With the exception of SAT and VSR, relations of 
VAT, BMI, and WC to hs-CRP appeared to be stronger in women than men. VAT, SAT, 
VSR, BMI, and WC were inversely related to TNF-α and to IL-6 in women, whereas in 
men only SAT was inversely related to TNF-α. Relations of VAT, SAT, VSR, BMI, and 
WC to IL-6 were stronger in men than women. 
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Table 13: Associations between adiposity measures with parameters of systemic chronic inflammation in 
subgroups defined by sex, BMI, smoking status, and use of aspirin or NSAIDs. 
 Women (n=55) Men (n=42) 
 
VAT SAT VSR BMI WC VAT SAT VSR BMI WC 
ß p ß p ß p ß p ß p ß p ß p ß p ß p ß p 
log hs-
CRP 
0.18 0.40 0.22 0.24 0.04 0.86 0.19 0.42 0.21 0.31 0.03 0.90 0.31 0.14 -0.22 0.23 0.12 0.58 0.19 0.39 
log 
TNF-α 
-0.03 0.89 -0.14 0.49 -0.06 0.76 -0.22 0.38 -0.24 0.32 0.32 0.18 -0.05 0.85 0.12 0.58 0.23 0.32 0.30 0.17 
log 
IL-6 
-0.17 0.93 -0.03 0.84 -0.01 0.98 -0.15 0.43 -0.14 0.46 0.47 0.01 0.25 0.19 0.16 0.37 0.36 0.049 0.33 0.09 
log Re-
sistin 
0.11 0.67 0.28 0.23 -0.20 0.40 0.14 0.63 -0.19 0.85 -0.44 0.07 0.02 0.95 -0.36 0.08 -0.25 0.32 -0.22 0.39 
log 
Adipo-
nectin 
-0.30 0.14 0.05 0.79 -0.28 0.13 -0.42 0.045 -0.16 0.47 -0.27 0.26 -0.22 0.31 0.11 0.60 -0.35 0.11 -0.30 0.19 
 BMI<25.0 kg/m² (n=36) BMI≥25.0 kg/m² (n=61) 
 
VAT SAT VSR BMI WC VAT SAT VSR BMI WC 
ß p ß p ß p ß p ß p ß p ß p ß p ß p ß p 
log hs-
CRP 
0.05 0.83 0.38 0.11 -0.48 0.10 -0.22 0.40 0.22 0.39 0.16 0.41 0.33 0.04 -0.10 0.56 0.32 0.08 0.18 0.37 
log 
TNF-α 
0.05 0.84 0.30 0.29 -0.55 0.10 0.17 0.59 0.25 0.40 0.30 0.17 -0.09 0.62 0.24 0.18 0.19 0.39 0.29 0.16 
log 
IL-6 
0.07 0.65 0.18 0.31 -0.15 0.49 -0.16 0.39 0.08 0.64 0.39 0.03 0.04 0.82 0.19 0.28 0.33 0.13 0.34 0.09 
log Re-
sistin 
-0.11 0.67 0.32 0.26 -0.53 0.11 0.27 0.37 0.06 0.84 -0.22 0.30 0.15 0.46 -0.25 0.15 -0.34 0.14 0.00 0.99 
log 
Adipo-
nectin 
-0.07 0.78 0.28 0.29 0.07 0.82 -0.42 0.10 -0.15 0.60 -0.34 0.08 -0.25 0.18 -0.04 0.84 -0.47 0.02 -0.46 0.01 
Results 
 
 
4
7
 
Table 13 continued: Associations between adiposity measures with parameters of systemic chronic inflammation in 
subgroups defined by sex, BMI, smoking status, and use of aspirin or NSAIDs. 
 Current non-smoking (n=78) Current smoking (n=19) 
 
VAT SAT VSR BMI WC VAT SAT VSR BMI WC 
 
ß p ß p ß p ß p ß p ß p ß p ß p ß p ß p 
log hs-
CRP 
0.18 0.22 0.35 0.01 -0.13 0.37 0.23 0.12 0.22 0.12 0.74 0.001 0.49 0.049 0.56 0.08 0.80 0.00003 0.88 0.0003 
log 
TNF-α 
0.19 0.23 -0.12 0.44 0.19 0.10 0.07 0.65 0.11 0.48 0.34 0.18 -0.25 0.34 0.49 0.09 0.08 0.74 0.29 0.30 
log 
IL-6 
0.36 0.01 0.13 0.39 0.11 0.39 0.29 0.048 0.24 0.10 0.43 0.13 -0.01 0.99 0.28 0.60 0.20 0.46 0.17 0.61 
log Re-
sistin 
-0.18 0.28 0.13 0.41 -0.16 0.23 -0.08 0.66 -0.06 0.74 0.43 0.12 0.42 0.14 -0.40 0.38 0.46 0.08 0.59 0.05 
log 
Adipo-
nectin 
-0.25 0.09 -0.11 0.44 0.02 0.85 -0.34 0.01 -0.27 0.049 -0.27 0.28 -0.09 0.72 0.07 0.86 -0.19 0.43 -0.37 0.18 
 Non-use of aspirin or NSAIDs (n=81) Use of aspirin or NSAIDs (n=16) 
 
VAT SAT VSR BMI WC VAT SAT VSR BMI WC 
 
ß p ß p ß p ß p ß p ß p ß p ß p ß p ß p 
log hs-
CRP 
0.30 0.06 0.41 0.01 0.01 0.92 0.31 0.04 0.31 0.04 0.57 0.04 0.53 0.13 0.29 0.27 0.63 0.12 0.72 0.03 
log 
TNF-α 
0.30 0.049 -0.05 0.74 0.25 0.30 0.17 0.30 0.17 0.28 -0.42 0.27 -0.46 0.30 0.07 0.86 -0.85 0.30 -0.31 0.41 
log 
IL-6 
0.29 0.046 0.15 0.32 0.15 0.23 0.17 0.25 0.12 0.41 -0.27 0.50 -0.78 0.46 0.31 0.44 -0.73 0.66 -0.07 0.87 
log Re-
sistin 
-0.14 0.39 0.16 0.34 -0.10 0.42 -0.03 0.85 0.01 0.93 -0.20 0.90 0.13 0.86 0.05 0.87 0.42 0.67 -0.30 0.89 
log 
Adipo-
nectin 
-0.26 0.08 -0.06 0.73 -0.25 0.83 -0.30 0.04 -0.24 0.10 -0.22 0.84 -0.05 0.93 0.09 0.78 -0.55 0.28 -0.89 0.001 
Models were adjusted for age, physical activity level, sex, menopausal status (women only), smoking, aspirin or NSAID use, and mutually adjusted for all parameters of systemic chronic 
inflammation. In these models, VAT and SAT, respectively VSR and BMI, and BMI and WC were not mutually adjusted. In each case, the stratification variable was excluded from the 
model. VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-to-subcutaneous-fat ratio, BMI=body mass index, WC=waist circumference, ß=standardized linear 
regression coefficient, p=p-value. 
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In non-obese participants, no significant relations were found for VAT, SAT, VSR, 
BMI, or WC to any of the inflammatory parameters (Table 13). In overweight/obese 
participants, VAT showed a positive association with IL-6 (ß=0.39; p=0.03), and SAT 
was positively associated with hs-CRP (ß=0.33; p=0.04). BMI and WC were inversely 
associated with adiponectin (ß=-0.47; p=0.02 and ß=-0.46; p=0.01, respectively). In 
general, VAT and BMI showed stronger relations to inflammatory parameters in 
overweight/obese participants than in normal weight participants, whereas associations 
between SAT and inflammatory parameters were stronger in normal weight than in 
overweight/obese participants.  
In an analysis restricted to current non-smokers, VAT was positively associated 
with IL-6 (ß=0.36; p=0.01) and SAT showed a significant association with hs-CRP 
(ß=0.35; p=0.01) (Table 13). BMI was positively associated with IL-6 (ß=0.29; p=0.048) 
and it showed an inverse association with adiponectin (ß=-0.34; p=0.01). WC also 
showed an inverse association with adiponectin (ß=-0.27; p=0.049). By comparison, in 
an analysis restricted to current smokers, VAT, BMI, and WC showed strong positive 
associations with hs-CRP (ß=0.74; p=0.001, ß=0.80; p=0.00003, and ß=0.88; p=0.0003, 
respectively) and a positive association was found between SAT and hs-CRP (ß=0.49; 
p=0.049). Associations between VAT and inflammatory markers were stronger in current 
smokers than non-smokers. No associations were found between VSR and any of the 
inflammatory parameters in smokers or non-smokers.  
In an analysis limited to non-users of aspirin or NSAIDs, VAT showed positive 
associations with IL-6 (ß=0.29; p=0.046) and TNF-α (ß=0.30; p=0.049) (Table 13). SAT, 
BMI, and WC showed positive associations with hs-CRP (ß=0.41; p=0.01, ß=0.31; 
p=0.04, and ß=0.31; p=0.04, respectively). BMI was inversely related to 
adiponectin (ß=-0.30; p=0.04). In an analysis restricted to participants using aspirin and 
NSAIDs, VAT showed a positive association with hs-CRP (ß=0.57; p=0.04). WC showed 
a positive association with hs-CRP (ß=0.72; p=0.03) and an inverse association with 
adiponectin (ß=-0.89; p=0.001). In general, VAT, SAT, BMI, and WC were inversely 
related to TNF-α and IL-6 in aspirin or NSAID users, whereas VAT, BMI, and WC were 
positively related to those parameters in non-users of aspirin and NSAIDs. No significant 
relations were found for VSR to any of the inflammatory in users or non-users of aspirin 
and NSAIDs. 
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 Metabolomics study 3.4
Characteristics of the study population are presented in Table 14. The mean age of 
study participants was 51.96 years and 13.2% of the participants were fasting. Women 
had lower VAT (p<0.001), VSR (p<0.001), BMI (p=0.008) and WC (p<0.001) than men. 
In contrast, women had a higher SAT (p=0.011) than men. Differences between men 
and women, fasting and non-fasting participants as well as between subjects with 
elevated urinary glucose and subjects with no urinary glucose were found for urinary and 
serum metabolites (Supplementary Table 13 and 14). There were no significant 
differences in the distribution of the characteristics between urinary (n=228) and serum 
(n=200) study population.  
 
Table 14: Sex-dependent characteristics of the study population. 
  
Total 
mean (SD) 
Women 
mean (SD) 
Men 
mean (SD) 
p-value 
N   228 121 107  
Age (years)  51.96 (12.55) 52.80 (12.00) 50.97 (13.15) 0.388 
Non-fasting   198 105 93 0.511 
Current smoking  31 12 19 0.075 
Physical activity level*  1.67 (0.27) 1.67 (0.27) 1.68 (0.28) 0.888 
VAT thickness US (cm)   6.79 (2.85) 6.29 (2.80) 7.38 (2.81) <0.001 
SAT thickness US (cm)   2.06 (0.85) 2.17 (0.89) 1.93 (0.78) 0.011 
VSR  3.77 (2.14) 3.23 (1.70) 4.41 (2.41) <0.001 
BMI (kg/m²)   26.61 (4.66) 25.97 (4.99) 27.36 (4.13) 0.008 
WC (cm)   91.16 (13.56) 85.53 (11.99) 97.75 (12.30) <0.001 
Entries are mean (standard deviation) for continuous variables and absolute numbers for categorical variables. VAT=visceral 
adipose tissue, SAT=subcutaneous adipose tissue, BMI=body mass index, WC=waist circumference, US=ultrasonography, n=228. 
*Calculated from Metabolic Equivalents of Task. p-value from Kruskal-Wallis test (continuous variable) or Χ² test (categorical 
variables). 
 
3.4.1 Results from targeted metabolomics approach 
Pearson correlation analyses to assess correlations between metabolites showed 
moderate (r≥0.4) or strong (r≥0.6) correlations between 36% of the urinary metabolites 
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(Figure 9). By comparison, Figure 10 displays Pearson correlation coefficients between 
serum metabolites, showing that 66% of all serum metabolites were weakly correlated 
with one another and only few metabolites (12%) being strongly correlated with one 
another. 
 
Figure 9: Pearson correlation matrix between creatinine-normalized urinary 
metabolite concentrations. 
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Figure 10: Pearson correlation matrix between serum metabolite concentrations. 
 
Linear regression analyses of urinary metabolites revealed significant inverse 
associations of VAT, BMI, and WC with urinary formic acid after adjustment for study, 
age and sex and correcting p-values for multiple testing (Table 15). These associations 
did not remain significant in fully adjusted models considering further adjustments for 
smoking, menopause status, physical activity, urinary glucose, and eGFR (Model 2). 
Logistic regression models of urinary metabolites dichotomized as detectable and 
undetectable showed significant inverse and positive relations of VAT, BMI, and WC to 
urinary metabolites in age and sex adjusted models (Model 1) and in fully adjusted 
models (Model 2). Specifically, VAT was inversely related to the detection of choline 
(ß=-0.18, p=2.73*10-3), guanidinoacetic acid (ß=-0.12, p=0.04), and glycolic acid 
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(ß=-0.20, p=0.02), and positively related to the detection of ethanolamine (ß=0.18, 
p=0.02) and dimethylamine (ß=0.32, p=0.02) in fully adjusted models (Model 2). Note 
that the obtained choline concentrations were most likely influenced by related 
molecules due to the presence of partial overlap in the analyzed NMR spectra. Further, 
BMI and WC were inversely related to the detection of glutamine and lactic acid in fully 
adjusted models (Model 2). Moreover, WC was inversely associated with the detection 
of serine in fully adjusted models (Model 2). However, when obesity measures were 
mutually adjusted (Model 3), only VAT remained significantly inversely related to the 
detection of choline (ß=-0.18; p=0.01) and glycolic acid (ß=-0.20, p=0.046) and 
positively related to the detection of dimethylamine (ß=0.33, p=0.046). No relations were 
found between SAT or VSR and urinary metabolites in any of the analyses. 
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Table 15: Significant# associations between obesity measures and urinary metabolite levels. 
 Metabolite Model1 Model 2 Model 3 
  ß p ß p ß p 
All subjects (n=228) 
VAT Formic acid* -0.09 4.81*10-4 -0.07 0.19 -0.05 0.76 
 Choline -0.12 5.26*10-4 -0.18 2.73*10-3 -0.18 0.01 
 Methanol 0.23 0.01 0.10 0.29 0.14 0.30 
 Ethanolamine 0.15 0.03 0.18 0.02 0.23 0.05 
 Dimethylamine 0.23 0.01 0.32 0.02 0.33 4.69*10-2 
 Guanidinoacetic acid -0.14 0.03 -0.12 0.04 -0.27 0.05 
 Glycolic acid -0.16 0.03 -0.20 0.02 -0.20 4.64*10-2 
        
BMI Formic acid* -0.04 0.03 -0.04 0.20 -0.01 0.92 
 Alanine 0.10 0.01 0.17 0.01 0.01 0.99 
 Betaine -0.10 0.01 -0.13 0.03 -0.00 0.99 
 Choline -0.11 0.01 -0.17 0.01 0.04 0.99 
 Creatine -0.10 0.01 -0.10 0.10 -0.08 0.94 
 Dimethylamine 0.18 5.51*10-4 0.26 0.01 0.11 0.94 
 Ethanolamine 0.13 2.10*10-3 0.15 0.02 0.01 0.99 
 Glutamine -0.12 3.32*10-3 -0.16 0.01 -0.05 0.04 
 Glycolic acid -0.15 6.74*10-4 -0.19 0.01 -0.16 0.60 
 Guanidinoacetic acid -0.14 1.30*10-3 -0.17 0.01 -0.07 0.94 
 Lactic acid -0.08 0.02 -0.16 0.01 -0.09 0.94 
 Methanol 0.12 0.01 0.05 0.36 0.00 0.99 
 Taurine -0.08 0.03 -0.10 0.10 -0.06 0.94 
        
WC Formic acid* -0.02 0.01 -0.02 0.21 -0.01 0.94 
 Alanine 0.05 1.93*10-3 0.07 0.05 0.07 0.08 
 Betaine -0.05 1.67*10-3 -0.05 0.12 -0.05 0.12 
 Choline -0.05 1.67*10-3 -0.08 3.99*10-3 -0.10 0.21 
 Creatine -0.04 0.01 -0.03 0.13 -0.02 0.51 
 Dimethylamine 0.07 7.71*10-5 0.09 3.99*10-3 0.11 0.06 
 Ethanolamine 0.06 6.87*10-4 0.06 0.01 0.06 0.05 
 Glutamine -0.06 8.49*10-4 -0.06 0.01 -0.06 0.87 
 Glycolic acid -0.05 1.67*10-3 -0.06 0.01 -0.06 0.05 
 Guanidinoacetic acid -0.06 6.87*10-4 -0.07 0.01 -0.06 0.05 
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Table 15 continued: Significant# associations between obesity measures and urinary metabolite levels. 
 Metabolite Model1 Model 2 Model 3 
  ß p ß p ß p 
WC Lactic acid -0.03 0.02 -0.06 0.01 -0.05 0.16 
 Methanol 0.03 0.04 0.02 0.30 0.02 0.48 
 Phenylalanine -0.04 0.03 -0.02 0.28 -0.02 0.45 
 Serine -0.04 0.02 -0.05 0.02 -0.04 0.20 
 Taurine -0.03 0.02 -0.04 0.10 -0.02 0.34 
Model 1: linear or logistic regression model adjusted for study, age (non-linear) and sex. 
Model  2: linear or logistic regression model adjusted for study, age and sex interaction (non-linear), smoking status, menopausal status (women only), physical activity, urinary glucose, 
and eGFR. In logistic regression models: 0=metabolite undetected, 1=metabolite detected.    
Model 3: linear regression or logistic model adjusted for all variables from model 2 plus VAT and SAT mutually adjusted and BMI and WC mutually adjusted.  
VAT=visceral adipose tissue, BMI=body mass index, WC=waist circumference, ß=standardized regression coefficient, p-value=corrected for multiple testing by controlling the false 
discovery rate. 
*linear regression model was applied. 
#
p-values<0.05 after correction for multiple testing were considered significant 
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After stratifying by sex, results from logistic regression models showed inverse 
relations of VAT to the detection of choline (ß=-0.18; p=2.73*10-3), glycolic acid 
(ß=-0.58, p=0.04), guanidinoacetic acid (ß=-0.36, p=0.04), lactic acid (ß=-0.32, p=0.04), 
and serine (ß=-0.41, p=0.04) and positive relations to the detection of ethanolamine 
(ß=0.71, p=0.04) and dimethylamine (ß=0.65, p=0.04) in fully adjusted models among 
men (Table 16). These relations remained significant after mutual adjustment for SAT 
(Model 3). By comparison, BMI and WC were additionally inversely associated with the 
detection of betaine and glutamine in fully adjusted models, but no relation was found 
between BMI and serine in fully adjusted models among men. In addition, none of the 
relations remained statistically significant when BMI and WC were mutually adjusted 
(Model 3). No significant associations were found between SAT or VSR and urinary 
metabolites among men. Among women, VAT was inversely associated with formic acid 
(ß=-0.11, p=3.22*10-3) in model 1. However, this relation did not remain significant in 
fully adjusted models (Model 2) or mutually adjusted models (Model 3). In addition, VAT 
was positively related with the detection of dimethylamine (ß=0.12; p=0.04) in the fully 
adjusted model. BMI was significantly inversely related to the detection of creatine and 
glycolic acid and positively related to the detection of dimethylamine and methanol in the 
age and sex adjusted models. However, after full adjustment, estimated relations were 
attenuated and associations of BMI with the detection of urinary metabolites were no 
longer statistically significant. WC was positively associated with the detection of 
dimethylamine in fully adjusted models (Model 2) among women. No significant relations 
were found between SAT or VSR and urinary metabolites among men or women.  
After stratifying by fasting status and full adjustment for covariates (Model 2), VAT, 
BMI, and WC were inversely associated with the detection of choline and positively 
associated with the detection of dimethylamine and ethanolamine in non-fasting subjects 
(Table 16). After mutual adjustment for other anthropometric variables (Model 3), only 
VAT remained significantly related to the detection of choline (ß=-0.17; p=1.62*10-4), 
dimethylamine (ß=0.34; p=4.90*10-2), and ethanolamine (ß=0.34; p=4.69*10-2). By 
comparison, no significant relations were found for VAT, SAT, VSR, BMI, or WC with 
urinary metabolites among fasting participants.  
Analyses stratified by urinary glucose revealed an inverse relation between VAT 
and the detection of choline (ß=-0.24; p=9.34*10-5) in fully adjusted models (Model 2) 
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among subjects with no urinary glucose (Table 16). The inverse association between 
VAT and choline (ß=-0.22; p=1.94*10-4) remained statistically significant after further 
adjustment for SAT (Model 3). By comparison, BMI and WC showed positive relations to 
the detection of dimethylamine and ethanolamine and inverse relations to glutamine and 
glycolic acid in fully adjusted models. No significant results were found between SAT or 
VSR and urinary metabolites. In addition, no significant results were found in glucose 
subjects.  
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Table 16: Significant# associations between measures of obesity and urinary metabolite levels among subgroups. 
 Metabolite Model 1 Model 2 Model 3 
  ß p ß p ß p 
Men (n=107) 
VAT Formic acid* -0.11 3.21*10-3 -0.04 0.87 -0.03 0.91 
 Choline -0.21 4.23*10-4 -0.18 2.73*10-3 -0.18 3.21*10-5 
 Dimethylamine 0.41 0.01 0.65 0.04 0.63 0.03 
 Ethanolamine 0.21 0.03 0.71 0.04 0.71 0.01 
 Glycolic acid -0.17 0.06 -0.58 0.04 -0.57 0.03 
 Guanidinoacetic acid -0.19 0.03 -0.36 0.04 -0.41 0.02 
 Lactic acid -0.13 0.12 -0.32 0.04 -0.38 0.04 
 Serine -0.20 0.03 -0.41 0.04 -0.39 0.04 
BMI Alanine 0.17 0.04 0.16 0.10 0.09 0.93 
 Betaine -0.30 0.01 -0.35 0.01 -0.22 0.49 
 Choline -0.22 0.01 -0.48 0.01 -0.28 0.49 
 Dimethylamine 0.27 0.01 0.28 0.04 0.02 0.94 
 Ethanolamine 0.24 0.01 0.44 0.01 0.25 0.49 
 Glutamine -0.37 0.01 -0.46 0.01 -0.55 0.03 
 Glycolic acid -0.24 0.01 -0.34 0.01 -0.23 0.49 
 Guanidinoacetic acid -0.24 0.01 -0.36 0.01 -0.23 0.49 
 Lactic acid -0.16 0.04 -0.31 0.01 -0.30 0.49 
WC Alanine 0.05 0.04 0.05 0.08 0.03 0.80 
 Betaine -0.11 0.00 -0.10 0.01 -0.05 0.73 
 Choline -0.08 0.01 -0.14 0.01 -0.08 0.56 
 D-Glucose -0.06 0.03 -0.14 0.01 -0.15 0.53 
 Dimethylamine 0.11 0.01 0.11 0.02 0.12 0.51 
 Ethanolamine 0.09 0.01 0.14 0.01 0.08 0.56 
 Glutamine -0.10 0.01 -0.11 0.01 0.03 0.80 
 Glycolic acid -0.07 0.01 -0.10 0.01 -0.04 0.73 
 Guanidinoacetic acid -0.08 0.01 -0.11 0.01 -0.05 0.73 
 Lactic acid -0.05 0.04 -0.08 0.02 0.00 0.96 
 Phenylalanine -0.05 0.05 -0.01 0.66 0.01 0.96 
 Serine -0.06 0.03 -0.09 0.02 -0.07 0.56 
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Table 16 continued: Significant# associations between measures of obesity and urinary metabolite levels among 
subgroups. 
 Metabolite Model 1 Model 2 Model 3 
  ß p ß p ß p 
Women (n=121) 
VAT Formic acid* -0.11 3.22*10-3 -0.04 0.87 -0.02 0.89 
 Dimethylamine 0.16 0.02 0.12 0.04 0.12 0.25 
BMI Creatine -0.12 4.51*10-2 -0.10 0.42 -0.09 0.95 
 Dimethylamine 0.15 0.03 0.30 0.08 0.17 0.89 
 Glycolic acid -0.12 4.51*10-2 -0.12 0.42 -0.13 0.89 
 Methanol 0.15 4.51*10-2 0.06 0.63 -0.01 0.96 
WC Dimethylamine 0.06 0.03 0.11 4.46*10-3 0.06 0.70 
Non-fasting subjects (n=198) 
VAT Formic acid* -0.11 6.63*10-5 -0.09 0.04 -0.07 0.23 
 Choline -0.20 6.68*10-6 -0.17 1.84*10-4 -0.17 1.62*10-4 
 Dimethylamine 0.24 0.03 0.43 0.02 0.34 4.90*10-2 
 Ethanolamine 0.20 0.03 0.36 0.02 0.34 4.69*10-2 
BMI Formic acid* -0.05 0.01 -0.06 0.09 -0.04 0.86 
 Choline -0.10 0.04 -0.19 0.02 -0.02 0.96 
 Creatine -0.11 0.02 -0.12 0.08 -0.21 0.83 
 Dimethylamine 0.17 0.01 0.25 0.01 0.11 0.83 
 Ethanolamine 0.13 0.01 0.19 0.02 0.06 0.94 
 Glutamine -0.14 0.01 -0.19 0.01 -0.12 0.04 
 Glycolic acid -0.14 0.01 -0.18 0.02 -0.13 0.83 
 Guanidinoacetic acid -0.13 0.01 -0.15 0.03 -0.01 0.96 
 Lactic acid -0.09 0.05 -0.21 0.01 -0.15 0.83 
 Methanol 0.13 0.04 0.04 0.46 -0.12 0.83 
WC Formic acid* -0.02 0.01 -0.01 0.12 -0.01 0.93 
 Alanine 0.03 0.03 0.06 0.06 0.06 0.38 
 Betaine -0.04 0.02 -0.05 0.02 -0.06 0.38 
 Choline -0.04 0.02 -0.08 0.01 -0.07 0.38 
 Creatine -0.04 0.03 -0.03 0.21 0.04 0.67 
 Dimethylamine 0.07 1.84*10-3 0.09 0.01 0.06 0.39 
 Ethanolamine 0.05 4.72*10-3 0.07 0.01 0.05 0.39 
 Glutamine -0.05 4.72*10-3 -0.07 0.01 -0.03 0.67 
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Table 16 continued: Significant# associations between measures of obesity and urinary metabolite levels among 
subgroups. 
 Metabolite Model 1 Model 2 Model 2 
  ß p ß p ß p 
WC Glycolic acid -0.04 0.02 -0.06 0.01 -0.02 0.68 
 Guanidinoacetic acid -0.05 4.72*10-3 -0.06 0.01 -0.06 0.38 
 Lactic acid -0.03 0.04 -0.07 0.01 -0.03 0.67 
 Methanol 0.04 0.04 0.03 0.22 0.07 0.38 
 Serine -0.04 0.03 -0.07 0.01 -0.07 0.38 
Subjects with no urinary glucose (n=183) 
VAT Choline -0.26 8.21*10-7 -0.24 9.34*10-5 -0.22 1.94*10-4 
 Dimethylamine 0.61 0.05 0.64 0.03 0.45 0.62 
 Ethanolamine 0.60 0.05 0.29 0.01 0.10 0.96 
BMI Alanine -0.10 0.03 -0.15 0.06 0.04 0.83 
 Creatine -0.12 0.03 -0.11 0.19 -0.14 0.83 
 Dimethylamine 0.17 1.86*10-3 0.27 0.01 0.09 0.83 
 Ethanolamine 0.15 4.02*10-3 0.20 0.02 0.05 0.83 
 Glutamine -0.14 0.02 -0.22 0.01 -0.18 0.03 
 Glycolic acid -0.19 1.85*10-3 -0.25 0.01 -0.23 0.52 
WC Alanine 0.04 0.02 0.07 0.08 0.08 0.32 
 Betaine -0.04 0.04 -0.04 0.12 -0.05 0.51 
 Choline -0.05 0.04 -0.09 0.05 -0.10 0.32 
 Creatine -0.04 0.05 -0.03 0.28 0.01 0.90 
 Dimethylamine 0.07 7.85*10-4 0.11 0.01 0.08 0.32 
 Ethanolamine 0.06 2.48*10-3 0.08 0.02 0.07 0.39 
 Glutamine -0.05 0.02 -0.08 0.02 -0.02 0.85 
 Glycolic acid -0.06 3.45*10-3 -0.07 0.02 -0.01 0.90 
 Guanidinoacetic acid -0.04 0.04 -0.05 0.08 -0.04 0.72 
 Taurine -0.04 0.05 -0.04 0.20 -0.04 0.72 
Model 1: linear or logistic regression model adjusted for study, age (non-linear) and sex.  
Model  2: linear or logistic regression model adjusted for study, age and sex interaction (non-linear), smoking status, menopausal status (women only), physical activity, urinary glucose, 
and eGFR. In logistic regression models: 0=metabolite undetected, 1=metabolite detected.    
Model 3: linear regression or logistic model adjusted for all variables from model 2 plus VAT and SAT mutually adjusted and BMI and WC mutually adjusted.  
In each case, the stratification variable was excluded from the model. VAT=visceral adipose tissue, BMI=body mass index, WC=waist circumference, ß=standardized regression coefficient, 
p-value=corrected for multiple testing by controlling the false discovery rate. 
*linear regression model was applied. 
#
p-values<0.05 after correction for multiple testing were considered significant. 
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When linear and logistic regression models were applied to serum metabolites, 
results showed no significant results between VAT, SAT, VSR, BMI, and WC and 
concentrations of serum metabolites for the overall population and among subgroups. 
Also no significant results were found between the highest and lowest quartiles of VAT, 
SAT, VSR, BMI, or WC and serum metabolites in the overall population or among 
subgroups.  
3.4.2 Results from untargeted metabolomics approach 
Urine and serum spectral areas showed only a small degree of unbalanced data 
(Supplementary Figures 2 and 3). To normalize unbalanced data 60% of the urinary and 
65% of the serum features were transformed using variance stabilization (VSN) (177). 
To obtain a general overview about differences between fingerprints among subjects, 
AP clustering analyses with no a priori assumption was applied. For the whole study 
population, AP clustering based on urinary metabolic fingerprints formed nine clusters. 
Results from age and sex adjusted regression analyses showed that there were no 
significant differences between clusters in the distribution of VAT, SAT, VSR, or WC 
(Table 17). By comparison, the regression-adjusted BMI of cluster 4 (p=0.01) and cluster 
6 (p=0.02) differed statistically significantly compared to the predicted grand mean of 
BMI. The distributions of the predicted mean values of phenotypes among clusters are 
presented in Figure 11. 
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Figure 11: Age and sex adjusted distribution of phenotypes among clusters 
formed from urinary fingerprints (overall study population). 
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Table 17: Clusters formed from urinary fingerprints (overall study population). 
Cluster 
Mean VAT 
(95% CI) 
p 
Mean SAT 
(95% CI) 
p 
Mean VSR 
(95% CI) 
p 
Mean BMI 
(95% CI) 
p 
Mean WC 
(95 % CI) 
p 
1 
7.69 
(6.80-8.57) 
0.50 
2.04 
(1.78-2.30) 
0.31 
4.16 
(3.50-4.83) 
0.43 
28.06 
(26.65-29.46) 
0.48 
94.00 
(90.44-97.57) 
0.54 
2 
7.59 
(6.61-8.57) 
0.86 
2.11 
(1.82-2.40) 
0.65 
4.57 
(3.83-5.30) 
0.34 
28.14 
(26.60-29.67) 
0.93 
93.77 
(89.89-97.66) 
0.92 
3 
8.01 
(7.02-9.00) 
0.59 
2.17 
(1.88-2.46) 
0.45 
4.04 
(3.29-4.78 
0.78 
28.39 
(26.83-29.95) 
0.72 
96.78 
(92.82-100.73) 
0.24 
4 
6.77 
(5.70-7.85) 
0.14 
1.78 
(1.47-2.10) 
0.16 
4.49 
(3.68-5.31) 
0.47 
25.59 
(23.88-27.30) 
0.01 
89.91 
(85.57-94.25) 
0.10 
5 
8.25 
(6.98-9.53) 
0.41 
2.36 
(1.99-2.73) 
0.10 
3.94 
(2.98-4.90) 
0.66 
28.99 
(26.98-31.00) 
0.39 
99.36 
(94.26-104.45) 
0.05 
6 
6.55 
(5.10-8.00) 
0.14 
1.73 
(1.31-2.16) 
0.18 
3.99 
(2.90-5.09) 
0.77 
25.12 
(22.82-27.43) 
0.02 
89.82 
(83.96-95.68) 
0.18 
7 
7.05 
(1.64-12.47) 
0.82 
2.42 
(0.83-4.00) 
0.64 
3.11 
(0.97-7.19) 
0.62 
30.86 
(22.24-39.48) 
0.53 
88.75 
(66.87-110.62) 
0.64 
8 
9.06 
(3.40-14.72) 
0.63 
3.41 
(1.75-5.07) 
0.10 
3.09 
(1.18-7.35) 
0.62 
33.49 
(24.49-42.50) 
0.24 
113.36 
(90.51-136.21) 
0.10 
9 
8.33 
(2.82-13.84) 
0.82 
3.34 
(1.72-4.95) 
0.11 
2.53 
(1.62-6.68) 
0.44 
28.44 
(19.67-37.21) 
0.93 
96.11 
(73.86-118.36) 
0.85 
Mean VAT, SAT, VSR, BMI and WC=predictive margins from linear regression adjusted for age and sex, grand mean=reference category, VAT=visceral adipose tissue, 
SAT=subcutaneous adipose tissue, VSR=visceral-to-subcutaneous-fat ratio, BMI=body mass index, WC=waist circumference, p=p-value for the comparison to the grand mean. 
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AP-clustering was repeated in men and women separately and detected six 
clusters for men and women, respectively (Supplementary Table 15). Among men and 
women, clusters did not differ with regard to VAT, SAT, VSR, BMI, and WC. When 
analyses were restricted to non-fasting participants, eight clusters were formed and 
showed that the predicted mean VAT of cluster 5 (p=0.03) differed statistically 
significantly compared to the overall mean VAT. No significant differences between 
clusters were found for SAT, VSR, BMI, and WC. By comparison, three clusters were 
formed in the subsample of fasting participants. In fasting participants, clusters did not 
differ statistically significantly with regard to VAT, SAT, VSR, BMI, or WC. Further 
stratification of non-fasting participants by sex resulted in six clusters for men and 
women respectively. None of the formed clusters differed statistically significantly in any 
of the considered phenotypes. When the study population was stratified by urinary 
glucose, seven clusters were generated among subjects with no urinary glucose and 
three clusters were formed among subjects with elevated glucose. No significant 
differences between clusters among these groups were found for VAT, SAT, VSR, BMI, 
or WC. 
Multiple linear regression models to detect relations of VAT and SAT to the urinary 
metabolic fingerprints in the overall population showed statistically significant 
associations between VAT and 39 urinary bins in fully adjusted models (Model 2) (Table 
18). Metabolite identification was performed by comparison with reference spectra of 
pure compounds. In case that more than one compound contributed to a given bin all 
corresponding molecules are shown in Table 18. Positive relations were found to lysine, 
dimethylamine, and tyrosine/creatinine, while negative relations were found to 4-
hydroxyhippuric acid, acetone, citric acid, glycine, L-pyroglutamic acid, methylmalonic 
acid, scyllo-inositol, and formic acid. In addition, significant associations were found 
between BMI and 35 bins and between WC and 62 bins (Figure 12 and Figure 13). Most 
bins that were significantly associated with VAT were also found to be significant in 
models with BMI and WC. However, VAT but none of the other anthropometric 
parameters was inversely related to 4-hydroxyhippuric acid in the overall study 
population in fully adjusted models (Model 2). By comparison, no significant relations 
were found between SAT or VSR and urinary bins.  
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Table 18: Significant# results from multiple regression analyses on the relation of VAT to urinary bins (all subjects). 
  Model 1 Model 2  
Anthropometric variable bin (ppm) ß p ß p metabolite identification 
VAT 3.795 0.0341 0.0106 0.0388 0.0155 Lysine 
 1.485 0.0981 0.0500 0.0918 0.0285 Lysine 
 1.355 0.0234 0.0271 0.0226 0.0392 unknown 
 2.435 -0.0354 0.0316 -0.0329 0.0318 
3-Hydroxy-3-methylglutaric 
acid, others 
 2.475 -0.0334 0.0695 -0.0355 0.0102 
3-Hydroxy-3-methylglutaric 
acid/others 
 3.945 -0.0452 0.0695 -0.0475 0.0320 4-Hydroxyhippuric acid/others 
 6.955 -0.0717 0.0277 -0.0860 0.0100 4-Hydroxyhippuric acid 
 6.965 -0.0803 0.0277 -0.0843 0.0227 4-Hydroxyhippuric acid 
 2.235 -0.0480 0.0562 -0.0526 0.0318 Acetone 
 2.725 0.0518 0.0546 0.0601 0.0304 Dimethylamine/citrate 
 3.205 -0.0324 0.0546 -0.0458 0.0097 Choline, others 
 3.525 -0.0455 0.0562 -0.0463 0.0344 Choline, others 
 4.065 -0.1101 0.0546 -0.1337 0.0175 Choline, creatinine, others 
 2.605 -0.0119 0.0346 -0.0508 0.0217 unknown 
 2.615 -0.0157 0.0446 -0.0613 0.0162 unknown 
 2.625 -0.0198 0.0018 -0.0511 0.0045 unknown 
 2.645 -0.0468 0.0546 -0.0454 0.0449 unknown 
 2.675 -0.1161 0.0546 -0.1358 0.0304 Citric acid 
 2.735 0.0633 0.0772 0.0813 0.0304 Dimethylamine 
 3.565 -0.0661 0.0546 -0.0669 0.0349 Glycine, others 
 2.405 -0.0540 0.0277 -0.0583 0.0100 L-Pyroglutamic acid 
 2.515 -0.0430 0.0313 -0.0430 0.0297 L-Pyroglutamic acid 
 1.235 -0.0428 0.0546 -0.0457 0.0318 Methylmalonic acid 
 2.395 -0.0283 0.1068 -0.0308 0.0465 L-Pyroglutamic acid 
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Table 18 continued: Significant# results from multiple regression analyses on the relation of VAT to urinary bins (all subjects). 
  Model 1 Model 2  
Anthropometric variable bin (ppm) ß p ß p metabolite identification 
VAT 3.355 -0.0503 0.0277 -0.0561 0.0223 scyllo-Inositol 
 3.055 0.0952 0.0587 0.1149 0.0304 Tyrosine, creatinine 
 3.535 -0.0324 0.0695 -0.0320 0.0465 Sugar compounds, unknown 
 2.325 -0.0303 0.0661 -0.0307 0.0320 unknown 
 2.335 -0.0259 0.1025 -0.0276 0.0320 unknown 
 2.365 -0.0362 0.0562 -0.0377 0.0320 unknown 
 2.425 -0.0318 0.0695 -0.0348 0.0320 L-Pyroglutamic acid 
 2.645 -0.0368 0.0562 -0.0386 0.0320 unknown 
 2.965 -0.0347 0.0772 -0.0394 0.0435 Asparagine, unknown 
 2.975 -0.0331 0.0772 -0.0674 0.0381 Asparagine, unknown 
 6.585 -0.0657 0.0277 -0.0692 0.0223 unknown 
 6.785 -0.0369 0.0772 -0.0439 0.0320 unknown 
 6.805 -0.0632 0.0433 -0.0807 0.0223 unknown 
 6.945 -0.0384 0.1147 -0.0489 0.0320 unknown 
 8.455 -0.0911 0.0316 -0.1013 0.0223 Formic acid 
Model 1: linear regression model adjusted for study, age (non-linear) and sex.  
Model  2: linear regression model adjusted for study, age and sex interaction (non-linear), eGFR, smoking status, menopausal status (women only), fasting status, urinary glucose, and 
physical activity. In each case, the stratification variable was excluded from the model. VAT=visceral adipose tissue, bin=spectra position (ppm), ß=standardized linear regression 
coefficient, p=corrected p-value by controlling the false discovery rate, n=228.  
#
p-values<0.05 after correction for multiple testing were considered significant. 
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Figure 12: Heat map showing significant# relations of BMI and urinary bins in the overall study population. 
X axis shows individual BMI value from lowest (left corner) to highest (right corner). 
#
 p-values<0.05 after correction for multiple testing are considered significant. 
 
 
 
Figure 13: Heat map showing significant# relations of waist circumference and urinary bins in the overall study 
population. 
X axis shows individual value of waist circumference from lowest (left corner) to highest (right corner). 
#
 p-values<0.05 after correction for multiple testing are considered significant. 
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In subgroup analyses stratified by sex, no significant relations were found between 
VAT, SAT, VSR, BMI, or WC and urinary bins. However, when analyses were restricted 
to non-fasting participants, significant associations were found between VAT and 80 bins 
in fully adjusted models (Model 2) (Supplementary Table 17). No relations were found 
between SAT or VSR and urinary bins. By comparison, BMI, and WC were significantly 
related to 99 and 70 bins, respectively (Supplementary Table 18 and Supplementary 
Table 19). Significant results from analyses among all subjects were reproduced in 
sensitivity analyses among non-fasting subjects. For instance, the positive relations of 
VAT, BMI and WC to dimethylamine/citrate were also found among non-fasting 
participants. Moreover, VAT, BMI and WC were inversely associated with acetone, 
choline, citric acid, asparagine/unknown, and L-pyroglutamic acid in this group. No 
significant results were found between VAT, SAT, VSR, BMI, or WC and urinary bins 
after further stratification of the non-fasting group by sex. Significant associations were 
found between VAT, BMI, and WC to urinary bins in analyses restricted to subjects with 
no urinary glucose in fully adjusted models (Model 2). Specifically, VAT was related to 
11 bins among subjects with no urinary glucose (Supplementary Table 17). These 
results were also found to be significant in the overall study population (e.g., 4-
hydroxyhippuric acid or L-pyroglutamic acid). By comparison, among the subjects with no 
urinary glucose, BMI and WC were related to 29 and 12 bins, respectively. No relations 
were found between SAT or VSR and urinary bins in subjects with no urinary glucose 
and no significant relations were found between any of the obesity measures and urinary 
bins among subjects with elevated glucose.  
Based on serum metabolic fingerprints, the AP algorithm formed six clusters for 
the overall study population. Results from age and sex adjusted regression analyses 
showed that there were no significant differences between clusters in the distribution of 
VAT, SAT, BMI, or WC (Table 19). The distributions of the age and sex adjusted mean 
values of phenotypes among clusters are presented in Figure 14. 
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Table 19: Distribution of phenotypes among clusters formed from serum fingerprints (overall study population). 
Cluster 
Mean VAT 
(95% CI) 
p 
Mean SAT 
(95% CI) 
p 
Mean VSR 
(95% CI) 
p 
Mean BMI 
(95% CI) 
p 
Mean WC 
(95% CI) 
p 
1 
7.41 
(6.57-8.26) 
0.67 
2.04 
(1.78-2.30) 
0.48 
4.26 
(3.66-4.86) 
0.51 
27.25 
(25.83-28.67) 
0.59 
93.81 
(90.25-97.37) 
0.61 
2 
7.09 
(6.14-8.05) 
0.53 
2.10 
(1.81-2.39) 
0.69 
3.68 
(3.01-4.34) 
0.11 
27.93 
(26.33-29.54) 
0.42 
94.72 
(90.70-98.74) 
0.67 
3 
7.07 
(5.93-8.21) 
0.56 
1.94 
(1.59-2.29) 
0.59 
4.15 
(3.34-4.95) 
0.79 
27.44 
(25.56-29.32) 
0.85 
93.00 
(88.29-97.72) 
0.74 
4 
7.87 
(6.60-9.15) 
0.50 
2.06 
(1.68-2.45) 
0.91 
4.10 
(3.19-4.99) 
0.72 
28.13 
(25.99-30.28) 
0.44 
93.31 
(87.93-98.69) 
0.86 
5 
7.39 
(6.05-8.73) 
0.97 
1.67 
(1.26-2.08) 
0.08 
4.92 
(3.97-5.87) 
0.17 
27.31 
(25.05-29.57) 
0.96 
92.14 
(86.47-97.81) 
0.56 
6 
6.64 
(1.29-12.00) 
0.78 
0.70 
(0.93-2.33) 
0.11 
6.16 
(4.37-9.95) 
0.46 
22.02 
(12.99-31.04) 
0.26 
79.34 
(56.72-101.97) 
0.21 
Predictive margins from linear regression adjusted for age and sex, grand mean=reference category, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-to-
subcutaneous-fat ratio, BMI=body mass index, WC=waist circumference, p=p-value for the comparison to the grand mean. 
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Figure 14: Age and sex adjusted distribution of phenotypes among clusters 
formed from serum fingerprints (overall study population). 
 
In sensitivity analyses (Supplementary Table 16), four clusters were formed for 
men and three clusters were formed for women. Among women, the regression-adjusted 
mean SAT of cluster 2 (p=0.02) and 3 (p=0.002) differed statistically significantly 
compared to the overall predicted mean SAT. No significant differences between 
clusters were found for VAT, VSR, BMI, or WC. In addition, no significant differences 
between clusters regarding the considered phenotypes were found among men. 
Analyses stratified by fasting status formed four clusters and showed that in cluster 3, 
the regression-adjusted mean SAT differed statistically significantly compared to the 
grand mean of SAT among non-fasting participants. No significant differences between 
clusters were found for VAT, VSR, BMI, or WC. In addition, no significant results were 
found among fasting participants. A further stratification of the non-fasting participants by 
sex showed that cluster 3 differed statistically significantly regarding the regression-
adjusted mean SAT (p=0.02) compared to the overall predicted mean SAT among non-
fasting women. No statistically significant differences between clusters were found 
regarding VAT, VSR, BMI, or WC. Also no significant differences between clusters with 
regard to the adiposity measures were found among non-fasting men. Finally, when the 
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study population was stratified by urinary glucose, three clusters were formed among 
subjects with no urinary glucose. No significant differences between clusters among 
these groups were detected for VAT, SAT, VSR, BMI, or WC. 
Linear regression models to detect relations of VAT and SAT to serum bins 
showed no significant results in the overall population. VSR, BMI, and WC also showed 
no significant relations to individual serum bins. When analyses were stratified by sex, 
significant results were found between VAT and 20 serum bins among men in fully 
adjusted models (Model 2) (Table 20). Of these significantly related 20 bins, twelve 
could be assigned to specific metabolites. In case that more than one compound 
contributed to a significant bin all corresponding molecules were indicated (e.g., 
isobutyric acid and unknown compound at 1.065 ppm). VAT was positively related to 
tryptophan, and showed an inverse relation to ketoleucine. In addition, positive relations 
were found between VAT and essential amino acids, including valine, phenylalanine, 
and isoleucine. Note that the bin corresponding to isoleucine shows partial overlap with 
ketoleucine. By comparison, among women VAT was inversely related to three serum 
bins in fully adjusted models (Model 2). Those bins were not related to VAT among men. 
However, only one of the significantly inversely related bins was identified as lipid-
cholesterol. No relations were found between SAT, VSR, BMI, or WC and serum bins 
among men or women. 
Among non-fasting participants, there were also no significant relations of VAT, 
SAT, VSR, BMI, or WC to serum bins. When the non-fasting group was further stratified 
by sex, VAT showed significant relations to 17 bins among non-fasting men in fully 
adjusted models (Model 2) (Table 20). By comparison, among non-fasting women, VAT 
was inversely related to three bins (Model 2). Significantly related bins in both non-
fasting men and women were also significantly related in all men and women 
irrespectively of their fasting status. No relations were found between SAT, VSR, BMI, or 
WC and serum bins among non-fasting men or women. When analyses were restricted 
to subjects with no urinary glucose, no significant results were found for any of the 
obesity measures. 
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Table 20: Significant results# from multiple regression analyses on the relation between VAT and serum bins. 
  Model 1 Model 2  
Anthropometric variable bin (ppm) ß p ß p metabolite identification 
Men (n=98) 
VAT 0.995 0.0413 0.0146 0.0588 0.0015 Valine 
 0.985 0.0381 0.0476 0.0138 0.0285 Valine 
 0.935 0.0008 0.9952 0.0466 0.0178 Isoleucine, ketoleucine 
 1.065 0.0444 0.8602 0.0993 0.0006 Isobutyric acid, unknown 
 1.075 0.0314 0.8602 0.0798 0.0017 Isobutyric acid, unknown 
 1.085 0.0271 0.8602 0.0638 0.0202 unknown 
 1.105 0.0102 0.9818 0.0826 0.0161 unknown 
 1.035 0.0813 0.0246 0.0562 0.0128 Valine 
 2.595 0.0203 0.9746 0.0538 0.0285 unknown 
 2.605 -0.0160 0.9746 -0.0508 0.0117 Ketoleucine 
 2.615 -0.0175 0.9746 -0.0613 0.0060 Ketoleucine 
 2.625 -0.0084 0.9818 -0.0502 0.0047 Ketoleucine 
 2.635 0.0167 0.9746 0.0672 0.0003 unknown 
 2.655 0.0186 0.8602 0.0442 0.0093 Methionine, unknown 
 4.345 -0.2167 0.7141 -0.4572 0.0013 unknown 
 6.745 0.4734 0.8602 0.7706 0.0351 unknown 
 7.375 0.0170 0.9746 0.0669 0.0202 Phenylalanine, unknown 
 7.485 -0.2613 0.8602 -0.4372 0.0388 unknown 
 7.555 0.0485 0.9802 0.1351 0.0274 Tryptophan 
 7.675 -0.2390 0.7141 -0.3350 0.0082 unknown 
Women (n=102) 
 0.605 -0.4264 0.1599 -0.3640 0.0136 unknown 
 0.735 -0.0242 0.5579 -0.0482 0.0136 Lipid-cholesterol 
 7.845 -0.2337 0.1888 -0.4020 0.0368 unknown 
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Table 20 continued: Significant results from multiple regression analyses on the relation between VAT and serum 
bins. 
  Model 1 Model 2  
Anthropometric variable bin (ppm) ß p ß p metabolite identification 
Non-fasting men (n=78) 
VAT 0.935 0.0413 0.0146 0.0588 0.0015 Isoleucine, ketoleucine 
 0.985 0.0381 0.0476 0.0138 0.0285 Valine 
 0.995 0.0210 0.5806 0.0454 0.0309 Valine 
 1.035 0.0694 0.0993 0.0962 0.0020 unknown 
 1.075 0.0494 0.2005 0.0764 0.0034 Isobutyric acid, unknown 
 1.085 0.0399 0.3770 0.0594 0.0467 unknown 
 1.105 0.0311 0.3770 0.0507 0.0219 unknown 
 2.595 0.0409 0.3770 0.0548 0.0467 unknown  
 2.605 0.0405 0.1133 0.0505 0.0136 Ketoleucine 
 2.615 0.0410 0.1447 0.0606 0.0085 Ketoleucine 
 2.625 0.0321 0.3385 0.0486 0.0034 Ketoleucine 
 2.635 0.0358 0.1447 0.0571 0.0006 unknown 
 2.655 0.0282 0.3384 0.0584 0.0023 Methionine, unknown 
 4.345 -0.2383 0.2005 -0.3690 0.0125 unknown 
 6.535 0.4483 0.3770 0.7294 0.0467 unknown 
 7.375 0.0356 0.4929 0.0761 0.0134 Phenylalanine, unknown 
 7.675 -0.2247 0.3932 -0.3475 0.0117 unknown 
Non-fasting women (n=94) 
VAT 0.605 -0.4988 0.1530 -0.4837 0.0033 unknown 
 0.735 -0.0341 0.5236 -0.0631 0.0049 Lipid-cholesterol 
 7.845 -0.2551 0.3720 -0.5066 0.0373 unknown 
Model 1: linear regression model adjusted for study, age (non-linear) and sex.  
Model  2: linear regression model adjusted for study, age and sex interaction (non-linear), smoking status, menopausal status (women only), fasting status, urinary glucose, and physical 
activity. In each case, the stratification variable was excluded from the model.  
VAT=visceral adipose tissue, bin= spectra positions (ppm), ß=standardized linear regression coefficient, p=corrected p-value by controlling the false discovery rate. 
#
p-values<0.05 after correction for multiple testing were considered significant. 
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4 Discussion 
The research underlying present thesis was conducted using a systematic and 
multistep approach to address several challenges of obesity research in an 
epidemiologic setting. First, a method capable of differentiating and quantifying 
abdominal adipose tissue compartments was investigated with respect to its 
reproducibility, validity, and feasibility in the context of epidemiological studies. Further, 
different measures of obesity and their associated metabolic consequences were 
examined extensively by numerous investigations, proceeding from hypothesis-driven 
analyses of inflammatory parameters in serum samples to more complex and 
unsupervised approaches studying urinary and serum metabolomic profiles.  
 Summary of the findings 4.1
Results from the current study revealed that ultrasound represents a reproducible 
and valid method for assessing VAT and SAT. The intra- and inter-observer 
reproducibility was high for measurements of VAT and SAT. Further, the correlations of 
ultrasonographic measurements of VAT and SAT with measurements of VAT and SAT 
derived from MRI were strong. The present findings add to the growing evidence that 
ultrasound is a useful method for estimating abdominal fat compartments and represents 
a suitable method for large-scale epidemiologic studies.  
When examining relationships of different obesity phenotypes, distinct associations 
with selected parameters of chronic inflammation and urinary and serum metabolites 
were found for VAT, SAT, VSR, BMI, and WC, indicating that each of the anthropometric 
variables provides distinct information regarding metabolic processes related to 
inflammatory parameters and metabolite regulation. VAT most consistently 
demonstrated relations to inflammatory parameters, individual urinary and serum 
metabolites. SAT was the strongest correlate for increased hs-CRP concentrations but 
was not related to urinary or serum metabolites. VSR represented a stable association 
with decreased resistin levels but was not related to urinary or serum metabolites. By 
comparison, BMI was the strongest correlate for decreased adiponectin levels and was 
consistently related to urinary metabolites. WC represented less consistent relations 
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when examining associations with inflammatory parameters and serum metabolites. 
However, WC was consistently related to urinary metabolites.  
4.1.1 Reproducibility and validity of the sonographic-based quantification of 
visceral and subcutaneous adipose tissue 1 
In the present study, the reproducibility of the ultrasound measurements of VAT 
and SAT was high, as indicated by ICC values exceeding 0.9. Both study centers 
performed the ultrasound measurements according to a protocol that provided detailed 
procedures regarding the precise anatomic placement of the transducer, the specific 
amount of pressure to be applied to the abdomen by the transducer, and the exact 
timing of the ultrasound measurement in relation to the timing of respiration. Other 
studies using a similar protocol also reported favorable results, with ICCs of 0.90-0.99 
(157, 159) and mean differences ranging from 0.25-0.69 mm (153, 160). An earlier study 
not employing a standardized protocol reported less favorable results for reproducibility 
(r=0.64) (161).  
According to the results presented in this thesis, ultrasound can be considered a 
valid method for assessing VAT and SAT when compared to MRI measurements of VAT 
and SAT area. The correlation between the two methods was high, particularly for VAT. 
Our results are consistent with previous studies that reported modest to high correlations 
between VAT thickness as assessed by ultrasound and VAT measured by MRI or CT, 
with correlation coefficients ranging from 0.67 to 0.91 (52, 140, 148-158). Two previous 
studies reported a modest correlation coefficient of 0.67. Both studies were conducted 
among overweight women with sample sizes of 50 (150) and 101 subjects (148). 
Authors from these investigations reported slightly higher correlations of 0.71 and 0.74 in 
a second study they conducted among 100 and 119 overweight women (151, 156). 
Other studies included men and women and showed correlations of ≥0.79 (52, 140, 149, 
152-155, 157, 158).  
In subgroup analyses stratified by BMI, the correlations between the two methods 
were lower for obese than lean subjects. Similarly, a previous study showed a slightly 
                                            
1
 In the framework of this thesis, parts of the discussion on reproducibility and validity of the quantification 
of VAT and SAT have already been published in: Schlecht, I., et al., Reproducibility and validity of 
ultrasound for the measurement of visceral and subcutaneous adipose tissues. Metabolism, 2014. 63(12): 
p. 1512-1519. 
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weaker correlation for VAT of 0.75 among obese subjects (BMI ≥30) compared to an 
overall correlation of 0.82 (140). One possible reason for a weaker correlation among 
obese than lean subjects is that measuring a greater distance (fat thickness) may be 
more prone to measurement error. In addition, in this study might be underpowered to 
detect subtle differences across BMI groups. 
In general, higher correlations were found in studies that used a protocol that 
included instructions to perform the examination at the end of a normal exhalation and to 
place a minimal amount of pressure on the probe during the ultrasound examination 
(152, 154, 157). Although the use of different anatomic landmarks in measuring visceral 
fat may influence the results, no clear recommendations can be made as to whether 
visceral fat thickness should be defined as the distance between the internal face of the 
rectus abdominis muscle and the anterior wall of the aorta (r=0.67-0.86) (52, 140, 148-
150, 154, 156, 178) or the corpus of the lumbar vertebra (r=0.73-0.91) (152, 153, 155, 
157).  
The correlation coefficients between SAT thickness as assessed by ultrasound 
and SAT as assessed by MRI or CT ranged from 0.33 to 0.83 in previous studies (149, 
152, 153, 155, 156). One study reported a correlation coefficient as low as 0.33 in their 
study among overweight women (156). In that study (156), ultrasound measurements 
were performed with the transducer placed 1 cm above the umbilicus, which is differed 
from another study that showed a correlation of 0.52 when they took measurements 
5 cm cranial to the umbilicus (153). Other studies showed higher correlations of ≥0.63 
when they placed the transducer at the cut-point between the left and right midpoint of 
the lower rib and the iliac crest on the median line of the abdomen (152) or placed it at 
the umbilicus level (149, 155). In addition, the highest correlation of 0.82 was yielded 
when ultrasound measurements of SAT were performed according to a protocol that 
emphasized the need for applying minimal pressure to the skin (155). Another reason for 
the higher correlations found in the validation study may be the location of the MRI 
examination at L2-L3 (L2-L3±). Previous validation studies used L4-L5 or L4 for VAT 
and SAT measurements by MRI (52, 140, 148-158). In the present study, L2-L3 was 
chosen because a recent study found the highest correlation (r=0.96) at this location 
(179). In addition, the locations of L2-L3, L2-L3- and L2-L3+ are anatomically closer to 
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our ultrasound measurement at the cut-point between the left and right midpoint of the 
lower rib and the iliac crest on the median line of the abdomen. 
In summary, CT and MRI have been considered the most accurate and 
reproducible instruments for the measurement of VAT and SAT. However, CT and MRI 
scans are costly and time-consuming. In addition, CT exposes subjects to ionizing 
radiation. Thus, those methods are not feasible for use in large-scale epidemiologic 
studies of non-diseased individuals. BMI, WC, and WHR are the most common methods 
for estimating body fat, and several studies have reinforced the role of those parameters 
in the prediction of morbidity and mortality of obesity-associated diseases (45, 120, 180). 
Although BMI, WC and WHR are convenient and cost-effective methods for estimating 
body fat, they are inadequate for individuals with high levels of BMI (156) and the fact 
that WHR might not change with weight loss, reduces their utility in follow-up studies 
(181). In addition, BMI, WC, and WHR cannot distinguish between VAT and SAT, which 
is essential for distinguishing between abdominal fat components as they relate to the 
development of obesity and associated chronic diseases. It has been recognized that 
obesity-related chronic diseases, including cardiovascular disease, type 2 diabetes, and 
several types of cancer, are more strongly related to body fat distribution than to total 
body fat (43, 139, 182). Several reports have revealed the significance of VAT in 
obesity-related diseases, whereas SAT may play a protective role for the development 
of type 2 diabetes (18, 51, 183). The addition of reproducible, accurate, and feasible 
methods to quantify abdominal fat components in large-scale epidemiologic studies 
contributes to increased statistical power and reduced measurement error that may help 
advance the field of obesity epidemiology that seeks to identify the etiology and 
sequelae of obesity. 
4.1.2 Relations of adiposity measures to parameters of chronic inflammation 
The present population-based study of healthy adults showed distinct associations 
between VAT, SAT, VSR, BMI, and WC with selected parameters of chronic 
inflammation. Specifically, VAT, SAT, BMI, and WC demonstrated a positive relation to 
hs-CRP. The strongest relation was found between SAT and hs-CRP. Compared to the 
other anthropometric variables, BMI showed a stronger inverse association with 
adiponectin. Albeit not statistically significant, VAT was the strongest correlate for 
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increased levels of IL-6 and TNF-α. VSR presented the strongest associations with 
increased resistin levels. WC was only weakly related to most of the inflammatory 
parameters. These findings were fairly consistent throughout subgroups defined by sex, 
BMI, current smoking, and use of aspirin and NSAIDs.   
Similar to the presented results, previous studies among healthy adults reported 
that VAT, SAT, BMI, or WC were positively associated with CRP (83, 93-95, 98, 184). 
Several investigations reported comparable relations of VAT and SAT to CRP (94, 98) or 
a stronger association with VAT (93, 95, 97), whereas other studies found a stronger 
relation with SAT (96, 98, 184). However, none of the aforementioned studies mutually 
adjusted for inflammatory parameters or VAT and SAT (93-98, 184). When VAT and 
SAT were mutually adjusted, only SAT remained significantly positively associated with 
hs-CRP, indicating that abdominal SAT may have pathogenic function, as additionally 
evidenced by endocrine and inflammatory responses (28, 38, 51, 76). No relation was 
found between VSR and hs-CRP which is in line with the only previous study that 
examined the association between those two parameters (79). 
Associations of VAT, BMI, and WC with hs-CRP were stronger in women than 
men, which is in agreement with previous studies (80, 81, 94, 98). This finding is likely to 
be the result of enhanced estrogen production in the adipose tissue with upregulation of 
pro-inflammatory gene expression in women (185, 186). The findings in women of 
similar relations of VAT, SAT, BMI, and WC, but weaker relations of VSR to hs-CRP 
suggest that in women, associations with CRP are more strongly determined by overall 
fat mass than by fat distribution. In contrast, in men, SAT, but not VAT, BMI, or WC was 
moderately associated with CRP, which is consistent with previous studies (96, 98, 184). 
Together with the observed inverse association between VSR and hs-CRP, these 
findings indicate that adiposity relations with CRP in men may be less strongly 
influenced by overall fat mass. 
The observation of a more pronounced relation of SAT to hs-CRP than VAT in 
overweight/obese subjects has not yet been reported. Only one previous study stratified 
by BMI and found no significant association between SAT and CRP in obese subjects 
(97). However, different from that study, adjustments for potential confounding variables 
were considered in the present analyses. In obese individuals, the limited ability of 
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abdominal SAT to store excess energy may cause an increase in FFA flux to the portal 
vein and the systemic circulation (55). Increased FFA levels may then raise CRP (187).   
All anthropometric variables showed stronger associations with hs-CRP in current 
smokers than non-smokers. Cigarette smoking is associated with increased CRP levels 
(188), which may, at least in part, reflect the mechanisms believed to underlie the 
adverse effects of smoking on cardiovascular disease and several types of cancer (189). 
None of the previous studies that examined the relation between adiposity and CRP 
reported results stratified by smoking status (83, 93-95, 98, 184). Also, previous studies 
examining the relations of obesity to CRP and other inflammatory parameters did not 
report findings stratified by aspirin or NSAIDs use (83, 93-95, 98, 184). Associations of 
anthropometric factors to hs-CRP were found to be more pronounced among users of 
aspirin or NSAIDs. Because NSAIDs down-regulate inflammatory cytokine production 
including CRP (190, 191), it was expected that associations with inflammatory 
parameters among users of aspirin or NSAIDs were less pronounced than among non-
users. This unexpected finding may be explained by the unequal distribution of aspirin or 
NSAIDs users and non-users and the small number of participants particularly in the 
group the aspirin or NSAIDs users. 
The findings from multivariable analyses are consistent with those from previous 
studies reporting a positive association between VAT and IL-6 (94, 95, 97, 98, 104) and 
no relation between SAT and IL-6 (97, 98, 104). However, the positive relation of VAT to 
IL-6 was rendered non-significant after mutual adjustment for other parameters of 
systemic chronic inflammation and when SAT was included in the model. Only one 
previous study examined the relation between VSR and IL-6 and also found no 
significant association between the two parameters (79). Positive associations between 
VAT and IL-6 emerged in additional analyses among men, overweight/obese individuals, 
current non-smokers, and participants not using aspirin and NSAIDs. In these analyses, 
we additionally found that associations between VAT and IL-6 were stronger than those 
between BMI and IL-6, indicating that collecting data on VAT may represent metabolic 
information captured by IL-6 that is not accounted for by BMI. Only one previous study 
stratified their population by sex and reported a stronger relation between VAT and IL-6 
in women than men (98). However, that study was limited to elderly individuals, which 
may explain the difference in comparison to the results of the present study. Men have 
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larger visceral fat depots than women (192, 193) and IL-6 is predominantly expressed 
and secreted by VAT (194).  
No overall relations of VAT, SAT, VSR, BMI, or WC to TNF-α were found, which is 
similar to other studies that addressed these associations (94, 95, 97). Albeit not 
statistically significant, the relation of VAT to TNF-α was stronger than the relations of 
other obesity measures to TNF-α. In further exploratory analyses, positive relations of 
VAT to TNF-α and IL-6 among non-users of aspirin or NSAIDs was noted, which may be 
due to NSAID-mediated down-regulation of inflammatory cytokine production (190, 191). 
The available literature includes one study that reported a positive relation between VAT 
and TNF-α in adults aged 70 to 79 years, but no association between SAT and TNF-α 
(98), and another study that found positive relations of both VAT and SAT to TNF-α 
among obese adolescents (104). However, none of those studies mutually adjusted for 
inflammatory parameters or VAT and SAT. 
No associations were detected between VAT, SAT, BMI, or WC and resistin 
levels. This is consistent with most previous studies that found no correlations between 
markers of adiposity and resistin (88-90, 195-200), whereas other studies reported a 
positive relation of obesity to resistin levels (100, 101, 201-204). Only one population-
based study that examined the relation of VAT and SAT to resistin reported results from 
multivariable analyses and found similar relations of VAT and SAT to resistin in women 
and no association between VAT and resistin in men (101). No previous study has 
targeted the relation between VSR and resistin before. In the presents study, VSR 
showed a moderate inverse relation to resistin. Albeit not statistically significant, the 
relations of VAT (inversely) and SAT (positively) appeared in opposite directions. Taken 
together, these findings indicate, that the distribution of VAT relative to SAT may be 
more relevant regarding the secretion of resistin than the individual amount of VAT or 
SAT alone. Moreover, resistin is not expressed by adipocytes, but is secreted by 
macrophages located within adipose tissue depots (205). Hence, circulating resistin is 
not directly related to adiposity levels, but to the degree of inflammation within the 
adipose tissue depots (55).  
Largely similar to results in the present thesis, previous studies reported that VAT, 
SAT, BMI, or WC were inversely associated with adiponectin (96, 102-104, 206). In the 
present study, the inverse relation of VAT to adiponectin was attenuated and rendered 
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statistically non-significant after mutual adjustment for other parameters of systemic 
chronic inflammation and when SAT was included in the model. BMI was found to be a 
stable indicator of decreased adiponectin levels, showing an inverse association in the 
overall population before and after adjustment for other variables and across a number 
of stratified analyses. In addition, the relation of BMI to adiponectin was found to be 
stronger than those with other markers of adiposity in all analyses. This suggests that 
adiponectin may better represent metabolic processes that are associated with BMI than 
those related to VAT or SAT. 
To summarize, in the present thesis VAT, SAT, VSR, BMI, and WC showed 
distinct associations with selected parameters of chronic inflammation. These results 
suggest that each of the anthropometric variables provides distinct information regarding 
metabolic processes related to inflammatory parameters. Compared to VAT, BMI, and 
WC, SAT presented the strongest association for increased hs-CRP concentrations. BMI 
was the strongest correlate for decreased adiponectin levels and VSR showed the 
strongest associations with decreased resistin levels. Albeit not statistically significant, 
VAT was the strongest correlate for increased levels of IL-6 and TNF-α. WC represented 
a less consistent parameter when examining relations to inflammatory parameters. 
Subgroup analyses showed that sex, BMI, current smoking, and use of aspirin or 
NSAIDs modify the relations of adiposity measures to levels of inflammation parameters. 
The distinct relations of VAT, SAT, VSR, BMI, and WC to selected parameters of 
systemic chronic inflammation emphasize the importance of accurately differentiating 
between body fat compartments when evaluating the role of adiposity-associated 
systemic chronic inflammation in the development of metabolic diseases.  
4.1.3 Relations of adiposity measures to quantified urinary and serum 
metabolites 
Results from the targeted metabolomics approach showed that only urinary but no 
serum metabolites were significantly related to adiposity measures. VAT, in particular, 
was associated with urinary metabolites in fully and mutually adjusted models among 
the overall population and stratified subgroups. SAT showed no significant relations to 
urinary or serum metabolites in any of the analyses. By comparison, BMI and WC were 
consistently associated with urinary metabolites in the overall study population and 
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among subgroups. In this study, the absolute number, the effect sizes, and significance 
levels of relations between measures of obesity and urinary metabolites were generally 
greater among men than women. This is concordant with previous studies that reported 
sexual dimorphism of obesity and the metabolic profile (132, 207). Prior studies reported 
significant positive or inverse associations between obesity and lipids, amino acids 
including alanine, glutamine, and valine, and gut flora-derived metabolites such as 
hippuric acid (128, 129, 131, 133-135) or dimethylamine (133) (Supplementary Table 2).  
In the present study, significant positive and inverse relations of VAT, BMI, and 
WC to urinary metabolites were detected in the overall study population and in stratified 
analyses among men and women, non-fasting subjects, and subjects with no urinary 
glucose. Specifically, VAT, BMI, and WC were consistently inversely related to the 
detection of urinary choline in the overall study population and stratified subgroups 
including men, non-fasting participants, and subjects with no urinary glucose. The 
strongest and most significant associations were found between VAT and choline. In 
addition, when VAT and SAT on the one hand and BMI and WC on the other hand were 
mutually adjusted, only VAT but none of the other parameters remained statistically 
significantly and inversely related to choline in the overall study population and in 
stratified subgroups. This indicates that predominantly VAT is related to choline 
metabolism. Choline is an essential nutrient, playing a complex role in human 
metabolism (208). Specifically, choline is needed for neurotransmitter synthesis 
(acetylcholine), cell-membrane signaling (phospholipids), lipid transport (lipoproteins), 
and methyl-group metabolism (homocysteine reduction) (209).  
Previous metabolomics studies reported inverse relations of serum choline to type 
2 diabetes (210) and cardiovascular disease (211). A lack of choline can lead to liver fat 
accumulation and consequently to non-alcoholic hepatic steatosis (NAFLD) including 
non-alcoholic steatohepatitis (NASH) due to lack of very low density lipoprotein (VLDL), 
which shuttles lipids away from the liver (208). NAFLD and NASH are considered 
components of hepatic manifestation of the metabolic syndrome and a potential causal 
factor in the development of type-2 diabetes and cardiovascular disease (212, 213). In 
addition, choline deficiency is associated with increased levels of several inflammatory 
markers that link obesity to obesity-associated diseases, including CRP, homocysteine, 
IL-6, and TNF (208, 214). A possible mechanism is that with inadequate choline stores, 
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the capacity to methylate homocysteine to methionine is diminished and consequently, 
plasma levels of homocysteine increase (208). Homocysteine was demonstrated to 
contribute to the initiation and progression of vascular disease by activating monocytes, 
resulting in the secretion of cytokines that amplify the inflammatory response (215).  
In addition, VAT, BMI, and WC were positively related to the detection of urinary 
dimethylamine in the overall population, among men and women, non-fasting 
participants, and subjects with no urinary glucose. Compared to other measures of 
obesity, the strongest relations were found between VAT and dimethylamine and only 
weak relations were found between WC and dimethylamine. This indicates that VAT 
may be the main indicator for increased dimethylamine levels. A positive association of 
BMI with urinary dimethylamine was reported recently by the international study of 
macro- and micro-nutrients and blood pressure (INTERMAP), which was replicated in 
INTERMAP UK (133). Dimethylamine is a gut microbial metabolite that is related to the 
gut microbial metabolism of choline. The impact of the gut microbiota on dietary choline, 
for the most part originating from carnitine and lecithin, to produce trimethylamine by 
choline trimethylamine-lyases and subsequently the conversion of trimethylamine to 
trimethylamine-N-oxide to dimethylamine describes a pathway that has been linked to 
the development of atherosclerosis and cardiovascular disease (216, 217).  
Increased urinary excretion of microbial metabolites from co-metabolic processing 
of choline has also been related to steatosis and insulin resistance in animals fed high-
fat diets (218). In humans, an increase in energy intake from high-fat diets rapidly 
influences the composition of the gut microbiota (219). These compositional changes in 
microbiota may lead to increases in systemic endotoxin levels (220) that consequently 
may contribute to the low-grade inflammation, insulin resistance, adipocyte hyperplasia, 
and decreased β-cell function that characterizes the metabolic syndrome (219). Another 
source of dimethylamine is the catabolic pathway of asymmetric dimethylarginine that is 
hydrolyzed by dimethylarginine dimethylaminohydrolases (221). Elevated levels of 
asymmetric dimethylarginine have been reported to cause endothelial dysfunction in 
various etiologies of cardiovascular disease such as essential hypertension and 
metabolic syndrome (222, 223) thus leading to atherosclerosis (224) and development 
of coronary artery disease (225). 
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BMI and WC, but none of the other adiposity measures showed inverse relations 
to the detection urinary glutamine among the overall study population and in stratified 
analyses among men, non-fasting participants, and subjects with no urinary glucose. 
BMI showed stronger relations with glutamine than WC in the analyses, and when WC 
and BMI were mutually adjusted, only BMI remained significantly inversely related to 
glutamine. This suggests that glutamine may better represent metabolic processes that 
are associated with BMI than other obesity measures. This finding is in agreement with 
previous studies that reported inverse associations between obesity and serum (135, 
136) or urinary (133) glutamine. Glutamine is a non-essential amino acid and presents 
the most abundant free amino acid in skeletal muscle tissue and plasma (226), playing 
an important role in maintaining skeletal muscle, immune system function as well as 
glucose and glycogen metabolism (227). 
No significant relations were found between VAT, SAT, VSR, BMI, or WC and 
quantified serum metabolites. Although the human urine metabolome is generally 
believed to constitute a subset of the human serum metabolome (228), a few hundred 
compounds identified in urine still await their detection in blood (229). The fact that so 
many compounds seem to be unique to urine most likely reflects the ability of the kidney 
to concentrate certain metabolites from blood with urinary levels of some metabolites 
exceeding those in serum more than a 1000-fold (e.g., histamine) (229). In addition, the 
use of ultrafiltration in sample pretreatment allows only measurement of the protein-
unbound fraction of metabolites (230). As a result, many serum metabolites may go 
undetected. This holds particularly true for NMR spectroscopy, a fairly insensitive 
method with lower limits of quantification in the low to medium micromolar range (231).  
In conclusion, when different measures of adiposity are considered, VAT showed 
the strongest and most significant relations to urinary metabolites, even when VAT and 
SAT were mutually adjusted. By comparison, SAT showed no associations with urinary 
metabolites. Additional important relations were found between BMI or WC and urinary 
metabolites. However, when BMI and WC were mutually adjusted, most of the relations 
were altered and did not remain significant. Only BMI remained significantly related to 
urinary glutamine in mutually adjusted models. In addition, stronger and more significant 
associations were noted between adiposity measures and urinary metabolites compared 
to the relations to serum metabolites. In general, the present findings support the notion 
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that VAT is more strongly involved in metabolite regulation than abdominal SAT. The 
distinct relations of VAT, BMI, and WC to metabolites and the null-findings for 
associations of SAT and VSR with metabolites emphasize the importance of accurately 
differentiating between body fat compartments when evaluating the potential role of 
adiposity-associated metabolic regulation in the development of obesity-related 
diseases. 
4.1.4 Relations of adiposity measures to the urinary and serum metabolic 
fingerprints  
Results from the untargeted metabolomics approach showed that the 
unsupervised classification of urinary and serum metabolic fingerprints is not capable of 
grouping subjects by their VAT or SAT thickness in the overall study population. 
However, in stratified analyses among women, clusters from serum fingerprints were 
formed that differed statistically significantly by SAT. Specifically, among women, SAT, 
but none of the other measures of obesity influenced the metabolic fingerprint that 
significantly differed between groups of high, medium, and low SAT. This is to be 
expected, as the metabolic fingerprints of generally healthy individuals are influenced by 
a multitude of factors including among others diet, exercise, time of the day, and gut 
flora composition. In addition, although obesity is frequently associated with metabolic 
disorders (11-13), not all obese individuals display a clustering of metabolic risk factors. 
Recent interest has focused on an obese subgroup with a healthy metabolic profile 
despite increased adiposity and has been investigated by several researchers (232-
234).  
When multiple linear regression models were applied, VAT, BMI, and WC were 
consistently related to numerous urinary bins in the overall study population and in 
stratified subgroups. No relations were found between SAT or VSR and urinary bins. By 
comparison, VAT but none of the other measures of obesity was related to serum bins. 
Moreover, relations to serum bins were found in stratified analyses only, indicating that 
serum metabolites might be more strongly influenced by sex differences than urinary 
metabolites. With the application of the untargeted metabolomics approach in 
combination with multiple linear regression models, further candidate metabolites were 
identified that were not included in the set of quantitated metabolites. For instance, in 
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addition to choline, VAT was inversely related to numerous urinary bins identified as 4-
hydroxyhippuric acid, acetone, L-pyroglutamic acid, citric acid, and scyllo-inositol. 
Moreover, in addition to urinary dimethylamine, VAT was positively related to lysine and 
creatinine. Note that for the latter bin, below the dominating creatinine signal a minor 
contribution of tyrosine was observed. These significant relations were also reproduced 
in stratified analyses among non-fasting subjects. Notably, VAT but none of the other 
adiposity measures was significantly inversely related to 4-hydroxyhippuric acid. As a 
glycine conjugate of 4-hydroxybenzoic acid, 4-hydroxyhippuric acid is an end-product 
derived of polyphenol metabolism by the intestinal microflora (235). A previous study 
suggested that the intake of fruits containing polyphenols rich in anthocyanins (i.e., 
berries and grapes) may increase 4-hydroxyhippuric acid in the urine (236). 
Anthocyanins are naturally occurring polyphenols with anti-inflammatory activity (237, 
238). Hence, the observed inverse relations of VAT to 4-hydroxyhippuric acid found in 
the present study may reflect a diet lacking in health benefitting nutrients among 
participants with increased VAT. However, concentrations of 4-hydroxyhippuric acid 
were not quantitated in the present study. Nevertheless, 4-hydroxyhippuric acid may be 
a promising candidate metabolite for future obesity research. 
Associations between VAT and serum bins were found in sex-stratified analyses 
only. This indicates a possible interaction of sex on the association between VAT and 
serum metabolites that needs further investigation. Among men and non-fasting men, 
VAT was significantly related to serum bins that were not significantly related in women. 
Two previous studies demonstrated major differences in metabolic fingerprints between 
men and women (130, 132). Specifically, the authors reported that the serum metabolic 
profile showed no significant difference between lean and obese participants in the 
overall study population. Moreover, similar to the present study, one study reported 
differences in abundance of serum metabolites between lean and obese men, but not 
between lean and obese women (132). Interestingly, no relations were found between 
SAT, VSR, BMI, or WC and serum metabolites, indicating that VAT may be 
predominantly responsible for metabolite alterations in serum among men. Note that the 
significant relations found between VAT and serum bins were detected in untargeted 
analyses could not be corroborated by targeted analyses. However, results from 
targeted analyses showed that the association between VAT and valine (ß=0.07; 
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p=0.06) was “borderline significant” after the correction for multiple testing in fully 
adjusted models. These differences may be explained by the fact that in targeted 
analyses only those integrals are considered that were above the LLOQ, whereas in 
untargeted analyses all integrals for one bin were considered. Moreover, the additional 
normalization of spectral areas using VSN on untargeted data may have attenuated 
some of the relations. 
The positive relations found between VAT and serum valine is consistent with 
findings from previous studies that reported significantly higher levels of BCAA, including 
valine in obese participants compared to lean participants (128, 131, 132, 239). 
Moreover, plasma BCAA levels were positively correlated with insulin resistance in a 
previous study (128). Another study concluded, that BCAAs and aromatic amino acids 
could serve as predictors for the development of diabetes (240). No relations of SAT, 
VSR, BMI, or WC to serum BCAAs were found in the present study, indicating that VAT 
is predominantly involved in the BCAA metabolism. This supports findings from previous 
studies that identified adipose tissue and adipocytes to be a main contributor to whole-
body, branched-chain amino acid catabolism (241). However, the mechanisms 
explaining the elevated levels of BCAAs in obesity are not fully understood. Because 
BCAAs are essential amino acids, a diet high in protein may be one possible explanation 
(242). Yet, two previous studies examining the associations of BCAAs with the risk for 
diabetes and insulin resistance concluded that elevated BCAA levels were not 
influenced by protein consumption (240, 243). Another possible underlying mechanism 
may be a genetic variation in the expression of genes encoding key BCAA catabolic 
enzymes or proteins that control protein synthesis and turnover (242). Interestingly, a 
recent study postulated a potential role of inflammation in controlling the BCAA 
metabolism pathway, indicating that the accumulation of serum leucine, isoleucine, and 
valine may partly be explained by decreased BCAA metabolism in inflamed visceral 
adipose tissue (244). 
In conclusion, in the present study, neither the urinary nor the serum metabolic 
fingerprint was capable to steadily cluster groups that differed by their age and sex 
adjusted mean VAT, SAT, VSR, BMI, or WC. However, VAT was consistently related to 
urinary and serum metabolites in multiple regression analyses. By comparison, SAT and 
VSR showed no relation to urinary or serum metabolites, further indicating that VAT is a 
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major contributor to metabolite regulation. In addition, relations between VAT and serum 
metabolites occurred in sex stratified analyses only. The present findings suggest 
potential pathways that may explain possible mechanisms underlying obesity-associated 
diseases. Specifically, metabolites and their related pathways could be identified that 
may explain mechanisms of obesity-induced low-grade inflammation. In addition, the 
accumulation of VAT may be, at least in part, responsible for dysregulation of BCAAs in 
serum. BMI and WC were consistently related to urinary metabolites but no relations 
were found between BMI or WC and serum metabolites. Compared to the relations of 
WC and BMI to urinary metabolites, relations between VAT and metabolites were 
generally stronger. In addition, some relations of metabolites such as 4-hydrxyhippuric 
acid were unique to VAT. Nevertheless, the number of metabolites that were 
significantly associated with VAT was smaller than the number of metabolites related to 
BMI and WC. This might indicate that the impact of VAT, BMI, and WC differs regarding 
metabolic regulation and metabolic pathways associated with VAT cannot precisely be 
reflected by BMI or WC alone.  
 Strengths and limitations 4.2
The present study is based on a cross-sectional study design. All information 
refers to the same point in time and represents a snapshot of the study population 
regarding the exposure and outcome variables. Thus, the cross-sectional nature of our 
study design precludes an assessment of temporality and reverse causality, i.e., that the 
metabolite changes were due to overt and undiagnosed disease conditions and are not 
explained by body fat composition. Nevertheless, using a data-driven approach, as 
chosen in this study, cross-sectional studies can be instrumental in generating 
hypotheses for future studies. The study population consisted of a rather small sample 
size, potentially resulting in insufficient statistical power to detect associations, 
particularly in subgroup analyses. In addition, the present study population was limited to 
Caucasians, which bears the potential shortcoming that findings may not strictly apply to 
non-Caucasian ethnicities.  
Although gold standard methods to measure VAT and SAT are MRI or CT, these 
approaches are limited in field conditions due to the associated costs and issues 
regarding accessibility, contraindications, and in terms of CT examinations, potential 
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adverse effects of radiation. The major strength regarding the exposure assessment in 
the present thesis is that by the use of ultrasound, abdominal fat compartments could be 
differentiated and quantified. However, the ultrasound method to quantify VAT and SAT 
is not trivial and it requires experienced examiners with considerable skills. A further 
asset of the present study is that all analyses also included classical anthropometric 
variables, such as BMI and WC as exposures, which enabled comparison of results with 
those from VAT and SAT.  
To evaluate the reproducibility and validity of the sonographic-based quantification 
of VAT and SAT, a single MRI slice was used to quantify the area of VAT and SAT. The 
volume of the body fat compartments in the entire abdomen would have been a more 
suitable gold standard criterion because individual variation in the distribution of VAT 
and SAT across the abdominal area may exist (245, 246). However, validation studies 
with large sample sizes (n>668) showed high correlations between single slice MRI or 
CT measurements and volume of abdominal fat compartments (r>0.96) (179, 247). 
Additionally, it was not possible to examine the true agreement between the two 
methods because the ultrasound and MRI measurements were based on different 
dimensions or units (thickness vs. area). However, there was strong agreement between 
ultrasound and MRI measures when using thickness measurements as a substitute for 
abdominal fat area. The ICC was calculated as a measure of reproducibility in the 
present thesis. An advantage of the ICC is that it accounts for both variance 
components: between- and within-person variation and their relation (173, 248). 
The present data is based on data retrieved from the pre-test studies of the GNC. 
Therefore, compromises had to be taken in biological specimen collection because of 
logistic reasons and cost constraints. Participants of the study were examined only once 
and consequently, urinary and serum analyses were based on a single laboratory 
measurement and they may not represent the true long-term average urinary and serum 
concentrations of inflammatory parameters and metabolites. In addition, all participants 
of pre-test I were non-fasted and only a small proportion of participants from pre-test II 
provided fasting blood and urine samples. Hence, the inflammation study included non-
fasting participants only, whereas the metabolomics study population was 
heterogeneous and it included fasting and non-fasting participants. However, the focus 
was directed on inflammatory parameters that are unaffected by fasting status (249, 
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250) and a previous study on the reliability of metabolite concentrations over time stated 
that for most metabolites, a single measurement may be sufficient (251).  
The inflammation study accounted for correlations between individual parameters 
of systemic inflammation by mutual adjustment in multivariable models, which has not 
been done in any previous study. In addition, numerous informative exploratory 
subgroup analyses were conducted. Due to the numerous additional analyses 
performed, some of the findings may have been the result of multiple testing. 
In the main metabolomics analysis, data of fasted and non-fasted participants were 
combined. Differences in diet (e.g., meat or dairy consumption) may induce variation in 
both serum and urinary metabolites (252). However, one study reported that habitual 
diet had only a small impact on serum metabolites (253). Unfortunately, the majority of 
the urine and blood specimens were non-fasting, and stratifying by fasting status may 
have resulted in reduced statistical power in fasting participants. Stratified analyses 
among the non-fasting participants showed that associations between anthropometric 
measurements and urinary and serum metabolites had the same direction and were of 
similar strength compared to the overall study population, which indicates that these 
associations might not be affected by fasting status. Nevertheless, among non-fasting 
participants, more significant results were found between VAT and urinary bins in 
untargeted analyses than in the overall study population, indicating that fasting status 
may affect some urinary metabolites.  
The metabolomics study included both, a targeted and an untargeted approach on 
urine and serum specimens and it represents an innovative and comprehensive 
approach to study biological mechanisms related to VAT and SAT. However, the 
statistical approach of NMR-obtained metabolomics data is challenging due to large and 
complex datasets. Data normalization is an essential step in NMR-based metabolomics 
to improve data quality and to remove unwanted bias such as differences in fluid intake, 
experimental error, or technical variation (177). In the present thesis, urinary data were 
creatinine-normalized to account for dilution effects due to differences in fluid intake. The 
assumption is that creatinine is an indicator of the concentration of urine due to a 
constant excretion of creatinine into urine (254). However, the application of the 
creatinine normalization is faced by technical and biological difficulties. For instance, 
from a technical perspective, the determination of the creatinine concentration can be 
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interfered by metabolites with peaks overlapping with creatinine signals (e.g., creatine at 
3.04 ppm) (255). Moreover, the pH of samples determines the chemical shift of 
creatinine at 4.05 ppm necessitate a sophisticated peak-picking algorithm. Biological 
challenges in the context of creatinine normalization are changes of the concentrations 
of creatinine caused by metabolomic responses, which has been shown in previous 
studies (256, 257). 
In the present thesis, two main statistical strategies were followed. On the one 
hand, data reduction strategies by AP clustering were applied. AP uses pairwise 
similarities as inputs and iteratively determines clusters along with samples that are 
representative for the clusters, so-called exemplars (175). The aim of AP clustering was 
to determine if this unsupervised classification was capable of separating groups based 
on their VAT or SAT thicknesses. Advantages of this method are that the number of 
clusters does not need to be pre-specified, that exemplars are real samples instead of 
hypothetical averages, and that the algorithm is rather deterministic and not sensitive to 
initialization (258). However, the interpretation of the results from cluster analyses is 
difficult and most often, clusters cannot be reproduced by other data sets. In general, a 
cluster is simply a collection of cases that are more “similar” to each other than they are 
to cases in other clusters. 
By comparison, regression models are easier to interpret with the drawback of 
multiple testing. Specifically, by conducting multiple analyses, the results are expected 
to be false positive by chance due to type I error. Based on a common significance level 
of α=0.05, there is a 5% chance of having a falsely significant result. One possibility to 
address these concerns is to adjust the significance level α by setting a lower threshold. 
In general, multiple testing corrections successfully decrease type I error and the 
number of false positives but on the cost of increasing type II error and the number of 
false negative results. A very common but conservative approach to correct for multiple 
testing among independent tests is the use of the Bonferroni method (259). This 
procedure controls the overall experiment-wise type I error rate through adjusting the 
threshold of the significance level by dividing this level by the number of all performed 
tests. However, the analytical metabolomics dataset includes in part highly correlated 
metabolites, so that the assumption of independent tests is not appropriate. In case of 
highly correlated metabolites, the type II error and therefore the number of false negative 
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results would increase even more when applying this method. In the present thesis, an 
alternative approach was applied to control the problem of multiple testing by controlling 
the FDR according to the Benjamini-Hochberg method (260). This approach is less 
conservative compared to Bonferroni and type II error appears less often (261).  
Another challenge of high throughput metabolomic analysis is the subsequent 
identification of compounds. This is crucial in order to confer a biological meaning to the 
associated features from data analyses. However, biological specimens contain 
hundreds of metabolites that vary considerably in quantity and can produce highly 
overlapping peaks (262). In addition, it is not unusual that for one bin a number of 
database records exist, leading to an exploration of a combinatorially large space of 
candidate metabolites. Further, numerous factors, e.g., changes in pH and ionic 
strength, or a potential pH and ionic interaction, may shift generated peaks from the 
expected position of the metabolite, thereby introducing “positional uncertainty” (262, 
263). 
In general, the major strength of the present thesis is the interdisciplinary nature of 
the study, drawing on methods from radiology, clinical chemistry, functional genomics, 
and epidemiology. Certainly, every discipline represented in this study offers virtually 
unlimited potential itself for explicit research with respect to obesity and obesity-related 
diseases. However, the applied interdisciplinary approach provides a unique 
comprehensive insight into the complex domain of obesity research, which none of the 
individual disciplines could have done on their own. 
 Conclusion and outlook 4.3
The present thesis represents one of the first studies that successfully adopted the 
ultrasonographic measurement of VAT and SAT in a population-based context to 
investigate correlations with systemic low-grade inflammation as well as urinary and 
serum metabolite regulation. In particular, VAT and SAT measured in the pre-test 
studies of the GNC were systematically studied with regard to their reproducibility and 
validity. Results showed that the intra- and inter-observer reproducibility of the 
ultrasound measurements of VAT and SAT was high. Compared to MRI measurements 
of VAT and SAT area, ultrasound can be evaluated as a valid method for assessing VAT 
and SAT. The correlation between the two methods was high, particularly for VAT. 
Discussion 
92 
 
However, among obese subjects, the correlation between the two methods was 
somewhat lower compared to lean subjects. Nevertheless, this work has shown that 
sonographic measurements of VAT and SAT are a reliable measurement technique that 
can be implemented in population-based studies that may help to better understand the 
mechanisms underlying the correlation with crude obesity phenotypes, such as BMI. 
Future research might also investigate whether VAT and SAT might help identify 
individuals at elevated risk of obesity-related diseases and whether these measures 
have clinical utility and are cost-effective. As a result, intervention strategies can be 
developed and applied early to enhance quality of life and reduce health care costs. 
The distinct relationships of VAT, SAT, VSR, BMI, and WC to selected parameters 
of systemic chronic inflammation and urinary and serum metabolites further emphasize 
the importance of accurately differentiating between body fat compartments in obesity 
research. VAT, but not SAT was most consistently related to systemic low-grade 
inflammation as well as to urinary and serum metabolite regulation. Interestingly, in the 
present study, WC represented a less consistent measure of adiposity. Confounders 
regarding WC may exist by the assumption that VAT represents a pathogenic fat depot 
and SAT represents a more protective or at least less metabolic active fat depot, 
showing only few relations with urinary or serum compounds in the present study. 
Hence, it could be argued that the measure of WC is inherently flawed, given that WC 
would represent a mixture of both pathogenic and protective fat depots (28). This would 
support why relations of WC to inflammatory parameters and metabolite levels were 
found to be less strong and less consistent in the present study. This may also explain 
the rare, respectively null findings for the associations between VSR and inflammatory 
parameters and urinary and serum metabolites. 
Deep phenotyping enables the precise examination of biological consequences of 
obesity (118). Specifically, biological mechanisms that are perturbed by obesity can 
precisely be linked to the obese phenotype and detect different dimensions of obesity. In 
the present study, the obese phenotype has been extensively characterized through 
examining VAT and SAT, calculating the ratio between these tissues, and measuring 
BMI and WC. Moreover, in addition to studying individual risk factors, more systematic 
approaches may help to better address and counteract the multifactorial genesis of 
obesity (105, 114, 115). Accordingly, in addition to the study of individual inflammatory 
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parameters, a targeted and untargeted metabolomics approach on urine and serum 
specimens was chosen to identify potential metabolite candidates that may explain 
mechanisms related to the development of obesity-associated diseases. In particular, 
compositional changes of gut microbial metabolites and dysregulation of BCAAs 
describe potential pathways that have been linked to the occurrence of low-grade 
systemic inflammation. Notably, urinary choline, dimethylamine, and 4-hydroxyhippuric 
acid may represent promising candidates that seem worthy of being addressed in future 
research. In addition, a replication study needs to be conducted, preferably in multiple 
independent population-based studies covering a broader geographic area and various 
ethnicities, to validate the findings of the present thesis. If the identified metabolites are 
replicated in independent data, future research should examine whether these novel 
metabolome biomarkers are related to disease onset.  
Summary 
Obesity is a complex multifactorial disease influencing several metabolic 
pathways. To better understand biological mechanisms that link obesity to obesity-
associated diseases, it is indispensable to comprehensively characterize the obese 
phenotype by including the examination of adipose tissue compartments. In line with the 
exhaustive characterization of the obese phenotype, the thorough investigation of the 
metabolic phenotype may enhance our understanding of the metabolic consequences of 
unhealthy body fat distribution. Taken together, these approaches may further improve 
the prediction of obesity-related diseases in the future. Consequently, persons at high 
risk for the development of those diseases may be identified early before the actual 
disease onset. Thus, intervention strategies can be implemented to prevent obesity-
related morbidity and mortality. 
Ultrasound represents a low-cost and widely available field method for assessing 
visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). Findings from 
the present study demonstrate that VAT and SAT thicknesses quantified by ultrasound 
provide highly reproducible estimates independent of observer, subject, or ultrasound 
device. For instance, the inter-rater reproducibility values for VAT and SAT were 0.998 
and 0.990, respectively. Moreover, compared to gold standard methods (magnetic 
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resonance imaging), the ultrasound measured VAT and SAT provides valid estimates 
with correlation coefficients of 0.898 (p<0.001) and 0.705 (p<0.001), respectively. 
Hence, the sonographic-based measurement of VAT and SAT can be considered a 
suitable method to assess abdominal fat in large-scale epidemiologic studies. 
Adipose tissue is characterized as an endocrine organ and its dysfunction has 
been considered a central component of obesity-related inflammation and the main 
instigator of the pathological consequences of obesity. There is a need of describing 
biologically sound, multifaceted, and robust phenotypes to provide useful information 
about physiological and pathological states. In particular, to negotiate the limitations of 
the body mass index (BMI), relations of abdominal obesity and different adipose tissues 
to metabolic regulation are examined to unravel metabolic pathways perturbed by 
obesity and may consequently improve our understanding of the development of 
obesity-related diseases.  
Results from the present thesis showed that different measures of body fat 
distribution differed in their relations to parameters of chronic inflammation. Specifically, 
VAT, SAT, BMI, and waist circumference (WC) were all associated with high sensitive 
C-reactive protein (hs-CRP). Additionally, BMI was inversely related to adiponectin and 
the ratio of visceral to subcutaneous body fat (VSR) was inversely related to resistin. In 
exploratory subgroup analyses, VAT was the strongest indicator for increased levels of 
interleukin-6 (IL-6). SAT was the most consistent indicator for increased levels of hs-
CRP and BMI was the most consistent indicator for decreased levels of adiponectin. WC 
represented a weak indicator for increased levels of hs-CRP and decreased levels of 
adiponectin. In addition, by investigation of the urine and serum metabolom, a more 
comprehensive approach that does not only focus on single biomarkers was applied in 
the present thesis. Nuclear magnetic resonance spectroscopy (NMR) based 
metabolomics simultaneously examines all measurable low-weight molecular 
compounds present in biological samples and aims to unravel biological mechanisms to 
identify pathways through which behavioral factors and phenotypes are linked to 
metabolism.  
VAT, BMI, and WC were inversely related to urinary metabolites including choline 
and also positively related to metabolites including dimethylamine, in multivariable 
regression models. In addition, inverse relations to the newly discovered urinary 4-
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hydrxyhippuric acid were solely found for VAT. By comparison, only BMI and WC 
showed inverse relations to urinary glutamine. VAT, but none of the other 
anthropometric parameters was related to serum metabolites including essential amino 
acids, such as valine and phenylalanine among men. Compared to SAT, VSR, BMI, and 
WC, VAT demonstrated the strongest and most often the most significant relations to 
urinary and serum metabolites. In addition, relations between VAT and serum 
metabolites occurred sex-specific. The distinct relations of VAT, SAT, VSR, BMI, and 
WC to inflammatory parameters and metabolites emphasize the importance of 
accurately differentiating between body fat compartments when evaluating the potential 
role of adiposity-associated metabolic regulation in the development of obesity-related 
diseases. The precise attribution of metabolic consequences to obesity measures is 
crucial when investigating the etiology of obesity-associated diseases. 
Zusammenfassung 
Adipositas stellt eine komplexe, multifaktorielle Erkrankung dar, die verschiedene 
Stoffwechselwege beeinflusst. Um die biologischen Mechanismen, der 
Zusammenhänge von Adipositas mit Adipositas-assoziierten Erkrankungen besser zu 
verstehen, ist es unumgänglich, den adipösen Phänotypen durch die Bestimmung der 
viszeralen und subkutanen Körperfettschichten umfangreich zu charakterisieren. 
Zusammen mit der umfassenden Charakterisierung des adipösen Phänotyps, sollen 
durch die systemische Untersuchung des metabolischen Phänotyps die Auswirkungen 
der Körperfettverteilung auf das metabolische Profil besser verstanden werden. Beide 
Ansätze in Kombination, können Adipositas-assoziierte Erkrankungen in der Zukunft 
möglicherweise besser vorhersagen als bisher. Daraus würde resultieren, dass 
Personen mit einem hohen Risiko für die Entwicklung Adipositas-assoziierter 
Erkrankungen früher erkannt werden könnten. Entsprechend könnte diesen 
Erkrankungen durch entsprechende Interventionen vorgebeugt werden.  
Ultraschall ist eine kostengünstige und weitgehend verfügbare Feldmethode zur 
Quantifizierung der viszeralen (VAT) und subkutanen (SAT) Körperfettkompartimente. 
Ergebnisse aus der vorliegenden Arbeit haben gezeigt, dass unter Anwendung eines 
standardisierten Untersuchungsprotokolls die mit Ultraschall gemessenen VAT und SAT 
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Dicken unabhängig von Untersucher, Studienteilnehmer und Ultraschallgerät 
reproduzierbar sind. Zum Beispiel waren die  Intraklassenkorrelationskoeffizienten von 
VAT und SAT für die Inter-Untersucher Reproduzierbarkeit mit 0.998 und 0.990 
besonders hoch. Des Weiteren liefert die sonographische Quantifizierung valide 
Messwerte für VAT (ρ=0.898; p<0.001) und SAT (ρ=0.705; p<0.001) im Vergleich zur 
Goldstandardmethode (Magnetresonanztomographie). Die ultraschallbasierte Erhebung 
von VAT und SAT kann somit als geeignete Methode zur Anwendung in 
epidemiologischen Studien bewertet werden.  
Das Fettgewebe wird als endokrines Organ bezeichnet, dessen Anomalien 
zentraler Bestandteil Adipositas-assoziierter Inflammation darstellen und als wesentliche 
Auslöser der pathologischen Konsequenz von Adipositas gelten. Eine wichtige 
Voraussetzung bei der Ermittlung nützlicher Informationen zum physiologischen und 
pathologischen Status ist die biologisch gründliche, vielfältige und robuste 
Charakterisierung der Phänotypen. Bei der Untersuchung der durch Adipositas 
gestörten Stoffwechselvorgänge, müssen die Limitationen des Body Mass Index (BMI) 
beachtet werden und sollten mit der Erhebung der abdominellen Adipositas und den 
verschiedenen Körperfettkompartimenten erweitert werden. Somit werden genauere 
Informationen gesammelt und die Mechanismen bei der Entstehung von Adipositas-
assoziierten Erkrankungen besser erklärt.  
Die Ergebnisse aus der vorliegenden Arbeit haben gezeigt, dass verschiedene 
Messungen der Körperfettverteilung unterschiedlich mit chronischen 
Inflammationsmarkern assoziiert sind. So waren VAT, SAT, BMI und der Taillenumfang 
(WC) positiv mit dem hochsensitiven C-reaktiven Protein (hs-CRP) assoziiert. BMI 
zeigte zusätzlich einen inversen Zusammenhang mit Adiponektin. Das Verhältnis 
viszerales Fett zu subkutanem Fett (VSR) war invers mit Resistin assoziiert. In 
explorativen Subgruppenanalysen zeigte VAT die stärkste Assoziation mit erhöhten 
Interleukin-6 (IL-6) Konzentrationen. SAT war eine konsistente Messgröße für erhöhte 
hs-CRP Level und BMI war die konsistenteste Messgröße für niedrige 
Adiponektinspiegel. WC zeigte schwache Zusammenhänge mit erhöhten hs-CRP 
Spiegeln und niedrigen Adiponektinkonzentrationen. Zusätzlich zur Untersuchung von 
einzelnen Biomarkern wurde in der vorliegenden Arbeit die eingehende Analyse des 
Urin- und Serummetaboloms angewandt. Die Kernresonanzspektroskopische (NMR) 
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Messung des Metaboloms ermöglicht die gleichzeitige Untersuchung aller messbaren 
niedermolekularen Stoffe in Bioproben mit dem Ziel, biologische Mechanismen und 
Stoffwechselwege zu identifizieren, welche durch Lebensstilfaktoren und Phänotypen 
beeinflusst werden. 
VAT, BMI und WC waren in multivariablen Regressionsmodellen unter anderem 
invers mit Cholin und positiv mit Dimethylamin im Urin assoziiert. Darüber hinaus konnte 
die inverse Beziehung zu dem neu entdeckten Metaboliten 4-hydroxy-hippursäure im 
Urin einzig für VAT gezeigt werden. Im Vergleich dazu waren nur BMI und WC invers 
mit Glutamin im Urin assoziiert. VAT, jedoch keine der anderen anthropometrischen 
Parameter, war mit Serummetaboliten, wie beispielsweise den essentiellen 
Aminosäuren Valin und Phenylalanin, bei Männern assoziiert. Im Vergleich zu SAT, 
VSR, BMI und WC waren die Zusammenhänge zwischen VAT und Urinmetaboliten am 
stärksten und oftmals am signifikantesten. Des Weiteren konnten 
geschlechtsspezifische Zusammenhänge zwischen VAT und Serummetaboliten gezeigt 
werden. Die unterschiedlichen Assoziationen von VAT, SAT, VSR, BMI und WC mit 
Inflammationsmarkern sowie Urin- und Serummetaboliten unterstreichen die 
Notwendigkeit, bei der Untersuchung der von Adipositas beeinflussten 
Stoffwechselvorgänge im Zusammenhang mit der Entstehung Adipositas-assoziierter 
Erkrankungen die Körperfettzusammensetzung umfassend zu betrachten. 
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Ziel 
Das Ziel ist bei TN der Nationalen Kohorte die abdominalen Körperfettdepots mittels 
Ultraschall zu differenzieren und zu quantifizieren.  
 
Geltungsbereich der SOP 
Die SOP gilt für alle Mitarbeiter, die mit diesem Modul befasst sind. Dies sind 
insbesondere Trainer/Monitore und das Untersuchungspersonal. 
 
Abkürzungen 
BMI  Body Mass Index 
Mango  Eingabetool zur Datenerfassung 
QS  Qualitätssicherung  
SAT  Subkutanes adipöses Fettgewebe  
SOP  Standard Operating Procedure 
SZ  Studienzentrum 
TN  Teilnehmer 
VAT  Viszerales adipöses Fettgewebe 
ZDM  Zentrales Datenmanagement 
 
Hintergrund 
Die Adipositas stellt ein multifaktorielles Geschehen dar und ist aufgrund ihrer zentralen 
Rolle bei der Entwicklung von bedeutenden chronischen Erkrankungen, wie z. B. kardio-
vaskuläre Erkrankungen, Typ 2 Diabetes und Krebs, für epidemiologische Forschungs-
projekte von wesentlichem Interesse. Vor allem das viszerale adipöse Fettgewebe 
(VAT) gilt als ein unabhängiger Risikofaktor für die Entwicklung Adipositas-assoziierter 
Erkrankungen. Hingegen weist das subkutane adipöse Fettgewebe (SAT) einen 
antiatherogenen Effekt auf und ist mit einer erhöhten Insulinsensitivität sowie mit einem 
geringeren Risiko für die Entwicklung von Typ 2 Diabetes und Dyslipidämien assoziiert. 
 
Die gängigen anthropometrischen Methoden zur Messung des Körperfetts wie z.B. 
Körpermassenindex (BMI), Hüftumfang oder Taillen-Hüft-Verhältnis unterscheiden nicht 
zwischen der viszeralen und subkutanen abdominellen Körperfettverteilung. Inzwischen 
ist jedoch bekannt, dass bei den Fettmessungen nicht nur die Größe bzw. Menge, 
sondern v.a. auch die anatomische/regionale Verteilung der Fettdepots entscheidend ist. 
Die präziseren Methoden wie Computertomographie und Magnetresonanztherapie 
eignen sich jedoch nicht für den Einsatz in großen Kohorten, da diese Methoden invasiv 
und kostenintensiv sind. Eine mögliche Alternative bietet die Ultrasonographie. Die 
Ultrasonographie ermöglicht die Quantifizierung der abdominalen Körperfettdepots. Sie 
verwendet Ultraschallwellen, die über einen Schallkopf in den Körper gestrahlt werden 
und im Körper reflektiert oder absorbiert werden. Die reflektierten Wellen werden 
anschließend vom Schallkopf aufgenommen. Die Schallwellen, die von festem Gewebe 
wie z. B. Knochen reflektiert werden, sind am größten und erscheinen weiß auf dem 
Bildschirm. Weiches Gewebe wird grau oder gefleckt dargestellt, während Flüssigkeiten 
schwarz erscheinen, da sie kein Echo abgeben. Aus diesen Wellen wird ein Bild 
berechnet und auf dem Monitor sichtbar gemacht. Diese bildgestützte Methode liefert 
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somit Informationen über die Dicke der verschiedenen abdominellen Körperfett-
kompartimente. Ultrasonographie gilt als valide Methode zur Quantifizierung von SAT 
und VAT, die nicht invasiv, schmerzfrei und kosteneffizient ist. 
 
 
 
Verantwortlichkeiten 
Tabelle 1 Übersicht Verantwortlichkeiten 
Funktion Verantwortlichkeiten 
Modulverantwortliche: 
 
Inga Schlecht 
Universität Regensburg 
Tel. 0941 944 52 16 
inga.schlecht@ukr.de 
 
 Autor des SOPs 
 Schulung und Zertifizierung von Trainern 
 Ansprechpartner  
Wissenschaftlicher Stab  Beteiligung am Review Prozess 
Trainer / Monitore  Lokale Schulung der Untersucher im eigenen SZ 
 Site Visits und Zertifizierung der Untersucher eines 
benachbarten SZ 
Untersuchungspersonal  Durchführung der Untersuchung 
Zentrales 
Qualitätsmanagement 
(zQM) 
 Begleitung und Überwachung des Reviewing-
Prozesses 
 Dokumentenverwaltung 
Externe QS 
 Site Visits und Meldung von Problemen bzgl. QS 
an jeweiliges SZ und an zQM 
 
Verweise 
Literaturhinweise zur Ultraschallmethode: 
 
 Manual für das Mindray DP 50  
 Stolk, R.P., et al., Validity and reproducibility of ultrasonography for the measurement 
of intra-abdominal adipose tissue. Int J Obes Relat Metab Disord, 2001. 25(9): p. 
1346-51. 
 
 
 
Prozesse 
Ausstattung des Untersuchungsplatzes / Messumgebung 
- Raumsituation 
Supplements 
104 
 
Der Raum sollte für die Ultraschalluntersuchung abgedunkelt werden und es sollte eine 
angenehme Raumtemperatur erreicht sein. 
 
- Messgeräte 
Mindray DP 50 
 
Relevante Bedienfelder:  
 
        
1. An- und Ausschalter 
ACHTUNG: Caps Lock Taste beim erstem Einschalten deaktivieren! 
 
2. Mauszeiger 
  Aktiviert Bewegung mit Trackball/Maus 
 
3. Linke Taste 
 ermöglicht Bestätigung 
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4. Konvexschallkopf auswählen 
 Preset/Schallkopf (Touchpanel) anwählen 
 C5-1 3,5-5 MHz (meist voreingestellt) 
 Abdomen Gefäße anwählen 
 
5. Patientendaten eingeben 
 Eingabe Nachname: IDS 
 Eingabe Patientennr.: IDS  
 Eingabe Untersucht von: Untersuchernummer 
 Auswahl Studientyp: Abdomen  Sortieren von Echo und Abdomen zu 
ermöglichen  
 Eingabe Kommentare.: ABD  Sortieren von Echo und Abdomen zu 
ermöglichen  
 Mit Schließen zurück zu Monitor 
 
 
 
6. iScan: 
 Automatische Bildoptimierung 
 
7. Gain: 
 Heller oder dunkler 
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8. Komprim.: 
 Kontraste härter oder weicher einstellen 
 
9. Frequenz (Touchpanel): 
Voreinstellung HAllg. 
 Tiefer: Pen, HPen 
 Näher: HAufl. 
 
10. Tiefe: 
- Anpassung der Eindringtiefe um relevante Messpunkte gut sichtbar darzustellen  
 
11. Einfrieren (Freezing Mode): 
 Erzeugt stehendes Bild 
 Distanzmessung erfolgt am stehenden Bild  
 
12. Messpunkt: 
 Ermöglicht Distanzmessung durchzuführen 
 
13. Eingeben:  
 Speichern des Bildes 
 
14. Untersuchung beenden 
 
15. Überprüfen: 
 Um abgespeicherte/abgeschlossene Untersuchungen aufzurufen 
 
Weitere Einrichtungs- und Ausstattungsgegenstände 
1. Untersuchungsliege 
2. Ganzkörperspiegel 
3. PC für die Dateneingabe ins Mango 
4. Xcelera Servive als Speicherplatz für Bilder 
 
Verbrauchsmaterialien 
1. Papierauflage für Untersuchungsliege 
2. Gel für die Messungen (z.B. Sonosid von ASID Bonz GmbH) 
3. Maßband  
4. Kajalstift zur Markierung der Messpunkte auf der Haut 
5. Geeignetes Desinfektionsmittel zur Reinigung des Schallkopfs (z.B. Cleanisept 
Wipes Desinfektionstücher) 
6. Tücher zum Abwischen des Gels 
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Software 
1. Gerätesoftware: Mindray DP 50 
2. Mango Datenbank in der aktuellsten Version 
 
Die Eingabe der Daten erfolgt zunächst manuell auf dem vorgesehenen Papierbogen. 
Die Daten müssen anschließend in das vorgesehene Formular im Mango übertragen 
werden. 
 
Vorbereitung vor Studienbeginn 
 Aufstellung der Geräte 
Das Ultraschallgerät sollte unmittelbar nahe, rechts oder links der 
Untersuchungsliege aufgestellt werden. Für die Ultraschalluntersuchung des 
Abdomen muss die C5-1 3,5-5 MHz Sonde angeschlossen sein. Es kann ein 
Barcode Scanner am Ultraschallgerät angeschlossen werden. 
 
 Grundeinstellungen der Gerätesoftware 
Das Ultraschallgerät wird mit einer Netzwerkverbindung zum Xcelera Server 
verbunden, sodass eine automatische Übertragung der Aufnahmen zum Server 
erfolgen kann. Die Ergebnisse der Distanzmessungen von VAT und SAT werden 
händisch in das vorgesehene Formular im Mango eingetragen. 
 
 
Durchführung 
Zusammenhänge mit anderen Modulen und Messbedingungen  
Die Untersuchung kann gut mit der anthropometrischen Untersuchung verknüpft 
werden, da die Messung des Taillenumfangs mit der Markierung des Messpunkts für die 
Ultraschalluntersuchung einhergeht.  
Vorbereitung vor jeder Messung 
Der Raum sollte für die Ultraschalluntersuchung abgedunkelt werden und es sollte eine 
angenehme Raumtemperatur erreicht sein. Das Ultraschallgerät Mindray DP 50  (2D) 
mit 3,5 – 5 MHz Konvexschallkopf muss vorbereitet und angeschaltet sein. 
Untersuchungsliege (mit Papier ausgelegt), Gel für die Messungen, Maßband, Stift zur 
Markierung der Messpunkte auf der Haut, Desinfektionsmittel zur Reinigung des 
Schallkopfs und ausreichend Tücher zum Abwischen des Gels sollten zur Verfügung 
stehen. Auch sollte der vorhandene Speicherplatz für Bilder überprüft werden. 
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Ausschlusskriterien 
Es gibt keine Ausschlusskriterien für die Ultraschalluntersuchung mit der Ausnahme 
einer fehlenden Einwilligung des TN für dieses Modul. Eine Messung bei 
fortgeschrittener Schwangerschaft (ab SSW 15) macht jedoch wenig Sinn. 
Aufklärung des Studienteilnehmers 
Zunächst wird dem TN das Verfahren und Vorgehen erklärt (siehe Punkt 4 Hintergrund 
und 7.3.7 Messprinzip). Die Sonographie sollte direkt im Rahmen der 
anthropometrischen Untersuchung durchgeführt werden. Eine Prozedur wird ca. 5-10 
Minuten dauern. Es sind keine möglichen Risiken bekannt.  
Start der Messungen über Mango 
 
 
 
 
 
Bei der Menüauswahl „Untersuchung durchführbar“ muss Ja ausgewählt werden damit 
sich die Eingabemaske für die SAT und VAT Werte öffnet. 
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Etwaige Auffälligkeiten können unter „Bemerkung zur Messung“ angelegt werden oder 
es kann eine Notiz zur Untersuchung angelegt werden. 
 
Durchführung der Messung 
 
Vor der Ultraschalluntersuchung wird am stehenden TN ein Messpunkt mit einem 
Kajalstift auf die Haut aufgetragen. Der Messpunkt ergibt sich aus der Messung des 
Taillenumfangs: Am Schnittpunkt aus den beiden lateralen Messpunkten beidseits exakt 
mittig zwischen unterem Rippenbogen und höchstgelegenem Punkt des Beckenkammes 
mit der ventralen Mittellinie (die Medianlinie und der Schwertfortsatz dienen hier zur 
Orientierung). Der Messpunkt wird direkt am oberen Rand des Maßbands gesetzt.  
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Während der Untersuchung liegt der TN in Rückenlage auf der Untersuchungsliege. Die 
Schulter, Arme, Fersen und das Gesäß müssen auf der Liege aufliegen. Die 
Oberbekleidung kann ausgezogen oder nach oben geschoben werden, so dass der 
Bauch für die Messung freiliegt. 
 
Messprinzip 
Die subkutane und viszerale Messung bilden eine schräg verlaufende Sichtweise zur 
Darstellung der Bauchmuskulatur (rectus abdominis) und Linea alba ab. Die Messung ist 
ohne Verformung (durch Kompression) auf der Haut mit der Nutzung von 
entsprechendem Gel durchzuführen. Die Linea alba ist bei der Messung horizontal im 
Zentrum des Bildes. Die Messung mit dem Caliper erfolgt ebenfalls senkrecht im 
Zentrum des Bildes.  
 
Das Ultrasonographieprotokoll beinhaltet 4 zweidimensionale Bilder mit insgesamt 4 
Distanzmessungen. Durch Regulierung der Eindringtiefe („Tiefe“ Drehtaste) werden die 
Feineinstellung zur Darstellung der Messpunkte von SAT und VAT vorgenommen. Für 
die Bestimmung von SAT und VAT werden jeweils 2 fixierte Bilder (Freezing Mode) 
gespeichert. Bei allen Bildern erfolgt eine Distanzmessung mit Hilfe des elektronischen 
Calipers/Trackball und der „Messpunkt“ Taste am Ultraschallgerät. Die Bilder sollen mit 
der Distanzmessung abgespeichert werden („Eingeben“ Taste).  
 
Alle Messungen erfolgen als stehendes Bild am Ende des (gewöhnlichen) Ausatmens 
(Hinweis für den TN: „Am Ende der Ausatmung die Luft anhalten“); das elektronische 
Caliper ist senkrecht im Zentrum des Bildes positioniert. 
 
Nach der ersten Distanzmessung wird die Sonde für das zweite Bild jeweils neu 
angesetzt. 
 
1. SAT:  
Zwei fixierte Bilder die jeweils auf Distanz vermessen werden. Für die Analyse des 
SAT erfolgt die Distanzmessung an der Medianlinie von der Hautoberfläche bis 
zur Linea alba (siehe Abbildung, S.12). 
 
 
 
2. VAT:  
Zwei fixierte Bilder die jeweils auf Distanz vermessen werden. Die 
Distanzmessungen von VAF erfolgen von der Linea alba zur Vorderkante des 
Lendenwirbelkörpers mittig, am Schnittpunkt aus den beiden lateralen 
Messpunkten und der ventralen Mittellinie (siehe Abbildung, S. 12). 
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Durch die Verwendung der Ultrasonographie können folgende Parameter bestimmt 
werden: 
 
1. Subkutane Fettdicke (cm) 
  
 
2. Viszerale Fettdicke (cm) 
  
 
 
 
 
 
SAT: Distanzmessung von der 
Hautoberfläche bis oberhalb 
der Linea alba. 
 
VAT: Distanzmessung von 
unterhalb der Linea alba bis 
zur Vorderkante des 
Lendenwirbelkörpers. 
 
Supplements 
112 
 
Tabelle 2 Schritte bei der Durchführung der Untersuchung 
1. Gerät einschalten Siehe Ein-Ausschalter (Kapitel 7.1.2: Messgeräte) 
2. TN lagern Markierung des Messpunkts auf der Haut ist 
erfolgt. TN in Rückenlage auf der 
Untersuchungsliege platzieren. Schultern, Arme, 
Fersen und das Gesäß müssen auf der Liege 
aufliegen. 
Oberbekleidung kann ausgezogen oder nach oben 
geschoben werden, so dass der Bauch für die 
Messung freiliegt. 
3. Position  
des Untersuchers 
Die Sitzposition kann der Untersucher selbst 
wählen. 
Es kann von rechts als auch von links geschallt 
werden. 
4. Schallkopf auswählen C 5-1  
 
 
 
5. TNdaten eingeben Eingabe der IDS, Untersuchernummer, des 
Studientyps  und Kommentar (Kapitel 7.1.2: 
Messgeräte) 
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6. Zur 
Untersuchung/Monitor 
Mit „Schließen“ gelangt man aus der Maske 
Patientendaten zur Untersuchung 
7. Schallkopf nehmen Schallkopf aus Halterung nehmen und Gel auf 
Schallfläche geben 
8. Positionierung  
des Schallkopfes 
Auf vormarkierte Stelle 
Dunkelgraue Markierung am Schallkopf zeigt vom 
Untersucher weg wenn dieser auf der linken Seit 
vom TN positioniert ist 
9. 1. Subkutanes Fett Gestartet wird mit der Messung von SAT. 
 
Druck vermeiden und Atemkommando geben! 
 
Vorgehen: 
erstes Ultraschallbild SAT 
1.Messung: eine Messung am stehenden Bild 
(Tiefe und iScan Optimierung, siehe Kapitel 7.1.2: 
Messgeräte) 
 Messpunkte mit Hilfe des Trackballs und der  
Messpunkt Taste setzten (siehe Kapitel 7.3.7: 
Messprinzip) 
 Bild mit Distanzmessung speichern (Eingeben) 
 Messwert mit zwei bzw. drei 
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Nachkommastellen auf dem Dokubogen 
eintragen (bei SAT Werten kleiner 1.00cm 
bitte drei Nachkommastellen eintragen) 
 
zweites Ultraschallbild SAT 
   selbiges Vorgehen 
 
 
10. 2. Viszerales Fett Anschließend erfolgt die Messung von VAT. 
 
Druck vermeiden und Atemkommando geben! 
 
Vorgehen: 
erstes Ultraschallbild VAT 
1.Messung: eine Messung am stehenden Bild 
(Tiefe iScan Optimierung, siehe Kapitel 7.1.2: 
Messgeräte) 
 Messpunkte mit Hilfe des Trackballs und der  
Messpunkt Taste setzten (siehe Kapitel 7.3.7: 
Messprinzip) 
 Bild mit Distanzmessung speichern (Eingeben) 
 Messwert auf dem Dokubogen eintragen 
 
zweites Ultraschallbild VAT 
   selbiges Vorgehen 
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11. Messprotokoll Alle 4 Werte aus 4 erfassten Bildern werden in das 
Messprotokoll bzw. Mango übertragen. 
12. Untersuchung 
beenden 
Taste „Untersuchung beenden“ drücken (Kapitel 
7.1.2: Messgeräte) 
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Rückmeldung an Teilnehmer 
Für den Ergebnisbericht sollen jeweils die Mittelwerte aus den 2 Distanzmessungen von 
SAT und VAT mitgeteilt werden.  Zur Erklärung sollten folgende Informationen mitgeteilt 
werden: 
Ergebnis Ultraschalluntersuchung 
Bisher gibt es keine Referenzwerte für die gemessenen Fettdicken in der Bauchregion. 
Mit Ihrer Studienteilnahme tragen sie wesentlich zur Erforschung möglicher Grenzwerte 
im Zusammenhang mit Gesundheit und Krankheit bei.   
 
Subkutane Fettdicke _________cm 
Das subkutane Fett wird auch als Unterhautfett bezeichnet und befindet sich direkt unter 
der Haut und über den Bauchmuskeln. 
 
Viszerale Fettdicke _________cm 
Das viszerale Fett wird als Organfett bezeichnet. Es liegt unterhalb der Bauchmuskeln 
und umhüllt die Organe. 
 
Nachbereitung 
 Das Gel nach der Untersuchung vom Teilnehmer und vom Schallkopf entfernen 
 Den Schallkopf desinfizieren 
 Das Papier von der Untersuchungsliege wechseln  
 Die Messwerte in das vorgesehene Formular im Mango übertragen 
 Die Konfiguration für den Datenexport der Untersuchung an den Zentralen 
Datenspeicher steht noch nicht fest und wird später mitgeteilt 
 
 
Problembehandlung 
 
In einigen Fällen verdeckt der Darminhalt die Wirbelsäule oder andere Strukturen. Unter 
gesteuertem Druck mit dem Schallkopf kann der Darminhalt verlagert werden, um die 
verdeckten Strukturen visualisieren zu können. Die gezielte Kompression kann behilflich 
sein, die exakte Position der Wirbelsäule zu bestimmen, indem langsam weniger Druck 
ausgeübt wird, wobei simultan versucht wird die Wirbelsäule sichtbar zu halten. Der 
Darminhalt bewegt sich konstant, so dass eine sich eine schlechte Bildqualität durch 
störenden Darminhalt innerhalb von wenigen Minuten ändern kann und eine bessere 
Messung möglich macht.  
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Glossar 
 
VAT Das viszerale Fett auch intraabdominales Fett genannt, bezeichnet 
das in der freien Bauchhöhle eingelagerte Fett, das die inneren 
Organe, vor allem des Verdauungssystems, umhüllt. Vor allem das 
VAT steht mit der Entwicklung von Adipositas-assoziierten 
Erkrankungen in direktem Zusammenhang. 
 
SAT Die Subkutis ist die untere Schicht der Haut. SAT wird mit potenziell 
protektiven Funktionen assoziiert. Es weist einen antiatherogenen 
Effekt auf und ist mit einer erhöhten Insulinsensitivität sowie mit 
einem geringeren Risiko für die Entwicklung von Typ 2 Diabetes und 
Dyslipidämien assoziiert.  
 
Linea alba Die Linea alba ist eine senkrechte Bindegewebsnaht in der Mitte 
des Bauches, die durch die Vereinigung der seitlichen 
Bauchmuskeln entsteht.  
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Supplementary Table 1: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
hs-CRP 
Festa et al. 
2001 (84) 
1559 tri-ethnic 
population 
 
 
      
r=0.41; p=0.0001 
 
 
 
 
r=0.28; p=0.0001 
r=0.42; p=0.0001 
 
 
 
 
r=0.29; p=0.0001 
age, gender, 
ethnicity, clinic, 
smoking, 
diabetic status 
 
+insulin 
sensitivity 
Forouhi et al. 
2001 (83) 
113 healthy 
adults 
 
57 healthy 
Europeans 
 
56 healthy 
South Asians 
CT 
  
 
 
ß=0.95; p=0.013 
 
 
ß=0.78; p=0.0004 
  
 
 
 
  
 
 
ß=0.14; 0.005 
 
 
ß=0.07; 0.058 
  
 
 
ß=0.04; p=0.027 
 
 
ß=0.04; p=0.002 
age, sex, 
smoking status 
Lemieux et al. 
2001 (184) 
159 healthy 
men 
CT r=0.28; p<0.0003 r=0.33; p<0.0001 r=0.36; p<0.0001 r=0.37; p<0.0001  
Saijo et al. 
2004 (93) 
119 healthy 
Japanese 
CT ß=0.39; p<0.001 ß=0.28; p<0.001 ß=0.35; <0.0001 ß=0.46; <0.0001 
sex, age, 
smoking status 
Panagiotakos 
et al. 2005 
(80) 
3043 healthy 
adults 
 
men 
 
women 
   
 
 
 
r=0.21; p<0.05 
 
r=0.22; p<0.05 
 
 
 
r=0.30; p<0.01 
 
r=0.34; p<0.01 
age, diet score, 
total cholesterol 
and glucose 
levels 
 
 
Park et al. 
2005 (97) 
46 obese and 
54 non-obese 
Koreans 
 
obese 
CT 
 
 
 
 
r=0.40; p<0.05 
 
 
 
 
r=0.30; n.s. 
r=0.69; p<0.0001 r=0.75; p<0.0001  
Piché et al. 
2005 (95) 
112 postmeno-
pausal women 
CT r=0.55; p<0.0001 r=0.50; p<0.0001 r=0.60; p<0.0001 r=0.61; p<0.0001 
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Supplementary Table 1 continued: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
Thorand et al. 
2006 (81) 
1238 healthy 
adults (55-74y) 
 
men 
 
women 
      
  
 
 
ß=0.015; p<0.001 
 
ß=0.018; p<0.001 
  
 
 
ß=0.002; p<0.001 
 
ß=0.003; p<0.001 
age, smoking 
habits, alcohol 
consumption 
and physical 
activity 
 
 
Pou et al. 
2007 (94) 
1250 healthy 
adults 
 
men 
 
 
women 
 
 
CT 
 
 
 
 
r=0.33; p<0.001 
r²=0.19; p<0.0001 
 
 
r=0.47; p<0.001 
r²=0.29; p<0.0001 
 
 
 
r=0.30; p<0.001 
r²=0.19; p<0.0001 
 
 
r=0.45; p<0.001 
r²=0.28; p<0.0001 
 
 
r=0.38; p<0.001 
 
 
 
r=0.52; p<0.001 
 
 
r=0.37; p<0.001 
 
 
 
r=0.51; p<0.001 
 age 
 
 
age, smoking, 
aspirin, alcohol 
intake, physical 
activity 
 
+ menopausal 
status, hormone 
replacement 
therapy 
Taksali et al. 
2008 (79) 
obese 
adolescents 
MRI 
VAT/SAT ratio 
p=0.40 
   
age, sex, 
race/ethnicity 
Beasley et al. 
2009 (98) 
2651 black and 
white elderly 
 
white men  
black men  
 
white women 
black women 
CT 
 
 
 
 
ß=0.12; p=0.01  
ß=-0.01;p=0.84 
 
ß=0.18; p=0.00 
ß=0.03; p=0.56 
 
 
 
 
 
ß=0.17; p=0.00 
ß=0.09; p=0.24 
 
ß=0.18; p=0.00 
ß=-0.09;p=0.23 
 
  
clinic site, age, 
BMI, marital 
status, 
education level, 
pack years, 
medical 
condiction, anti-
inflammatory 
drugs, oral 
steroids, 
physical acticity 
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Supplementary Table 1 continued: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
Saito et al. 
2012 (96) 
130 type 2 
diabetic adults 
men 
women 
 
CT 
r=0.346; p<0.001 
 
r=0.363; p<0.001 
r=0.341; p<0.001 
r=0.319; p<0.001 
 
r=0.412; p<0.001 
r=0.209; n.s. 
    
  
 
 
 
IL-6 
Panagiotakos 
et al. 2005 
(80) 
3043 healthy 
adults 
 
men 
women 
      
  
 
 
r=0.29; p<0.01 
r=0.29; p<0.01 
  
 
 
r=0.12; p<0.05 
r=0.42; p<0.01 
age, diet score, 
total cholesterol 
and glucose 
levels 
Park et al. 
2005 (97) 
46 obese and 
54 non-obese 
Koreans 
 
obese 
CT 
 
 
 
 
r=0.46; p<0.05 
 
 
 
 
r=0.13; n.s 
r=0.37; p<0.005 r=0.42; p<0.005  
Piché et al. 
2005 (95) 
112 postmeno-
pausal women 
CT 
 
r=0.49; p<0.0001 
 
r=0.34; p<0.01 
 
r=0.49; p<0.0001 
 
r=0.56; p<0.0001 
  
Thorand et al. 
2006 (81) 
1238 healthy 
adults (55-74y) 
 
men 
 
women 
   
 
 
 
 
ß=0.015; p<0.01 
 
ß=0.012; p<0.001 
 
 
 
 
ß=0.003; p<0.001 
 
ß=0.003; p<0.001 
age, smoking 
habits, alcohol 
consumption 
and physical 
activity 
 
 
Pou et al. 
2007 (94) 
1250 healthy 
adults 
CT 
r=0.23; p<0.001 
 
r²=0.12; p<0.0001 
r=0.23; p<0.001 
 
r²=0.12; p<0.0001 
r=0.27; p<0.001 r=0.25; p<0.001 
age, sex 
 
age, smoking, 
aspirin, alcohol 
intake, 
menopausal 
status, hormone 
replacement 
therapy, 
physical activity 
Taksali et al. 
2008 (79) 
obese 
adolescents 
MRI 
VAT/SAT ratio 
p=0.16 
   
age, sex, 
race/ethnicity 
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Supplementary Table 1 continued: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
Beasley et al. 
2009 (98) 
2651 black and 
white aged 70-
79 
 
 
white men 
black men 
 
white women 
black women 
CT 
 
 
 
ß=0.10; p=0.02 
ß=-0.11; p=0.05 
 
ß=0.22; p=0.00 
ß=0.11; p=0.05 
 
 
 
ß=-0.01; p=0.77 
ß=0.07; p=0.34 
 
ß=0.00; p=0.963 
ß=-0.07; p=0.34 
  
clinic site, age, 
BMI, marital 
status, 
education level, 
pack years, 
medical 
condiction, anti-
inflammatory 
drugs, physical 
acticity 
Lira et al. 
2011 (104) 
obese 
adolescents 
US r=0.42; p<0.02 n.s.        
TNF-α 
Panagiotakos 
et al. 2005 
(80) 
3043 healthy 
adults 
 
men 
 
women 
   
 
 
 
r=0.19; p<0.05 
 
r=0.29; p<0.05 
 
 
 
r=0.21; p<0.05 
 
r=0.42; p<0.01 
age, diet score, 
total cholesterol 
and glucose 
levels 
Park et al. 
2005 (97) 
46 obese and 
54 non-obese 
Koreans 
 
obese 
CT 
 
 
 
 
r=0.27; n.s. 
 
 
 
 
r=-0.02; n.s. 
r=0.24; p<0.05 r=0.32; p<0.05  
Piché et al. 
2005 (95) 
112 
postmenopausa
l women 
CT r=-0.03; n.s. r=-0.02; n.s. r=-0.009;n.s. r=-0.03; n.s.   
Pou et al. 
2007 (94) 
1250 healthy 
adults 
 
 
CT 
r=0.05; n.s. 
 
r²=0.04; p=0.06 
 
r=0.06; n.s. 
 
r²=0.03; p=0.08 
r=0.09; p<0.001 r=0.09; p<0.001 
age, sex 
 
age, smoking, 
aspirin, alcohol 
intake, 
menopausal 
status, hormone 
replacement 
therapy, 
physical activity 
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Supplementary Table 1 continued: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
Beasley et al. 
2009 (98) 
2651 black and 
white aged 70-
79 
 
white men 
black men 
 
white women 
black women 
CT 
 
 
 
 
ß=0.13; p=0.00 
ß=-0.09; p=0.12 
 
ß=0.19; p=0.00 
ß=0.20; p=0.00 
 
 
 
 
ß=-0.05; p=0.29 
ß=0.05; p=0.51 
 
ß=0.07; p=0.26 
ß=-0.04; p=0.61 
  
clinic site, age, 
BMI, marital 
status, 
education level, 
pack years, 
medical 
condiction, anti-
inflammatory 
drugs, oral 
steroids, 
physical acticity 
Lira et al. 
2011 (104) 
obese 
adolescents 
US r=0.40; p<0.05 r=-0.46; p<0.01     
  
 
 
 
Resistin 
Zhang et al. 
2002 (202) 
71 adults       r=n.s. r=n.s.   
Fehmann et 
al. 2002 (198) 
76 healthy 
controls 
 
76 type 2 
diabetics 
   
r=n.s. 
 
 
r=n.s. 
  
Azuma et al. 
2003 (100) 
79 adults CT r=0.5; p<0.01 r=0.32; p=0.06 r= 0.35, p < 0.01   
Degawa_Yam
auchi et al. 
2003 (203) 
27 lean, 50 
obese 
      r = 0.37; p = 0.002     
Heilbronn et 
al. 2003 (89) 
38 non-obese 
 
12 obese 
 
22 type 2 
dibetics 
 
34 obese 
   
r=n.s. 
 
r=n.s. 
 
r=n.s. 
 
 
ß=n.s. 
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Supplementary Table 1 continued: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
Lee et al. 
2003 (88) 
123 middle 
aged women 
 
 
120 healthy 
students 
      
ß=0.11; n.s. 
 
 
 
 
ß=0.07; n.s. 
ß=0.11; n.s. 
 
 
 
 
ß=0.17; n.s. 
age, 
menopausal 
status, estradiol 
level 
 
age, gender 
Pfutzner et al. 
2003 (199) 
78 type 2 
diabetics 
      r=n.s.     
Yang et al. 
2003 (200) 
51 untreated 
type 2 diabetic 
patients 
 
52 sex and age-
matched normal 
control subjects 
   r=n.s.   
Fujinami et al. 
2004 (204) 
90 type 2 
diabetics 
 
74 healthy 
controls 
   
r=0.412, p<0.0003 
 
 
r=0.395, p<0.0001 
 
 
 
 
 
 
 
Seow et a. 
2004 (196) 
17 PCOS 
women 
 
10 non-PCOS 
women 
      
r= 0.184, p= 0.479 
 
 
 
    
Chen et al. 
2005 (195) 
71 healthy 
adults 
 
36 males 
 
35 females 
   
 
 
 
r=0.084; p=n.s. 
 
r=-0.005; p=n.s. 
 
 
 
r=0.046, p=n.s. 
 
r=-0.097; p=n.s. 
age 
Jain et al. 
2009 (101) 
916 adults  
 
men 
 
women 
 
CT 
 
 
ES=1.04; p=0.07  
 
ES=1.06; p<0.001 
 
 
ES=1.05; p=0.008 
 
ES=1.06; p<0.001 
  
age, smoking, 
alcohol use, 
menopausal 
status (women 
only), and 
hormone 
replacement 
therapy 
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Supplementary Table 1 continued: Association of adiposity measures with chronic inflammation. 
Reference 
Study 
population 
VAT and SAT 
measurement 
Association VAT Association SAT Association BMI Association WC 
Adjustment 
variables 
Adiponectin 
Cnop et al. 
2003 (102) 
182 adults 
(USA) 
CT ß=-0.011; p=0.009 ß=0.001; p=0.77 ß=-0.115; p=0.084  
Age, Sex, BMI, 
VAT, SAT, 
Taksali et al. 
2008 (79) 
obese 
adolescents 
MRI 
VAT/SAT ratio 
p=0.08 
   
age, sex, 
race/ethni
city 
Mazzali et al. 
2006 (206) 
35 women       r=-0.306; n.s. r=0.3783; p<0.05   
Lira et al. 
2011 (104) 
obese 
adolescents 
US r=-0.4; p<0.03         
Saito et al. 
2012 (96) 
130 type 2 
diabetic men 
and women 
 
men 
 
women 
CT 
r=-0.332; p<0.01 
 
 
 
r=-0.360; p<0.01 
 
r=-0.327; p<0.01 
r=-0.262; p<0.01 
 
 
 
r=-0.293; p<0.05 
 
r=-0.390; p<0.01 
   
Guenther et. 
Al. 2014 (103) 
424 obese 
 
men 
 
women 
CT 
r=-0.22; p<0.001 
 
r=-0.25; p<0.001 
 
r=-0.22; p<0.001 
r=-0.2; p<0.001 
 
r=-0.12; n.s. 
 
r=-0.23; p<0.001 
r=-0.23; p<0.001 
 
r=-0.12; n.s. 
 
r=-0.27; p<0.001 
r=-0.29; p<0.001 
 
r=-0.21; p<0.01 
 
r=-0.33; p<0.001 
Age, Sex 
 
Age 
 
Age 
VAT= visceral adipose tissue; SAT= subcutaneous adipose tissue; BMI= body mass index; WC= waist circumference, CT=computer tomography, US=Ultrasound, PCOS=Polycystic ovary 
syndrome, ß=regression coefficient, r=Pearson correlation coefficient. 
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Supplementary Table 2: Metabolomics studies on obesity. 
Reference 
Anthropometric 
variable 
Metabolomics 
technique 
Metabolites positive associated 
with obesity 
Metabolites inverse associated 
with obesity 
Newgard et al. 
2009 (128) 
BMI (74 lean vs. 
67 obese) 
serum, 
targeted 
metabolomics, 
MS/MS 
leucine/isoleucine, valine, 
glutamate/glutamine, phenylalanine, 
tyrosine, C3 and C5 acylcarnitines 
 
Calvani et al. 
2010 (134) 
BMI (10 lean vs. 
15 obese) 
urine, 
untargeted 
metabolomics, 
NMR 
2-hydroxyisobutyrate hippuric acid, trigonelline, xanthine 
Oberbach et al. 
2011 (135) 
BMI (15 lean vs. 
15 obese) 
serum, 
targeted 
metabolomics, 
MS/MS 
glycerophosphocholine,  
diacylglycerophosphocholine, 
glycine, glutamine 
Cheng et al. 
2012 (129) 
BMI, WC (1015 
men and 
women) 
 
serum, 
targeted 
metabolomics, 
LC/MS 
BMI: lysine, N-carbomoyl-beta-
alanine, ornithine, phenylalanine, 
proline, tyrosine,  valine, xanthosine 
 
WC: methionine, N-carbomoyl-beta-
alanine, ornithine, phenylalanine, 
proline, tyrosine,  valine, xanthosine 
 
Szymansky et al. 
2012 (130) 
abdominal 
obesity by DXA, 
VAT, SAT by 
MRI (215 
overweight men 
and women) 
serum, 
targeted 1D 
NMR 
Men 
A/G ratio: alanine, isoleucine, tyrosine 
VAT: isoleucine 
 
Women 
A/G ratio: isoleucine, valine 
VAT: isoleucine 
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Supplementary Table 2 continued: Metabolomics studies on obesity. 
Reference 
Anthropometric 
variable 
Metabolomics 
technique 
Metabolites positive associated 
with obesity 
Metabolites inverse associated 
with obesity 
Wahl et al. 2012 
(264) 
BMI (40 lean vs. 
80 obese 
children) 
serum, 
targeted 
metabolomics 
LC/MS/MS 
acylcarnitine, acyl-alkyl-PC  
Lustgarten et al. 
2013 (136) 
Abdominal 
obesity by DXA 
image (73 
elderly) 
serum, 
ultrahigh 
performance 
LC/MS/MS, 
GC/MS 
2-hydroxy-3-methylvalerate, 3-
hydroxyisobutyrate, 
Isovalerylcarnitine, 3-dehydrocarnitine 
glycine, glutamine, 3-
methoxytyrosine 
Martin et.al. 
2013 (239) 
VAT/SAT, 
VAT/total fat by 
iDXA and CT 
(40 obese 
women) 
urine and 
serum, 
untargeted 
NMR and 
targeted MS 
tyrosine, glutamine, PC-O 44∶6, PC-O 
44∶4, PC-O 42∶4, PC-O 40∶4, and PC-
O 40∶3 lipid species 
 
Moore et al. 
2014 (131) 
BMI (974 men 
and women) 
serum and 
plasma, 
targeted 
metabolomics, 
LC/MS/MS, 
GC-MS 
3-(4-hydroxyphenyl)lactate, gamma-
glutamyltyrosine, butyrylcarnitine, 2-
hydroxybutyrate (AHB), 3-methyl-2-
oxobutyrate, gamma-glutamyl-
isoleucine, 7-alpha-hydroxy-3-oxo-4-
cholestenoate,  Alpha-hydroxyi-
sovalerate, 3-methyl-2-oxovalerate, 4-
methyl-2-oxopentanoate, 3-
hydroxyisobutyrate, glutamate, valine, 
mannose, Isoleucine, 
Isovalerylcarnitine, tyrosine, leucine, 
andro steroid monosulfate 2, 
lathosterol, kynurenine, glycerol, 
phenylalanine, hexanoylcarnitine, 
propionylcarnitine, carnitine, lactate 
1-oleoylglycerophosphocholine, 1-
eicosadienoylglycerophosphocholine, 
2-linoleoylglycerophosphocholine, 
benzoic acid, N-acetylglycine, 
palmitoyl sphingomyelin, histidine, 1-
5-anhydroglucitol, asparagine, 
glycine 
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Supplementary Table 2 continued: Metabolomics studies on obesity. 
Reference 
Anthropometric 
variable 
Metabolomics 
technique 
Metabolites positive associated 
with obesity 
Metabolites inverse associated 
with obesity 
Xie et al. 2014 
(265) 
BMI (105 lean 
vs. 106 healthy 
obese) 
serum, 
targeted 
metabolomics, 
LC/MS, 
GC/MS 
valine, creatine, beta-tyrosine, 
isoleucine, 4-hydroxycinnamic acid, 
adenine, leucine, delta-hydroxylysine, 
kynurenine, glutamic acid, 12a-
hydroxy-3-oxocholadienic acid, 
tryptophan, tyrosine, 8-hydroxy-7-
methylguanine, glycerylphosphate, 
carnitine, lysoPC, alanine, 
propionylcarnitine, glycolithocholic 
acid, allantoin, N-actylneuraminic 
acid, phenylalanine 
n-octadecanoic acid, histidinol, 
palmitoleic acid, bilirubin, cis-11,14-
eicosadienoic acid, 2-hydroxyglutaric 
acid, carnosine, myristic acid 
Elliot et al. 2015 
(133) 
BMI (1880 U.S. 
men and women 
plus 444 UK 
men and 
women) 
urine, targeted 
and 
untargeted 
metabolomics, 
NMR 
urinary glycoproteins, 
tyrosine+4hydroxymandelate, N-
acetyl neuraminate, 3-methylhistidine, 
citrate, creatinine, leucine, 
pseudourine, lysine, 2-
hydroxyisobutyrate, TMA, 
ethanolamine, glucose, 
dimethylamine, dimethylglycine, 
valine, alanine, O-acetyl carnitine 
ketoleucine, succinate, glutamine, 
hippuric acid, NMNA, formate, 4-
Cresyl sulfate, glycine, proline 
betaine, phenylacetylglutamine, 3-
hydroxymandalate, 
ketoleucine/leucine ratio 
BMI=body mass index, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, DXA=Dual X-ray absorptiometry LC/MS=liquid chromatography combined with mass 
spectroscopy, GC/MS=gas chromatography combined with mass spectroscopy, NMR=nuclear magnetic resonance spectroscopy. 
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Supplementary Table 3: Validation studies on sonographic-based measurement of visceral and subcutaneous 
adipose tissue. 
Reference 
Study 
population 
Measurement technique and 
location of measurement of 
reference method 
Measurement technique and 
location of ultrasound 
measurement 
Ultrasound 
vs. CT / MRI 
VAT SAT 
Armellini et al. 1990 
(148) 
50 overweight 
women 
CT single slice at L4 (cm²) 
VAT: linea alba – aorta 
SAT: skin – linea alba 
0.67  
Armellini et al. 1993 
(151) 
119 overweight 
women 
CT single slice at L4 (cm²) 
VAT: linea alba – aorta 
SAT: skin – linea alba 
0.74  
Tornaghi et al. 1994 
(158) 
24 volunteers CT single slice at L4-5 (cm²) VAT: internal face of rectus 
abdominis – lumbar vertebrar 
0.89-0.91  
Ribeiro-Filho et al. 2001 
(150) 
101 overweight 
women 
CT single slice at L4-5 (cm²) 
VAT: internal face of rectus 
abdominis - anterior wall of 
the aorta 
SAT: skin – external face of 
rectus abdominis 
1 cm above umbilicus 
0.67  
Stolk et al. 2001 (157)  
19 overweight 
patients 
CT single slice at L4-5 (cm²), 
MRI multiple slices at L4-L5 
(cm³)  
VAT: linea alba – lumbar 
spine 
5 different angles 
Quiet expiration, minimal 
pressure 
0.81-0.83  
Leite et al. 2002 (149) 29 volunteers CT single slice at L4-5 (cm²) 
VAT: linea alba – aorta 
SAT: skin – linea alba 
1 cm above umbilicus 
0.84 0.79 
Ribeiro-Filho et al. 2003 
(156) 
100 overweight 
women 
CT single slice at L4-5 (cm²) 
VAT: internal face of rectus 
abdominis – anterior wall of 
the aorta 
SAT: skin – external face of 
rectus abdominis 
1 cm above umbilicus 
0.71 0.33 
Kim et al. 2004 (52) 
75 adults 
CT single slice at L4-5 (cm²) 
VAT: linea alba – aorta 
1 cm above umbilicus 
0.80 
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Supplementary Table 3 continued: Validation studies on sonographic-based measurement of visceral and 
subcutaneous adipose tissue. 
Reference 
Study 
population 
Measurement technique and 
location of measurement of 
reference method 
Measurement technique and 
location of ultrasound 
measurement 
Ultrasound vs. CT / 
MRI 
VAT SAT 
      
Hirooka et al. 2005 (154) 87 patents CT single slice at L4 (cm²) 
VAT: linea alba – aorta 
End of normal exhalation 
0.86  
Koda et al. 2007 (155) 17 adults MRI volume of abdomen (cm³) 
VAT: linea alba – lumbar 
vertebra 
SAT: skin – external face of 
linea alba 
Umbilicus level 
0.73 0.82 
Berker et al. 2010 (140)  
104 adults, 
stratified by 
BMI (>/< 
30 kg/m²) 
CT single slice at L4-5 (cm²) 
 
VAT: internal face of linea 
alba – aorta at umbilicus 
0.82  
De Lucia Rolfe et al. 
2010 (152) 
41 men 
33 women 
MRI single slice at L4 (cm²) 
VAT: peritoneal boundry – 
corpus of lumbar vertebra 
SAT: cutaneous boundry – 
linea alba 
Xiphoid line intercept WC 
Respiration protocol 
0.82 
0.80 
0.63 
0.68 
Gradmark et al. 2010 
(153) 
29 men and 
women 
CT single slice 5 cm cranial to 
umbilicus (cm²) 
VAT: inside bowell wall-spine 
SAT: posterior line of dermis 
to outer bowell wall 
5 cm cranial to umbilicus 
0.79 0.52 
CT=computer tomography, MRI=magnetic resonance imaging, BMI=body mass index, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue. L4=lumbar vertebra 4, L4-5= 
lumbar vertebra 4-5. 
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Supplementary Table 4: Intra- and inter-rater reproducibility of ultrasound-based measurements of VAT and SAT 
thickness by study centers. 
(a) Reproducibility in southern study center, n=97 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95% CI) 
Mean difference 
(mm) 
(95% LOA) 
ICC 
(95% CI) 
Mean difference 
(mm) 
(95% LOA) 
ICC 
(95% CI) 
Mean difference 
(mm) 
(95% LOA) 
VAT 
0.995 
(0.993-0.997) 
-0.303 
(-3.62-3.01) 
0.999 
(0.998-0.999) 
-0.029 
(-3.20-3.26) 
0.998 
(0.997-0.999) 
-0.073 
(-2.60-2.45) 
SAT 
0.993 
(0.989-0.995) 
-0.091 
(-2.11-1.93) 
0.991 
(0.987-0.994) 
0.039 
(-2.15-2.23) 
0.992 
(0.989-0.994) 
0.155 
(-1.88-2.19) 
(b) Reproducibility in northern study center, n=30 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference 
(mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference 
(mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference 
(mm) 
(95% LOA) 
VAT 
0.998 
(0.996-0.998) 
0.052 
(-2.82-2.97) 
0.999 
(0.998-0.999) 
-0.462 
(-2.31-1.43) 
0.995 
(0.989-0.998) 
0.637 
(-3.25-6.38) 
SAT 
0.988 
(0.974-0.994) 
-0.027 
(-1.94-1.99) 
0.998 
(0.995-0.999) 
0.122 
(-0.89-0.79) 
0.971 
(0.941-0.986) 
0.209 
(-2.67-3.31) 
VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, ICC=Intra-class correlation coefficient, CI=confidence interval, LOA=limit of agreement. 
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Supplementary Table 5: Intra- and inter-rater reproducibility of ultrasound-based measurements of VAT and SAT 
thickness by subgroups. 
(a) Reproducibility among lean subjects: BMI ≤ 25.0, n=55 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.997 
(0.994-0.998) 
-0.106 
(-3.13-2.91) 
0.997 
(0.994-0.998) 
-0.168 
(-3.09-2.75) 
0.994 
(0.990-0.997) 
-0.095 
(-3.57-3.34) 
SAT 
0.988 
(0.979-0.993) 
-0.134 
(-2.04-1.78) 
0.991 
(0.985-0.995) 
0.052 
(-1.60-1.50) 
0.977 
(0.962-0.987) 
0.312 
(-2.20-2.82) 
 
 
(b) Reproducibility among obese subjects: BMI > 25.0, n=72 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.994 
(0.990-0.996) 
-0.060 
(-7.78-7.66) 
0.999 
(0.999-0.999) 
0.017 
(-3.00--3.04) 
0.998 
(0.997-0.999) 
-0.170 
(-4.77-4.43) 
SAT 
0.992 
(0.987-0.995) 
-0.031 
(-2.07-2.01) 
0.991 
(0.986-0.994) 
0.041 
(-2..14-2.22) 
0.992 
(0.987-0.995) 
0.063 
(-2.04-2.01) 
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(c) Reproducibility among lean subjects: Waist circumference < 102 cm in men and < 88 cm in women, n=61 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.977 
(0.962-0.986) 
-0.038 
(-8.27-8.35) 
0.997 
(0.995-0.998) 
-0.002 
(-3.13-3.13) 
0.993 
(0.988-0.996) 
-0.465 
(-5.15-4.22) 
SAT 
0.989 
(0.983-0.994) 
-0.050 
(-1.87-1.77) 
0.990 
(0.983-0.994) 
0.0221 
(-1.72-1.76) 
0.988 
(0.981-0.993) 
0.321 
(-1.56-2.21) 
 
 
(d) Reproducibility among obese subjects: Waist circumference ≥ 102 cm in men and ≥ 88 cm in women, n=66 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.999 
(0.998-0.999) 
-0.364 
(-4.03-3.30) 
0.999 
(0.998-0.999) 
0.153 
(-3.20--3.51) 
0.999 
(0.999-0.999) 
-0.014 
(-2.74-2.71) 
SAT 
0.991 
(0.983-0.995) 
-0.149 
(-2.40-2.11) 
0.988 
(0.977-0.994) 
0.065 
(-2..65-2.78) 
0.992 
(0.985-0.996) 
-0.102 
(-2.24-2.04) 
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(e) Reproducibility among VAT tertile 1: VAT ≤ 5.09 cm, n=43 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.989 
(0.980-0.994) 
-0.193 
(-2.94-2.55) 
0.988 
(0.979-0.994) 
-0.238 
(-3.00-2.53) 
0.990 
(0.981-0.994) 
-0.057 
(-2.70-2.59) 
SAT 
0.987 
(0.977-0.993) 
-0.001 
(-2.20-2.19) 
0.994 
(0.989-0.997) 
-0.181 
(-1.61-1.24) 
0.974 
(0.953-0.986) 
0.469 
(-2.57-3.51) 
 
(f) Reproducibility among VAT tertile 2: VAT > 5.09 cm - ≤ 7.25 cm, n=42 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.689 
(0.493-0.819) 
0.304 
(-8.77-9.38) 
0.972 
(0.948-0.985) 
0.050 
(-2.67--2.77) 
0.881 
(0.791-0.934) 
-0.283 
(-5.63-5.07) 
SAT 
0.990 
(0.983-0.995) 
-0.0814 
(-1.92-1.75) 
0.985 
(0.973-0.992) 
0.034 
(-2..29-2.36) 
0.993 
(0.988-0.996) 
0.112 
(-1.44-1.67) 
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(g) Reproducibility among VAT tertile 3: VAT > 7.25 cm, n=42 
 
Intra-rater reproducibility Inter-rater reproducibility 
Observer 1 Observer 2 Observer 1 – 2 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
ICC 
(95 % CI) 
Mean difference (mm) 
(95% LOA) 
VAT 
0.996 
(0.998-0.997) 
-0.347 
(-5.44-4.75) 
0.998 
(0.997-0.999) 
0.007 
(-3.43-3.44) 
0.997 
(0.995-0.999) 
-0.272 
(-4.03-3.48) 
SAT 
0.994 
(0.989-0.997) 
-0.142 
(-2.07-1.79) 
0.994 
(0.989-0.997) 
0.157 
(-1.80-2.11) 
0.995 
(0.990-0.997) 
-0.083 
(-1.89-1.73) 
VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, ICC=Intra-class correlation coefficient, CI=confidence interval, LOA=limit of agreement 
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Supplementary Table 6: Spearman correlation coefficients between VAT measurements and anthropometric 
measurements in lean subjects (BMI ≤25.0 kg/m²). 
 VAT area (mm²) MRT VAT thickness (cm) US VAT thickness (cm) MRT WC (cm) 
VAT thickness (cm) US ρ=0.777, p=<0.001    
    
VAT thickness (cm) MRT ρ=0.626, p=0.005 ρ=0.876, p=<0.001   
    
WC (cm) ρ=0.383, p=0.116 ρ=0.388, p=0.112 ρ=0.440, p=0.068  
    
BMI (kg/m²) ρ=0.480, p=0.044 ρ=0.482, p=0.043 ρ=0.417, p=0.085 ρ=0.780, p=<0.001 
    
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, BMI=body mass index, WC=waist circumference, ρ=Spearman correlation coefficient (ρ), p=p-value, 
n=18. 
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Supplementary Table 7: Spearman correlation coefficients between VAT measurements and anthropometric 
measurements in overweight/obese subjects (BMI >25.0 kg/m²). 
  VAT area (mm²) MRT VAT thickness (cm) US VAT thickness (cm) MRT WC (cm) 
VAT thickness (cm) US ρ=0.643, p=0.024    
    
VAT thickness (cm) MRT ρ=0.524, p=0.080 ρ=0.979, p=<0.001   
    
WC (cm) ρ=0.783, p=0.003 ρ=0.455, p=0.138 ρ=0.378, p=0.226  
    
BMI (kg/m²) ρ=0.587, p=0.045 ρ=0.322, p=0.308 ρ=0.280, p=0.379 ρ=0.916, p=<0.001 
    
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, BMI=body mass index, WC=waist circumference, ρ =Spearman correlation coefficient (ρ), p=p-value, 
n=12. 
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Supplementary Table 8: Spearman correlation coefficients between VAT measurements and anthropometric 
measurements in all subjects. 
 VAT area (mm²) MRT VAT thickness (cm) US VAT thickness (cm) MRT WC (cm) 
VAT thickness (cm) US ρ=0.898, p=<0.001    
    
VAT thickness (cm) MRT ρ=0.863, p=<0.001 ρ=0.971, p=<0.001   
    
WC (cm) ρ=0.834, p=<0.001 ρ=0.772, p=<0.001 ρ=0.781, p=<0.001  
    
BMI (kg/m²) ρ=0.841, p=<0.001 ρ=0.800, p=<0.001 ρ=0.793, p=<0.001 ρ=0.931, p=<0.001 
    
US=ultrasound, MRI=magnetic resonance imaging, VAT=visceral adipose tissue, BMI=body mass index, WC=waist circumference,  ρ=Spearman correlation coefficient (ρ), p=p-value, 
n=30. 
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Supplementary Table 9: Spearman correlation coefficients between SAT measurements and anthropometric 
measurements in lean subjects (BMI ≤25.0 kg/m²). 
 
 SAT area (mm²) MRT SAT thickness (cm) US SAT thickness (cm) MRT WC (cm) 
SAT thickness (cm) US ρ=0.802, p=<0.001    
    
SAT thickness (cm) MRT ρ=0.793, p=<0.001 ρ=0.969, p=<0.001   
    
WC (cm) ρ=0.398, p=0.102 ρ=0.301, p=0.225 ρ=0.345, p=0.161  
    
BMI (kg/m²) ρ=0.527, p=0.025 ρ=0.478, p=0.045 ρ=0.511, p=0.030 ρ=0.780, p=<0.001 
    
US=ultrasound, MRI=magnetic resonance imaging, SAT=subcutaneous adipose tissue, BMI=body mass index, WC=waist circumference, ρ=Spearman correlation coefficient (ρ), 
p=p-value, n=18. 
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Supplementary Table 10: Spearman correlation coefficients between SAT measurements and anthropometric 
measurements in overweight/obese subjects (BMI > 25.0 kg/m²). 
 SAT area (mm²) MRT SAT thickness (cm) US SAT thickness (cm) MRT WC (cm) 
SAT thickness (cm) US ρ=0.594, p=0.042    
    
SAT thickness (cm) MRT ρ=0.685, p=0.014 ρ=0.972, p=<0.001   
    
WC (cm) ρ=0.070, p=0.829 ρ=-0.091, p=0.779 ρ=-0.035, p=0.914  
    
BMI (kg/m²) ρ=0.189, p=0.557 ρ=0.063, p=0.846 ρ=0.126, p=0.697 ρ=0.916, p=<0.001 
    
US=ultrasound, MRI=magnetic resonance imaging, SAT=subcutaneous adipose tissue, BMI=body mass index, WC=waist circumference, ρ=Spearman correlation coefficient (ρ), 
p=p-value, n=12. 
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Supplementary Table 11: Spearman correlation coefficients between SAT measurements and anthropometric 
measurements in all subjects. 
 SAT area (mm²) MRT SAT thickness (cm) US SAT thickness (cm) MRT WC (cm) 
SAT thickness (cm) US ρ=0.705, p=<0.001    
    
SAT thickness (cm) MRT ρ=0.781, p=<0.001 ρ=0.965, p=<0.001   
    
WC (cm) ρ=0.663, p=<0.001 ρ=0.357, p=0.053 ρ=0.395, p=0.031  
    
BMI (kg/m²) ρ=0.697, p=<0.001 ρ=0.443, p=0.014 ρ=0.489, p=0.007 ρ=0.931, p=<0.001 
    
US=ultrasound, MRI=magnetic resonance imaging, SAT=subcutaneous adipose tissue, BMI=body mass index, WC=waist circumference, ρ=Spearman correlation coefficient (ρ), 
p=p-value, n=30. 
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Supplementary Table 12: Inflammatory parameter interaction with sex, BMI, 
smoking, and medication use. 
 
Sex 
p-value 
BMI 
p-value 
Smoking 
p-value 
Aspirin or 
NSAIDs use 
p-value 
hs-CRP (mg/dl) 0.878 <0.001 0.031 0.009 
TNF-α (pg/ml) 0.101 0.578 0.261 0.834 
IL-6 (pg/ml) 0.051 0.020 0.423 0.575 
Resistin (ng/ml) 0.457 0.374 0.841 0.630 
Adiponectin (µg/ml) 0.003 0.580 0.047 0.553 
BMI=body mass index  (lean ≤ 25 vs. obese > 25), NSAIDs=non-steroidal anti-inflammatory drugs, p-value from Kruskal-Wallis test. 
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Supplementary Table 13: Urinary metabolite interaction with sex, fasting status, 
and urinary glucose. 
 
Sex  
p value 
Fasting status  
p value 
Urinary glucose 
p value 
Alanine 0.142 0.002 0.548 
Glycine <0.001 0.125 0.056 
Taurine 0.795 0.780 0.006 
Glutamine 0.204 0.013 0.246 
3-Methylhistidine 0.024 0.218 0.003 
Betaine 0.413 0.078 0.028 
Phenylalanine <0.001 0.668 0.041 
Serine 0.459 0.146 0.007 
D-glucose 0.301 0.252 - 
Choline 0.302 0.768 0.017 
Lactic acid <0.001 0.180 0.005 
Methanol 0.007 0.003 <0.001 
Ascorbic acid 0.096 0.009 <0.001 
Creatine 0.001 0.165 <0.001 
L-Pyroglutamic acid 0.546 0.024 0.001 
Hippuricacid <0.001 0.043 <0.001 
Ethanolamine 0.019 0.463 0.001 
Trimethylamine-N-oxide 0.026 0.401 0.075 
Citric acid <0.001 0.032 0.013 
Dimethylamine <0.001 0.412 0.133 
D-Mannitol 0.002 0.037 0.001 
Guanidinoacetic acid <0.001 0.048 <0.001 
Glycolic acid 0.209 0.001 0.659 
Formic acid <0.001 0.004 <0.001 
Tyrosine 0.582 0.026 0.295 
Fumaric acid <0.001 0.061 0.853 
Orotic acid 0.217 0.442 0.002 
Leucine 0.112 0.325 0.668 
N,N-Dimethylglycine 0.013 0.083 0.070 
Trigonelline <0.001 <0.001 <0.001 
p-value from Kruskal-Wallis (continuous variables) or Χ² test (categorical variables). 
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Supplementary Table 14: Serum metabolite interaction with sex, fasting status, 
and urinary glucose. 
 
Sex 
p value 
Fasting status  
p value 
Urinary glucose 
p value 
Alanine 0.412 0.357 0.115 
Glycine 0.659 0.145 0.337 
Glutamine 0.934 0.514 0.705 
D-Glucose 0.854 0.776 0.015 
Lacticacid 0.352 0.466 0.029 
Methanol 0.568 0.374 0.291 
L-isoleucine 0.593 0.051 0.785 
Threonine 0.824 0.016 0.248 
Valine 0.894 0.038 0.741 
Acetone 0.396 0.430 0.317 
Formic acid 0.737 0.188 0.950 
Tyrosine 0.850 0.018 0.480 
Pyruvic acid 0.784 0.247 0.007 
Creatinine 0.042 0.024 0.118 
Acetic acid 0.688 0.939 0.227 
Creatine 0.234 0.800 0.948 
Ketoleucine 0.999 0.098 0.058 
Phenylalanine 0.909 0.010 0.145 
Leucine 0.410 0.055 0.712 
3-Hydroxybutyricacid 0.856 0.924 0.256 
p-value from Kruskal-Wallis test (continuous variables) or Χ² test (categorical variables). 
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Supplementary Table 15: Differences between phenotypes among clusters formed from urinary fingerprints in 
subgroup analyses. 
 
VAT SAT VSR BMI WC 
Cluster ß p ß p ß p ß p ß p 
Men 
1 -0.33 0.60 0.43 0.33 0.91 0.34 0.87 0.51 2.27 0.48 
2 0.33 0.62 -0.15 0.37 1.08 0.06 1.00 0.27 3.23 0.21 
3 0.31 0.73 0.38 0.09 -0.57 0.46 1.37 0.26 5.80 0.10 
4 -0.89 0.31 -0.06 0.78 -0.41 0.59 -0.70 0.57 -2.62 0.45 
5 -1.89 0.50 0.66 0.36 -1.84 0.46 1.49 0.70 0.88 0.94 
6 0.50 0.86 1.34 0.07 -1.48 0.55 1.19 0.76 4.08 0.71 
Women 
1 -0.12 0.66 0.29 0.50 0.45 0.93 1.61 0.38 2.59 0.43 
2 0.14 0.83 0.01 0.96 0.32 0.42 0.91 0.43 0.69 0.80 
3 0.32 0.68 0.25 0.31 0.07 0.89 1.19 0.39 3.92 0.23 
4 -0.79 0.30 -0.27 0.28 -0.13 0.78 -1.95 0.16 -3.13 0.33 
5 -1.03 0.71 0.36 0.69 -1.11 0.53 3.12 0.53 -5.84 0.62 
6 0.77 0.80 1.12 0.26 -0.62 0.74 4.78 0.38 17.31 0.18 
Non-fasting participants 
1 0.74 0.43 0.45 0.26 0.14 0.82 1.79 0.37 3.47 0.41 
2 0.67 0.21 0.14 0.36 0.66 0.12 1.43 0.08 3.08 0.16 
3 0.72 0.20 -0.20 0.23 0.83 0.06 -0.20 0.81 -1.10 0.63 
4 -0.63 0.39 -0.28 0.21 0.00 0.99 -1.88 0.10 -2.71 0.38 
5 1.62 0.03 0.27 0.23 0.47 0.42 1.21 0.30 5.20 0.10 
6 -0.16 0.96 0.39 0.63 -0.88 0.68 3.77 0.37 -3.98 0.73 
7 1.99 0.49 1.51 0.08 -1.11 0.62 7.05 0.11 20.46 0.09 
8 0.96 0.73 1.31 0.11 -1.44 0.51 1.16 0.79 3.37 0.77 
Fasting participants 
1 0.86 0.73 0.37 0.59 0.89 0.93 2.70 0.70 0.06 0.60 
2 -0.98 0.61 0.44 0.40 -1.01 0.14 -0.67 0.86 5.09 0.48 
3 -0.73 0.84 0.29 0.77 -0.98 0.44 -4.72 0.53 -5.20 0.71 
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Supplementary Table 15 continued: Differences between phenotypes among clusters formed from urinary 
fingerprints in subgroup analyses. 
 VAT SAT VSR BMI WC 
Cluster ß p ß p ß p ß p ß p 
Non-fasting men 
1 -0.58 0.68 0.56 0.34 0.17 0.62 1.23 0.51 2.88 0.51 
2 0.05 0.95 0.15 0.42 0.01 0.99 1.65 0.11 5.31 0.07 
3 -1.25 0.19 0.09 0.71 -1.13 0.18 -0.33 0.80 -1.55 0.67 
4 0.20 0.84 0.28 0.24 -0.73 0.38 1.22 0.35 3.93 0.29 
5 -2.14 0.47 0.79 0.29 -2.53 0.33 1.95 0.63 1.75 0.88 
6 0.25 0.93 1.47 0.05 -2.18 0.40 1.65 0.68 4.95 0.66 
Non-fasting women 
1 0.05 0.62 0.36 0.51 -0.74 0.55 2.31 0.33 3.53 0.46 
2 0.72 0.27 0.17 0.45 0.47 0.29 1.36 0.21 1.97 0.48 
3 -0.70 0.34 -0.25 0.32 -0.15 0.76 -1.69 0.18 -2.56 0.43 
4 0.16 0.87 -0.03 0.92 0.27 0.69 0.75 0.66 2.46 0.57 
5 -0.68 0.80 0.39 0.67 -1.00 0.58 3.52 0.44 -4.73 0.69 
6 0.75 0.82 1.50 0.17 -1.65 0.45 7.60 0.17 20.50 0.15 
Subjects with no urinary glucose 
1 0.26 0.62 0.17 0.30 0.23 0.59 1.38 0.10 2.57 0.23 
2 0.78 0.15 -0.15 0.37 0.77 0.07 -0.20 0.82 -0.66 0.76 
3 -0.66 0.36 -0.33 0.15 0.01 0.98 -2.12 0.06 -3.23 0.27 
4 0.58 0.68 -0.09 0.83 0.22 0.84 -0.56 0.80 2.03 0.72 
5 -0.22 0.93 0.33 0.70 -0.82 0.70 3.41 0.42 -5.03 0.64 
6 1.51 0.59 1.24 0.15 -0.79 0.71 5.38 0.22 17.73 0.11 
7 0.91 0.73 1.33 0.12 -1.55 0.46 1.18 0.78 3.48 0.75 
Glucose subjects 
1 -0.28 0.83 -0.21 0.49 -0.58 0.52 -0.60 0.79 -2.17 0.61 
2 -0.01 0.99 0.10 0.77 -0.42 0.66 -0.80 0.73 0.03 0.99 
3 -2.94 0.22 0.27 0.63 -1.74 0.30 -2.17 0.59 3.10 0.76 
Linear regression adjusted for age and sex, grand mean=reference category, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-to-subcutaneous-fat-ratio, 
BMI=body mass index, WC=waist circumference, ß=regression coefficient, p=p-value. In each case, the stratification variable was excluded from the model.  
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Supplementary Table 16: Differences between phenotypes among clusters formed from serum fingerprints in 
subgroup analyses 
 
VAT SAT VSR BMI WC 
Cluster ß p ß p ß p ß p ß p 
Men 
1 -0.31 0.64 0.12 0.81 0.47 0.62 0.26 0.39 1.23 0.25 
2 -1.02 0.11 -0.02 0.91 -0.66 0.21 -0.92 0.34 -3.30 0.21 
3 0.17 0.84 0.05 0.85 -0.26 0.71 -1.25 0.34 -4.34 0.23 
4 -0.07 0.98 0.33 0.68 -1.43 0.53 2.95 0.48 11.32 0.32 
Women 
1 -0.07 0.55 -0.57 0.01 -0.52 0.32 -0.51 0.55 -3.24 0.30 
2 -0.45 0.46 -0.46 0.02 0.44 0.25 -1.26 0.26 -4.62 0.07 
3 0.31 0.64 -0.67 0.002 1.50 0.06 0.25 0.84 -1.86 0.52 
Non-fasting participants 
1 0.45 0.64 0.03 0.36 -0.98 0.64 0.35 0.63 -0.07 0.63 
2 0.00 1.00 -0.11 0.48 0.05 0.89 -0.07 0.93 -0.29 0.89 
3 0.17 0.78 -0.42 0.04 0.96 0.05 0.14 0.89 -0.85 0.75 
4 0.62 0.33 0.03 0.87 -0.07 0.89 0.99 0.34 0.24 0.93 
Fasting participants 
1 0.35 0.53 0.09 0.70 -0.54 0.73 0.26 0.61 -1.31 0.61 
2 1.57 0.41 -0.11 0.82 0.83 0.19 2.32 0.56 2.65 0.72 
3 -0.87 0.65 0.28 0.57 -0.62 0.32 -1.81 0.66 -5.26 0.49 
Non-fasting men 
1 0.73 0.37 0.10 0.68 0.51 0.29 0.54 0.54 0.85 0.49 
2 0.69 0.35 0.07 0.73 -0.20 0.75 1.30 0.21 3.12 0.29 
3 0.77 0.39 0.12 0.62 -0.14 0.85 -0.22 0.86 -1.42 0.69 
Non-fasting women 
1 0.31 0.45 -0.48 0.04 1.42 0.87 0.34 0.35 -1.54 0.52 
2 -0.25 0.68 -0.39 0.06 0.37 0.38 -0.76 0.47 -3.66 0.18 
3 0.86 0.21 -0.57 0.02 1.68 0.06 1.44 0.23 0.59 0.85 
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Supplementary Table 16 continued: Differences between phenotypes among clusters formed from serum fingerprints 
in subgroup analyses 
 VAT SAT VSR BMI WC 
Cluster ß p ß p ß p ß p ß p 
Subjects with no urinary glucose 
1 -0.26 0.73 -0.91 0.69 -0.58 0.92 -2.60 0.19 -0.17 0.59 
2 0.43 0.96 0.14 0.72 1.86 0.36 -0.68 0.76 1.03 0.91 
3 -2.94 0.25 0.28 0.18 -1.26 0.39 -0.17 0.83 1.10 0.86 
Linear regression adjusted for age and sex, grand mean=reference category, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, VSR=visceral-to-subcutaneous-fat-ratio 
BMI=body mass index, WC=waist circumference, ß=linear regression coefficient, p=p-value. 
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Supplementary Table 17: Significant# results from regression analyses to detect relations of VAT to urinary bins 
among subgroups. 
  Model 1 Model 2  
Anthropometric 
variable 
bin (ppm) ß p ß p metabolite identification 
Non-fasting subjects (n=198) 
VAT 9.135 -0.153 0.0029 -0.160 0.0020 unknown 
 9.075 -0.126 0.0076 -0.128 0.0068 unknown 
 8.455 -0.089 0.0013 -0.095 0.0005 Formic acid 
 7.075 -0.083 0.0036 -0.083 0.0037 1-Methylhistidine, unknown 
 6.965 -0.074 0.0016 -0.078 0.0009 4-Hydroxyhippuric acid 
 6.955 -0.065 0.0022 -0.070 0.0008 4-Hydroxyhippuric acid 
 6.585 -0.068 0.0005 -0.072 0.0002 unknown 
 6.575 -0.056 0.0089 -0.061 0.0038 unknown 
 6.555 -0.057 0.0093 -0.062 0.0046 unknown 
 4.095 -0.036 0.0118 -0.039 0.0059 D-Saccharic acid 
 4.075 -0.131 0.0011 -0.133 0.0010 Creatinine 
 4.065 -0.118 0.0019 -0.119 0.0019 Choline/creatinine, others 
 3.945 -0.044 0.0064 -0.047 0.0034 4-Hydroxyhippuric acid, others 
 3.925 -0.047 0.0024 -0.050 0.0009 Tyrosine, unknown 
 3.565 -0.086 0.0001 -0.088 0.00004 Glycine, unknown 
 3.525 -0.056 0.0004 -0.058 0.0002 Choline, others 
 3.365 -0.095 0.0001 -0.096 0.0001 scyllo-Inositol, unknown 
 3.355 -0.052 0.0008 -0.053 0.0006 scyllo-Inositol 
 3.345 -0.062 0.0017 -0.066 0.0007 3-Methylhistidine 
 3.205 -0.055 0.0041 -0.055 0.0044 Choline, others 
 3.155 -0.032 0.0073 -0.032 0.0063 1-Methylhistidine, unknown 
 3.145 -0.032 0.0039 -0.033 0.0027 cis-Aconitic acid, unknown 
 3.115 -0.070 0.0057 -0.070 0.0061 3-aminoisobutyric acid, unknown 
 3.055 0.089 0.0069 0.093 0.0047 Tyrosine, creatinine 
 2.985 -0.030 0.0137 -0.033 0.0064 unknown 
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Supplementary Table 17 continued: Significant# results from regression analyses to detect relations of VAT to 
urinary bins among subgroups. 
  Model 1 Model 2  
Anthropometric 
variable 
bin (ppm) ß p ß p metabolite identification 
VAT 2.975 -0.036 0.0047 -0.040 0.0018 Asparagine, unknown 
 2.965 -0.037 0.0058 -0.041 0.0024 Asparagine, unknown 
 2.835 -0.038 0.0003 -0.040 0.0001 Methylguanidine 
 2.775 -0.025 0.0145 -0.028 0.0046 unknown 
 2.735 0.068 0.0047 0.067 0.0054 Dimethylamine 
 2.725 0.061 0.0004 0.063 0.0003 Dimethylamine/citric acid 
 2.705 -0.102 0.0061 -0.103 0.0061 Citric acid 
 2.675 -0.131 0.0011 -0.133 0.0010 Citric acid 
 2.645 -0.040 0.0017 -0.043 0.0006 unknown 
 2.605 -0.038 0.0010 -0.038 0.0009 Ketoleucine 
 2.515 -0.051 0.0001 -0.053 0.00003 L-Pyroglutamic acid 
 2.475 -0.041 0.0008 -0.043 0.0004 
Pyridoxine, isocitric acid, 
glutamine, 3-hydroxy-3-
methylglutaric acid, carnitine 
 2.465 -0.031 0.0029 -0.033 0.0017 
3-hydroxy-3-methylglutaric acid, 
carnitine 
 2.455 -0.032 0.0016 -0.033 0.0012 
Isocitric acid, glutamine, 3-
hydroxy-3-methylglutaric acid, 
carnitine 
 2.445 -0.040 0.0003 -0.041 0.0002 
Isocitric acid, glutamine, 3-
hydroxy-3-methylglutaric acid, 
carnitine 
 2.435 -0.040 0.0001 -0.042 0.0001 
Isocitric acid, glutamine, 3-
hydroxy-3-methylglutaric acid, 
carnitine 
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Supplementary Table 17 continued: Significant# results from regression analyses to detect relations of VAT to 
urinary bins among subgroups. 
  Model 1 Model 2  
Anthropometric 
variable 
bin (ppm) ß p ß p metabolite identification 
VAT 2.425 -0.036 0.0027 -0.039 0.0008 
Isocitric acid, glutamine, 3-
hydroxy-3-methylglutaric acid, 
carnitine 
 2.405 -0.051 0.0007 -0.054 0.0002 
L-Pyroglutamic acid, glutamine, 
3-hydroxy-3-methylglutaric acid, 
carnitine 
 2.395 -0.029 0.0139 -0.033 0.0041 L-Pyroglutamic acid 
 2.365 -0.040 0.0016 -0.042 0.0006 3-Hydroxyisovaleric acid 
 2.355 -0.033 0.0050 -0.036 0.0028 unknown 
 2.335 -0.028 0.0105 -0.031 0.0046 unknown 
 2.325 -0.035 0.0016 -0.038 0.0005 unknown 
 2.315 -0.036 0.0021 -0.039 0.0009 unknown 
 2.305 -0.039 0.0055 -0.041 0.0034 unknown 
 2.245 -0.030 0.0058 -0.033 0.0024 
5-Aminopentanonic acid, 
unknown 
 2.235 -0.084 0.0000 -0.086 0.00001 
Acetone, 5-aminopentanonic 
acid, unknown 
 2.225 -0.030 0.0119 -0.033 0.0058 
5-Aminopentanonic acid, 
unknown 
 2.215 -0.034 0.0067 -0.036 0.0036 unknown 
 2.205 -0.036 0.0080 -0.038 0.0053 unknown 
 2.195 -0.042 0.0045 -0.044 0.0030 
Suberic acid, sebacic acid, 
unknown 
 2.185 -0.058 0.0017 -0.061 0.0010 unknown 
 2.175 -0.044 0.0076 -0.046 0.0047 unknown 
 2.155 -0.032 0.0087 -0.034 0.0069 unknown, Hydroxyacetone 
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Supplementary Table 17 continued: Significant# results from regression analyses to detect relations of VAT to 
urinary bins among subgroups. 
  Model 1 Model 2  
Anthropometric 
variable 
bin (ppm) ß p ß p metabolite identification 
VAT 2.135 -0.035 0.0037 -0.036 0.0027 unknown 
 2.125 -0.039 0.0051 -0.040 0.0052 Glutamine, N-acetyl-L-glutamine 
 2.075 -0.030 0.0115 -0.032 0.0056 unknown 
 2.025 -0.030 0.0046 -0.032 0.0014 L-Pyroglutamic acid, unknown 
 2.015 -0.030 0.0074 -0.033 0.0026 L-Pyroglutamic acid, unknown 
 2.005 -0.034 0.0059 -0.037 0.0020 L-Pyroglutamic acid, unknown 
 1.815 -0.033 0.0149 -0.036 0.0062 
4-Guanidinobutyric acid, 
unknown 
 1.655 -0.035 0.0103 -0.038 0.0041 
Arginine, 5-aminopentanoic acid, 
2-aminoadipicacid 
 1.645 -0.036 0.0028 -0.039 0.0012 
Arginine, 5-aminopentanoic acid, 
glycyl-L-leucine, 2-
aminoadipicacid 
 1.635 -0.029 0.0089 -0.031 0.0038 
Arginine, 5-aminopentanoic acid, 
glycyl-L-leucine, 2-
aminoadipicacid 
 1.625 -0.029 0.0118 -0.031 0.0055 
Arginine, 5-aminopentanoic acid, 
glycyl-L-leucine, 2-
aminoadipicacid 
 1.615 -0.028 0.0146 -0.031 0.0071 
Arginine, 5-aminopentanoic acid, 
glycyl-L-leucine, 2-
aminoadipicacid 
 1.555 -0.033 0.0046 -0.035 0.0026 Suberic acid, sebacic acid 
 1.475 0.036 0.0067 0.037 0.0066 Alanine, lysone 
 1.355 0.032 0.0136 0.035 0.0070 unknown 
 1.235 -0.046 0.0021 -0.049 0.0009 unknown 
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Supplementary Table 17 continued: Significant# results from regression analyses to detect relations of VAT to 
urinary bins among subgroups. 
  Model 1 Model 2  
Anthropometric 
variable 
bin (ppm) ß p ß p metabolite identification 
VAT 1.225 -0.038 0.0095 -0.041 0.0047 unknown 
 1.185 -0.043 0.0073 -0.046 0.0039 unknown 
 1.145 -0.052 0.0104 -0.058 0.0039 Isobutyrylcarnitine, unknown 
 1.095 -0.039 0.0103 -0.042 0.0050 unknown 
 1.015 -0.032 0.0155 -0.035 0.0070 unknown 
Subjects with no urinary glucose 
 2.405 -0.052 0.0017 -0.055 0.0448 L-Pyroglutamic acid, glutamine 
 2.435 -0.033 0.0052 -0.036 0.0011 
3-Hydroxy-3-methylglutaric acid, 
others 
 2.605 -0.036 0.0039 -0.039 0.0010 unknown, ketoleucine 
 2.615 -0.049 0.0043 -0.056 0.0006 unknown, ketoleucine 
 2.465 -0.033 0.0052 -0.037 0.0009 
3-Hydroxy-3-methylglutaric acid, 
others 
 3.345 -0.057 0.0089 -0.070 0.0007 3-Methylhistidine, others 
 3.355 -0.050 0.0030 -0.055 0.0007 scyllo-Inositol 
 6.585 -0.056 0.0063 -0.064 0.0010 unknown 
 6.965 -0.078 0.0037 -0.086 0.0008 4-Hydroxyhippuric acid 
 8.455 -0.093 0.0014 -0.091 0.0009 unknown 
 9.135 -0.154 0.0036 -0.162 0.0010 unknown 
Model 1: linear regression model adjusted for study, age (non-linear) and sex. 
Model 2: linear regression model adjusted for study, age and sex interaction (non-linear), eGFR, smoking status, menopausal status (women only), fasting status, urinary glucose, and 
physical activity. In each case, the stratification variable was excluded from the model. VAT=visceral adipose tissue, bin=spectra position (ppm), ß=beta-coefficient p=corrected p-value. 
 
#
p-values<0.05 after correction for multiple testing are considered significant. 
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Supplementary Table 18: Significant# results from regression analyses to detect relations of BMI to urinary bins. 
  Model 1 Model 2 
Anthropometric variable bin (ppm) ß p ß p 
Non-fasting subjects (n=198) 
BMI 1.015 -0.028 0.010 -0.026 0.025 
 1.095 -0.032 0.009 -0.027 0.038 
 1.145 -0.046 0.007 -0.041 0.023 
 1.185 -0.038 0.005 -0.037 0.013 
 1.225 -0.033 0.006 -0.030 0.021 
 1.235 -0.041 0.001 -0.038 0.005 
 1.305 -0.030 0.006 -0.027 0.024 
 1.315 -0.029 0.008 -0.026 0.025 
 1.485 -0.026 0.015 -0.025 0.030 
 1.545 -0.026 0.011 -0.024 0.029 
 1.555 -0.028 0.005 -0.026 0.013 
 1.565 -0.023 0.014 -0.020 0.049 
 1.615 -0.024 0.011 -0.020 0.038 
 1.625 -0.023 0.012 -0.019 0.047 
 1.645 -0.027 0.007 -0.022 0.029 
 1.815 -0.029 0.008 -0.023 0.036 
 2.005 -0.028 0.006 -0.022 0.025 
 2.015 -0.025 0.008 -0.020 0.037 
 2.025 -0.025 0.004 -0.020 0.018 
 2.135 -0.025 0.010 -0.023 0.029 
 2.145 -0.025 0.008 -0.020 0.041 
 2.165 -0.035 0.007 -0.031 0.026 
 2.185 -0.041 0.008 -0.037 0.028 
 2.205 -0.026 0.015 -0.025 0.037 
 2.215 -0.024 0.015 -0.023 0.034 
 2.235 -0.038 0.006 -0.037 0.013 
 2.305 -0.030 0.008 -0.024 0.046 
 2.315 -0.027 0.006 -0.023 0.025 
 2.325 -0.028 0.003 -0.023 0.013 
 2.335 -0.023 0.011 -0.018 0.028 
 2.355 -0.026 0.007 -0.022 0.036 
 2.365 -0.031 0.003 -0.029 0.011 
 2.405 -0.042 0.001 -0.038 0.005 
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Supplementary Table 18 continued: Significant# results from regression analyses to detect relations of BMI to 
urinary bins. 
  Model 1 Model 2 
Anthropometric variable bin (ppm) ß p ß p 
BMI 2.425 -0.028 0.005 -0.026 0.013 
 2.435 -0.029 0.001 -0.026 0.007 
 2.445 -0.030 0.002 -0.027 0.008 
 2.455 -0.025 0.004 -0.022 0.013 
 2.465 -0.022 0.009 -0.020 0.029 
 2.475 -0.027 0.008 -0.024 0.025 
 2.515 -0.035 0.002 -0.030 0.011 
 2.525 -0.060 0.011 -0.061 0.021 
 2.645 -0.035 0.002 -0.034 0.004 
 2.675 -0.099 0.004 -0.111 0.005 
 2.705 -0.078 0.010 -0.083 0.013 
 2.725 0.058 0.000 0.062 0.000 
 2.735 0.047 0.015 0.060 0.008 
 2.755 -0.021 0.017 -0.020 0.029 
 2.775 -0.021 0.010 -0.019 0.025 
 2.835 -0.024 0.006 -0.023 0.013 
 2.925 -0.024 0.032 -0.026 0.030 
 2.935 0.021 0.065 0.028 0.029 
 2.965 -0.028 0.011 -0.027 0.024 
 2.975 -0.028 0.008 -0.028 0.013 
 2.985 -0.026 0.008 -0.027 0.013 
 2.995 -0.026 0.008 -0.026 0.013 
 3.055 0.051 0.056 0.065 0.026 
 3.145 -0.024 0.008 -0.024 0.015 
 3.225 -0.036 0.020 -0.038 0.025 
 3.245 -0.012 0.121 -0.017 0.044 
 3.255 -0.012 0.192 -0.019 0.047 
 3.265 -0.058 0.006 -0.066 0.007 
 3.345 -0.051 0.002 -0.045 0.013 
 3.355 -0.036 0.005 -0.034 0.013 
 3.365 -0.048 0.008 -0.048 0.018 
 3.375 -0.028 0.011 -0.024 0.039 
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Supplementary Table 18 continued: Significant# results from regression analyses to detect relations of BMI to 
urinary bins. 
  Model 1 Model 2 
Anthropometric variable bin (ppm) ß p ß p 
BMI 3.405 -0.025 0.008 -0.024 0.025 
 3.415 -0.031 0.008 -0.031 0.019 
 3.535 -0.031 0.011 -0.025 0.049 
 3.545 -0.032 0.011 -0.026 0.044 
 3.565 -0.061 0.001 -0.063 0.003 
 3.685 -0.026 0.026 -0.028 0.025 
 3.695 -0.026 0.028 -0.027 0.029 
 3.705 -0.025 0.055 -0.028 0.044 
 3.715 -0.033 0.018 -0.031 0.049 
 3.735 -0.019 0.085 -0.026 0.021 
 3.745 -0.016 0.128 -0.022 0.034 
 3.755 -0.026 0.035 -0.028 0.026 
 3.795 -0.026 0.043 -0.030 0.037 
 3.855 -0.020 0.011 -0.016 0.042 
 3.925 -0.033 0.008 -0.030 0.024 
 4.025 -0.020 0.048 -0.020 0.049 
 4.035 -0.027 0.008 -0.023 0.018 
 4.055 -0.079 0.011 -0.090 0.013 
 4.095 -0.035 0.004 -0.031 0.010 
 4.245 -0.027 0.005 -0.024 0.013 
 4.275 -0.020 0.015 -0.018 0.039 
 4.305 -0.016 0.015 -0.015 0.029 
 4.425 -0.025 0.008 -0.023 0.024 
 6.585 -0.049 0.003 -0.047 0.008 
 6.685 -0.031 0.021 -0.033 0.026 
 6.805 -0.038 0.021 -0.038 0.032 
 7.075 -0.059 0.010 -0.059 0.020 
 7.085 -0.062 0.021 -0.062 0.042 
 7.675 -0.021 0.006 -0.019 0.015 
 7.985 0.022 0.112 0.031 0.042 
 8.455 -0.069 0.003 -0.070 0.008 
 9.075 -0.092 0.015 -0.093 0.036 
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Supplementary Table 18 continued: Significant# results from regression analyses to detect relations of BMI to 
urinary bins. 
  Model 1 Model 2 
Anthropometric variable bin (ppm) ß p ß p 
BMI 9.165 -0.148 0.023 -0.163 0.027 
 9.385 -0.093 0.010 -0.086 0.024 
Subjects with no urinary glucose 
 1.015 -0.023 0.0324 -0.031 0.0468 
 1.445 -0.027 0.0198 -0.034 0.0468 
 2.165 -0.030 0.0279 -0.046 0.0446 
 2.185 -0.034 0.0349 -0.056 0.0387 
 2.235 -0.037 0.0151 -0.049 0.0432 
 2.355 -0.026 0.0177 -0.032 0.0387 
 2.365 -0.027 0.0198 -0.038 0.0178 
 2.405 -0.041 0.0071 -0.044 0.0248 
 2.425 -0.028 0.0117 -0.030 0.0468 
 2.645 -0.033 0.0090 -0.036 0.0372 
 2.725 0.034 0.0139 0.049 0.0453 
 2.735 0.030 0.1114 0.066 0.0468 
 3.225 -0.030 0.0756 -0.057 0.0432 
 3.265 -0.059 0.0117 -0.116 0.0055 
 3.325 -0.036 0.0213 -0.052 0.0253 
 3.365 -0.053 0.0119 -0.073 0.0156 
 3.375 -0.024 0.0418 -0.038 0.0432 
 3.415 -0.035 0.0117 -0.047 0.0258 
 3.925 -0.038 0.0107 -0.043 0.0468 
 4.025 -0.014 0.1479 -0.032 0.0468 
 4.055 -0.077 0.0213 -0.113 0.0432 
 4.095 -0.029 0.0218 -0.039 0.0432 
 6.685 -0.030 0.0397 -0.047 0.0251 
 7.985 0.026 0.0963 0.057 0.0203 
 8.455 -0.069 0.0088 -0.091 0.0094 
 8.685 -0.034 0.0567 -0.067 0.0083 
 9.075 -0.092 0.0263 -0.155 0.0464 
 9.135 -0.088 0.0363 -0.143 0.0182 
 9.165 -0.120 0.0988 -0.289 0.0099 
Model 1: linear regression model adjusted for study, age (non-linear) and sex. 
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Model  2: linear regression model adjusted for study, age and sex interaction (non-linear), eGFR, smoking status, menopausal status (women only), fasting status, urinary glucose, and 
physical activity. In each case, the stratification variable was excluded from the model. BMI=body mass index, bin=spectra position (ppm), ß=beta-coefficient p=corrected p-value.  
#
p-values<0.05 after correction for multiple testing are considered significant. 
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Supplementary Table 19: Significant# results from regression analyses to detect relations of WC to urinary bins. 
  Model 1 Model 2 
Anthropometric 
variable 
bin (ppm) ß p ß p 
Non-Fasting subjects (n=198) 
WC 1.095 -0.012 0.013 -0.011 0.037 
 1.145 -0.016 0.014 -0.016 0.021 
 1.185 -0.014 0.006 -0.014 0.010 
 1.235 -0.013 0.004 -0.013 0.009 
 1.485 -0.009 0.022 -0.008 0.049 
 1.645 -0.009 0.014 -0.008 0.046 
 2.005 -0.009 0.014 -0.008 0.044 
 2.025 -0.009 0.006 -0.007 0.025 
 2.135 -0.010 0.012 -0.009 0.039 
 2.165 -0.013 0.011 -0.011 0.045 
 2.185 -0.015 0.011 -0.014 0.043 
 2.235 -0.016 0.002 -0.016 0.004 
 2.325 -0.009 0.014 -0.008 0.030 
 2.365 -0.011 0.004 -0.011 0.005 
 2.405 -0.014 0.002 -0.014 0.003 
 2.425 -0.011 0.004 -0.010 0.006 
 2.435 -0.011 0.002 -0.010 0.005 
 2.445 -0.011 0.002 -0.010 0.005 
 2.455 -0.009 0.004 -0.008 0.013 
 2.465 -0.008 0.014 -0.007 0.046 
 2.475 -0.010 0.011 -0.010 0.020 
 2.515 -0.013 0.002 -0.012 0.006 
 2.525 -0.023 0.014 -0.027 0.006 
 2.555 -0.021 0.047 -0.023 0.047 
 2.645 -0.011 0.011 -0.012 0.004 
 2.665 -0.021 0.052 -0.025 0.047 
 2.675 -0.032 0.011 -0.039 0.005 
 2.705 -0.025 0.039 -0.029 0.026 
 2.715 0.019 0.075 0.026 0.028 
 2.725 0.018 0.002 0.020 0.002 
 2.735 0.016 0.041 0.023 0.005 
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Supplementary Table 19 continued: Significant# results from regression analyses to detect relations of WC to urinary 
bins. 
  Model 1 Model 2 
Anthropometric 
variable 
bin (ppm) ß p ß p 
WC 2.755 -0.008 0.017 -0.009 0.010 
 2.775 -0.008 0.014 -0.008 0.012 
 2.835 -0.011 0.002 -0.011 0.002 
 2.925 -0.008 0.075 -0.010 0.044 
 2.935 0.008 0.082 0.012 0.014 
 2.965 -0.010 0.021 -0.011 0.018 
 2.975 -0.009 0.025 -0.010 0.021 
 2.985 -0.009 0.027 -0.010 0.015 
 2.995 -0.009 0.012 -0.010 0.008 
 3.055 0.017 0.111 0.025 0.028 
 3.125 -0.010 0.026 -0.011 0.039 
 3.145 -0.010 0.002 -0.011 0.003 
 3.225 -0.014 0.021 -0.014 0.030 
 3.265 -0.022 0.006 -0.027 0.002 
 3.345 -0.019 0.002 -0.016 0.015 
 3.355 -0.012 0.014 -0.011 0.040 
 3.365 -0.022 0.002 -0.023 0.002 
 3.415 -0.010 0.021 -0.011 0.020 
 3.565 -0.021 0.002 -0.021 0.003 
 3.685 -0.009 0.049 -0.011 0.027 
 3.795 -0.009 0.061 -0.010 0.045 
 4.055 -0.026 0.031 -0.032 0.015 
 4.095 -0.012 0.009 -0.011 0.010 
 4.245 -0.008 0.016 -0.008 0.028 
 4.305 -0.006 0.039 -0.005 0.044 
 4.375 -0.007 0.078 -0.008 0.046 
 4.425 -0.009 0.023 -0.009 0.027 
 6.585 -0.019 0.002 -0.020 0.002 
 6.685 -0.014 0.009 -0.016 0.005 
 6.805 -0.015 0.023 -0.016 0.020 
 7.075 -0.022 0.012 -0.022 0.021 
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Supplementary Table 19 continued: Significant# results from regression analyses to detect relations of WC to urinary 
bins. 
  Model 1 Model 2 
Anthropometric 
variable 
bin (ppm) ß p ß p 
WC 7.085 -0.027 0.010 -0.029 0.012 
 7.675 -0.007 0.011 -0.007 0.015 
 8.455 -0.026 0.002 -0.029 0.002 
 8.685 -0.014 0.047 -0.016 0.040 
 9.075 -0.033 0.028 -0.035 0.047 
 9.135 -0.036 0.028 -0.038 0.043 
 9.285 -0.022 0.015 -0.025 0.011 
 9.385 -0.023 0.119 -0.029 0.047 
Subjects with no urinary glucose 
 2.365 -0.011 0.024 -0.014 0.023 
 2.555 -0.024 0.048 -0.036 0.043 
 3.265 -0.025 0.005 -0.043 0.004 
 3.365 -0.024 0.005 -0.028 0.012 
 6.685 -0.014 0.019 -0.016 0.047 
 7.985 0.009 0.194 0.022 0.013 
 8.455 -0.025 0.008 -0.028 0.047 
 8.685 -0.013 0.095 -0.023 0.013 
 9.135 -0.035 0.049 -0.054 0.019 
 9.165 -0.031 0.320 -0.095 0.031 
 2.365 -0.011 0.024 -0.014 0.023 
 2.555 -0.024 0.048 -0.036 0.043 
Model 1: linear regression model adjusted for study, age (non-linear) and sex. 
Model  2: linear regression model adjusted for study, age and sex interaction (non-linear), eGFR, smoking status, menopausal status (women only), fasting status, urinary glucose, and 
physical activity. In each case, the stratification variable was excluded from the model. WC=waist circumference, bin=spectra position (ppm), ß=beta-coefficient p=corrected p-value.  
#
p-values<0.05 after correction for multiple testing are considered significant. 
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Supplementary Figure 1: Bland-Altman Plots for the intra-observer agreement 
between VAT respectively SAT measurements.  
(a) Agreement between VAT measurements from observer 1; (b) Agreement between VAT measurements from observer 2;  
(c) Agreement between SAT measurements from observer 1; (d) Agreement between SAT measurements from observer 2; n=127. 
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Supplementary Figure 2: Distribution of urine spectral area. 
Mean standard deviation of the individual scaling factors of the selected reference features (mswsd). 
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Supplementary Figure 3: Distribution of serum spectral area. 
Mean standard deviation of the individual scaling factors of the selected reference features (mswsd). 
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